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List of Abbreviations and acronyms 
FD = Fabry disease 
ERT = Enzyme replacement therapy 
α-GAL A or GLA = human alpha galactosidase 
(α-)NAGA(L) = α-N-acetyl-galactosaminidase 
(α-)NAGAEL = modified α-N-acetyl-galactosaminidase 
α-GAL = any alpha galactosidase, including plant enzymes 
4MU = 4-Methylumbelliferyl  
ABP = Activity-based probe 
CBB = Coomassie brilliant blue 
ConA = Concanavalin A 
Gb3 = globotriaosylceramide 
GlcCer = glucosylceramide  
Cer = ceramide 
lysoGb3 = globotriaosylsphingosine 
LacCer = lactosylceramide 
lysoLacCer = lactosylsphingosine 
mAb = monoclonal antibodies 
Gal-DNJ = deoxygalactonojirimycin 
GBA = human lysosomal glucocerebrosidase 
GAA = human lysosomal alpha glucosidase 
βGLUR = human lysosomal beta glucuronidase 
αMAN = human alpha mannosidase 
αFUC = human alpha fucosidase 
βGAL = human beta galactosidase 
HPSE = Heparanase 
MPR = Mannose-6-phosphate receptor 
Man-6-P = Mannose-6-phosphate moieties 
MR = Molecular Replacement 
PD = Parkinson disease 
GD = Gaucher disease  
SDS-PAGE = sodium dodecyl sulfate polyacrylamide gel electrophoresis 
HPLC = High Performance Liquid Chromatography 
LC-MS/MS = Liquid chromatography–mass spectrometry with two mass 
spectrometers in tandem 
HRP = horseradish peroxidase 
NBD = nitrobenzoxadiazole 
NBD-Gb3 = NBD-C12-globotriaosylceramide 
PBS = Phosphate buffered saline 
DAPI = 4',6-diamidino-2-phenylindole 
BY2 cells= Bright Yellow 2 Nicotiana tabacum cells 
BSA = Bovine serum albumin 
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RT = real time 
A1.1 = Nicotiana benthamiana alpha galactosidase, identified in current thesis 
B56 = Nicotiana tabacum beta glucosidase, identified in current thesis 
 
List of activity-based probes coding 
 
TB474 = Cy5 labelled alpha galactosidase activity-based probe 
ME741 = Biotinylated alpha galactosidase activity-based probe 
ME569 = Cy5 labelled epoxide beta glucosidase activity-based probe 
ME869 = TAMRA/Biotinylated labelled epoxide beta glucosidase activity-based probe 
JJB111 = Biotinylated labelled aziridine beta glucosidase activity-based probe 
JJB367 = Cy5 labelled aziridine beta glucosidase activity-based probe 
JJB75 = Bodipy-red labelled aziridine beta glucosidase activity-based probe 
TB652 = Cy5 labelled aziridine beta galactosidase activity-based probe 
JJB381 = Cy5 labelled aziridine alpha fucosidase activity-based probe 
JJB383 = Cy5 labelled aziridine alpha glucosidase activity-based probe 
JJB392 = Cy5 labelled aziridine beta glucuronidase activity-based probe 
KY358 = aziridine beta glucosidase activity-based probe 
MDW944 = Bodipy-red labelled epoxide beta glucosidase activity-based probe 
TB482 = Cy5 labelled aziridine alpha mannosidase activity-based probe 
TB434 = Cy5 labelled aziridine beta mannosidase activity-based probe 
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Introduction 
Lysosomal enzymes and their function  
In 1955 Christian de Duve and colleagues were the first to observe the existence 
of distinct membrane-enclosed acidic cellular organelles, that were named 
lysosomes to reflect their “lytic” nature (Appelmans et al. 1955). Lysosomes 
fulfil various functions ranging from turnover of endogenous macromolecules 
from the extracellular space and the cell itself to the supply of the cytosol with 
vital nutrients and degradation of pathogens (Parkinson-Lawrence et al. 2010). 
Degradation of very different macromolecules such as sphingolipids, glycogen, 
mucopolysaccharides and glycoproteins takes place in lysosomes. 
Macromolecular substrates for degradation are delivered into lysosomes via 
endocytic and autophagy pathways (Futerman and van Meer 2004). Lysosomes 
contain over 60 soluble acid hydrolases mediating fragmentation of 
macromolecules to building blocks that are exported to the cytosol via 
transporters in the lysosomal membrane (Platt 2014). The lysosomal 
membrane contains several heavily glycosylated integral membrane proteins 
with function in transport, interactions with the cytosol, endosomes and 
autophagosomes and provide stability and integrity of the organelles (Schwake 
et al. 2013). 
        Lysosomal hydrolases are glycoproteins containing N-linked glycans. 
Exceptions to this are the enzymes lysozyme and chitotriosidase, specialized 
endoglycosidases of phagocytes (Bussink et al. 2006). Lysosomal proteins are 
all synthesized at the endoplasmic reticulum (ER). Co-translationally, the 
newly formed polypeptides enter the lumen of the ER and specific asparagine 
residues become N-glycosylated. After correct folding, newly formed lysosomal 
proteins are transported to the Golgi apparatus which they traverse from cis to 
trans structures (Neufeld et al. 1975). The N-glycans of integral lysosomal 
membrane proteins and the lysosomal β-glucosidase (glucocerebrosidase, GBA) 
are modified from high mannose-type structures to sialylated hybrid type- and 
complex type-structures (Aerts et al. 1988; Saftig and Klumperman 2009). The 
soluble lysosomal proteins undergo another unique modification of their N-
glycans in the Golgi apparatus, i.e. in a two-step process mannose-6-phosphate 
(M6P) moieties are generated in their high mannose-type N-glycans (Neufeld 
et al. 1975). Binding to mannose-6-phosphate receptors governs the sorting of 
soluble lysosomal proteins from other glycoproteins destined for secretion. 
Bound to M6P receptor lysosomal proteins are delivered to late endosomes from 
which their final destination, the lysosome, is reached (Braulke and Bonifacino 
200). M6P-mediated sorting also plays a role in re-uptake of secreted lysosomal 





types, endocytosis ensures their delivery to lysosomes (Neufeld et al. 1975; 
Vellodi 2005).  
 
Lysosomal storage disorders: therapies and diagnosis  
In 1963 Henri Hers was the first to demonstrate that Pompe disease, also 
known as glycogen storage disease type II, is caused by deficient activity of the 
lysosomal α-glucosidase (GAA, EC 3.2.1.3) (Hers 1963). Deficiency of this 
enzyme encoded by the GAA gene (locus 17q25.3) leads to accumulation of 
glycogen in the lysosomes of heart and skeletal muscle cells of Pompe patients, 
causing cardiac and respiratory failures (Van der Ploeg and Reuser 2008). 
Following the seminal discovery of the molecular basis of Pompe disease, 
identified are over 60 inherited diseases characterized by a defect in some 
function of lysosomes (Vellodi 2005; Ballabio and Gieselmann 2009; Cox and 
Cachón-González 2012). In a large number of these lysosomal storage diseases 
(LSDs) the primary cause is a mutation in a gene encoding a lysosomal 
hydrolase resulting in deficient enzymatic activity in lysosomes, so-called 
lysosomal enzymopathies (Figure 1) (Ballabio and Gieselmann 2009). LSDs can 
be also due to defects in non-enzymatic proteins in and beyond lysosomes. For 
example, there are LSDs originating from defects in lysosomal activator 
proteins (Gm2 activator protein and several saposin fragments of prosaposin) 
assisting lysosomal enzymes in their activity towards substrates (Sandhoff and 
Harzer 2013). Other LSDs are caused by primary defects in lysosomal 
membrane proteins, either acting as transporters or mediating interaction with 
other organelles (Schwake et al. 2013). Specific LSDs stem from inherited 
defects in proteins involved in transport of lysosomal proteins to lysosomes. 
Examples in this respect are deficiencies in enzymes involved in the generation 
of M6P sorting signal, defects in CLN8, an ER protein governing transport of 
newly formed lysosomal enzymes from the ER to the Golgi apparatus, and 
defects in LIMP-2, the membrane receptor transporting newly formed GBA 
from the ER to lysosomes (Reczek et al. 2007; Braulke and Bonifacino 2009; Di 































Figure 1. Examples of 3 different lysosomal enzymes and the diseases caused by their 
dysfunction. The PDB-IDs of the enzymes αGal, GBA and GAA are 1R46, 1OGS and 5KZW, 
respectively. 
 
        One group of LSDs concerns lysosomal accumulation of glycosphingolipids 
(Aerts et al. 2017; Marques and Saftig 2019) (Sandhoff and Harzer 2013). 
Common glycosphingolipidoses are Fabry disease (FD) and Gaucher disease 
(GD) (Ferraz et al. 2014). Fabry disease (FD) is an X-linked disorder caused by 
mutations in the gene GLA (locus Xq22.1) that encodes the lysosomal hydrolase 
α-galactosidase A (αGAL, EC 3.2.1.22)  (Brady et al. 1967; Ferraz et al. 2014). 
Fabry disease is characterized by intralysosomal accumulation of 
globotriaosylceramide (Gb3), also known as ceramidetrihexoside (Charles C. 
Sweeley and Bernard Klionsky 1963). The clinical expression of FD is very 
heterogenous (Desnick et al. 2003). Males with classic FD develop at young age 
angiokeratoma, acroparasthesias, corneal opacity and anhidrosis followed by 
renal, cardiovascular and neurological impairments later in life. Atypical 
variants of FD are recognized, manifesting not as multi-system disease but 
involving only single organs such as kidney and heart. It has also become 
apparent that a large proportion of female carriers of mutant GLA develop an 
ameliorated form of Fabry disease. All these phenotypic manifestations 
together make Fabry disease a relatively common disorder.  
        Gaucher disease is caused by deficiency of the lysosomal acid-β-glucosidase 
(GBA, EC.3.2.1.45), encoded by the GBA gene (locus 1q21) (Brady et al. 1966; 
Beutler and Grabowski 2001). GBA is responsible for the lysosomal hydrolysis 
α-Galactosidase, αGAL, EC 3.2.1.22, GH27, 
GLA (Xq22) 
Fabry disease, OMIM #301500 
β-Glucosidase, GBA, EC 3.2.1.45, GH30, 
GBA (1q21) 
Gaucher disease, OMIM #230800 
α-Glucosidase, GAA, EC 3.2.1.20, GH31, GAA 
(17q25.3) 
Pompe disease, OMIM #232300 
3 N-linked glycans 
4 N-linked glycans 





of glucosylceramide (GlcCer) into ceramide and glucose, the penultimate step 
in glycosphingolipid degradation. GD patients characteristically develop lipid-
laden tissue macrophages that accumulate in spleen, liver and bone marrow. 
These Gaucher cells are thought to underly the characteristic hepatomegaly, 
splenomegaly and impaired hematopoiesis and associated cytopenia in Gaucher 
patients (Beutler and Grabowski 2001; Ferraz et al. 2014). Other common 
symptoms of GD patients are skeletal deterioration and gammopathies. The 
manifestation of GD is remarkably diverse and different phenotypes are 
discerned (Beutler and Grabowski 2001). The common variant among 
Caucasians, type 1 GD, does not involve prominent symptoms in the central 
nervous system (CNS). More rare and severe are the acute neuronopathic 
variant (type 2 GD) and sub-acute neuronopathic variant (type 3 GD) 
manifesting at infantile and juvenile age respectively.  The most extreme form 
of GD is the collodion baby with a fatal abnormality in skin permeability at 
birth. In recent years it has become apparent that carriers of a mutant GBA 
allele are at increased risk for developing Parkinson disease (Siebert et al. 
2014).  
        GD has been the frontrunner among LSDs in the development of effective 
rational therapeutic interventions. In the 70’s, Roscoe Brady conceived enzyme 
replacement therapy (ERT) to treat type 1 GD (Brady 2003; Aerts and Cox 
2018). This approach is based on chronic supplementation of enzyme to relevant 
cells by means of intravenous infusions. Uptake of lysosomal enzyme and 
delivery to lysosomes in ERT is mediated by cellular lectin receptors. In the 
case of type 1 GD supplementation of macrophages with GBA is needed.  For 
this purpose, a recombinant GBA containing N-glycans with terminal mannose 
groups is employed allowing selective uptake via the mannose receptor (MR) 
expressed at the surface of tissue macrophages (Barton et al. 1991). In the case 
of other LSDs, such FD and Pompe disease, where multiple cells develop 
lysosomal storage, therapeutic recombinant enzymes contain N-glycans with 
M6P to allow uptake via M6P receptors A drawback of the ERT approach is 
that (neutralizing) antibodies against the infused recombinant enzyme may 
develop in patients that lack endogenous protein. This complication commonly 
occurs in infantile Pompe disease patients and males with classic Fabry disease 
(Linthorst et al. 2004; De Vries et al. 2016).  
        For some LSDs bone marrow transplantation is used as intervention. 
However, difficulties in the availability of suitable donors constitutes a major 
hurdle for this approach. Other therapeutic approaches for 
glycosphingolipidoses involve reduction of the glycosphingolipid substrates by 
inhibiting key enzymes involved in their biosynthesis. This substrate reduction 
therapy (SRT) was again first developed for type 1 GD (Cox et al. 2000; Aerts 




et al. 2006). Presently two inhibitors of glucosylceramide synthase (Miglustat 
and Eliglustat) are registered for SRT of type 1 GD (Shayman and Larsen 
2014).  Another considered intervention is enzyme enhancement therapy 
(EET), also known as pharmacological chaperone therapy (PCT). Here, small 
compounds entering the catalytic pocket (commonly inhibitors) are used to 
assist proper folding in the ER of amenable mutant enzymes and thus increase 
degrative capacity in lysosomes. Actively studied in clinical trials as chaperone 
for GBA is Ambroxol (Maegawa et al. 2009; Narita et al. 2016) and Migalastat 
(deoxygalactonojirimycin) is already registered as chaperone for GLA to treat 
FD patients (Müntze et al. 2019). Finally, gene therapy, even though still in 
experimental stages, prompts great expectation as cure of LSDs since it aims 
at life-long correction of the impaired glycosidase in patients’ cells. A major 
challenge for all therapy approaches is the prevention and correction of 
abnormalities in the CNS. In addition, it is increasingly realized that early 
intervention is desired since parts of the pathology in various LSDs seem 
irreversible (Ramaswami et al. 2019).  
        The diagnosis of LSDs is therefore receiving considerable attention and 
newborn screening is in place in some countries, or seriously considered, for 
some of these disorders. Traditionally diagnosis relied on examination of 
biopsies, but nowadays laboratory tests are increasingly used. DNA sequencing 
is broadly applied for several LSDs; however, this also leads to the detection of 
individuals with alterations of unknown significance. In the case of lysosomal 
enzymopathies measurement of residual enzymatic activity with chromogenic 
or fluorogenic artificial substrates is employed to demonstrate deficiency. 
Increasingly use is made of LC-MS/MS to demonstrate specific metabolite 
abnormalities. The detection of sphingoid bases derived from primary 
accumulating glycosphingolipids is found to have high diagnostic sensitivity for 
several glycosphingolipidoses (Aerts et al. 2011; Mirzaian et al. 2017). 
Examples are the markedly elevated glucosylsphingosine (GlcSph) and 
globotriaosylceramide (lysoGb3) in GD and FD, respectively (Aerts et al. 2008; 
Dekker et al. 2011). Dried blood spots are nowadays commonly used for routine 
enzyme activity and metabolite analysis. Plasma and urine samples are also 
used for detection of biomarker proteins stemming from storage cells (Aerts et 
al. 2011). Combining various tests mentioned above offers the most reliable 










Glycosidases in plants and humans 
The use of plants as medication for various diseases has a long history. Several 
plant-derived compounds have been identified over the years as therapeutic 
agents. Many of these are glycoconjugates. For example, aspirin, one of the 
most popular pain killers that also reduces inflammation and fever, is based on 
minor modification of salicylic acid from Salix alba, Spirea and Betula (Friend 
1974). Chapter 2 of this thesis provides a detailed review of this topic.  
Glycoconjugates are ongoingly synthesized and degraded, involving 
glycosyltransferases and glycoside hydrolases, respectively. All organisms 
contain multiple glycoside hydrolases (GHs, glycosidases) that hydrolyse 
specific glycosidic bonds in glycoconjugates. Glycosidases  have important  
functions, for example in lysosomal metabolism of glycolipids in animals, 
catabolism of cell wall polysaccharides in plants and biomass conversion by 
microorganisms (Ketudat Cairns and Esen 2010). The name of    glycosidases, 
e.g. β-glucosidase, reveals their preference for hydrolysis of specific glycosides.    
        Glycosidases are alternatively classified based on their amino acid 
sequence and structural similarity, as in the Carbohydrate Active EnZymes 
(CAZy) repository (Lombard et al. 2013). More than 150 GH families are listed 
in the CAZy database, revealing the plethora of glycosidases among various 
organisms.  In addition, glycosidases are classified based on their reaction 
mechanism, according to the stereochemical outcome of the hydrolysis reaction, 
into inverting or retaining enzymes (Koshland 1953; Sinnott 1990). Moreover, 
the glycosidases are characterized as exo or endo enzymes, depending on their 
ability to cleave at the end or in the middle of a carbohydrate chain (Davies and 
Henrissat 1995; Lairson et al. 2008). 
 
Mode of Action: catalytic mechanism and structure 
Two carboxyl-exposing residues like glutamic acid (Glu) and aspartic acid (Asp) 
(Glu/Glu, Asp/Asp or Glu/Asp), present in the active site of both inverting and 
retaining enzymes, are taking part in the hydrolysis of the glycosidic bond 
(Koshland 1953). The inverting reaction is a single step reaction, and it occurs 
when a water molecule is activated by the one carboxylic group at the active 
site which is acting as a base and attacks the water molecule at its anomeric 
centre (Guce et al. 2010). Simultaneously, the second carboxylic group enables 
the departure of the leaving group via acid catalysis. In the case of retaining 
glycosidases, a double displacement mechanism is employed. At first, a 
nucleophilic attack is happening to the anomeric centre and results at the 
formation of a glycosyl-enzyme intermediate (Koshland 1953). Then, the 
deprotonated carboxylate acts as a base and uses a water molecule, to hydrolyze 
the intermediate giving the reaction product (Figure 2).  




        GHs are grouped into structurally similar families that can be further sub-
grouped into clans. For instance, β-glycosidases, that belong to GH families 1, 
5, 30 (like the human GBA1), 35, 59, fall into the clan A of hydrolases with a 
catalytic (β/α)8 TIM barrel domain (Ben Bdira et al. 2018).  GH116 enzymes, 
like the cytosolic human GBA2 enzyme, belong to clan O and they have a (α/α)6 
catalytic domain. The majority of β-glycosidases have two glutamic acid amino 
acids at their active site, acting as their catalytic residues. Alpha galactosidases 
and glucosidases are listed in families 27, 31 and 36 and belong to clan D, with 
a (β/α)8 TIM barrel domain (Fujimoto et al. 2003; Guce et al. 2010). The 
enzymes’ active site is composed of two aspartic acid residues. In general, the 
active site of most glycosidases is rather conserved among species. 
Interestingly, the human enzymes such as GBA1 and αGAL enzymes are 
physiological dimers whereas research on plant enzymes reveals that they are 
















Ubiquitous glycosidases in plants 
Plants contain numerous carbohydrate active enzyme encoded genes, more 
than any other organism (Coutinho et al. 2003). For instance, Arabidopsis has 
over 400 different genes coding for glycosidases (Husaini et al. 2018). These 
include several α- and β-glucosidases, galactosidases and xylosidases. Their 
main function is the hydrolysis of glycosidic bonds between carbohydrates or 
another type of aglycone. The enzymes play various roles in processes in the 
plant cell, such as cell wall degradation, lignification, inactivation of 
phytohormones and activation of chemical defense compounds like cyanogenic 
glycosides (Ketudat Cairns and Esen 2010). Interestingly, some plant 
glycosidases are known to also act as transglycosidases, i.e. attaching sugar 
moieties from donor to acceptor molecules, forming new glycosides (Morant et 
al. 2008). As the matrix of the cell wall is of great complexity, the different 
glycosidases have inter connected roles and specificities. Therefore, there are 
many examples of plant glycosidases acting as trans enzymes in vitro. For 
instance, the linamarase from Manihot esculenta (cassava) which is acting on 
specific cyanogenic glucosides, is used for industrial applications for the 
production of alkyl β-glucosides (Svasti et al. 2003). In the case of human 
enzymes, transglycosylation activity have been proposed for chitotriosidase 
using as acceptor molecules sugars and also for the human GBA enzyme having 
acceptor molecules retinol or sterol (Vanderjagt et al. 1994; Aguilera et al. 
2003). Akiyama and Marques also described the formation of cholesterol 
glucoside by the transglucosylation activity of the human GBA 1 and 2 enzymes 
(Akiyama et al. 2013; Marques et al. 2016a). Important to mention that such 
specificities are not yet reported to happen in vivo. 
 
New tools exploring glycosidases: activity-based probes  
In 2010, Witte et al. were among the first to report the design of a fluorescent 
activity-based probes, APBs, visualizing active GBA molecules in complex 
biological samples (Witte et al. 2010). The ABPs for GBA have two structural 
elements: (1) the cyclophellitol-type “warhead” that covalently binds to the 
catalytic nucleophile of the enzyme, and (2) a variable reporter group which 
allows visualization of bound enzyme or its enrichment for identification 
through proteomics. The reporter group is linked to the warhead via a spacer 
(Kallemeijn et al. 2014; Willems et al. 2014c, d) (Figure 3). With biotin as 
reporter group, ABPs can be used for streptavidin-mediated enrichment, 
followed by identification of bound protein with proteomics. 
        The first described ABP for GBA consisted of a cyclophellitol with attached 
at C6 the spacer and reporter group (Witte et al. 2010). A hydrophobic extension 
at this position of cyclophellitol increases markedly the affinity for GBA and 




renders specificity (Kuo et al. 2019; Artola et al. 2019). Other β-glucosidases do 
not react with this ABP. Next, a cyclophellitol-aziridine type ABP was designed 
with the spacer and reporter attached to the nitrogen (Kallemeijn et al. 2012). 
This type of ABP reacts with all retaining β-glucosidases in class: GBA, cytosol-
faced GBA2, cytosolic GBA3 and lactase phlorizin hydrolase (LPH) (Kallemeijn 
et al. 2012).  
        After the generation of ABPs for β-glucosidases, a plethora of ABPs was 
developed for other retaining glycosidases by changing the cyclophellitol 
configuration. ABPs (usually cyclophellitol-aziridine type) are now available for 
the detection of α-galactosidases, β-galactosidases, α-fucosidases, β-
glucuronidases, α-glucosidases, α-iduronidases α-mannosidases, and β-
mannosidases (Willems et al. 2014a, b; Jiang et al. 2015, 2016; Marques et al. 





























Targeting enzymes Literature 
β-glucosidases Witte et al. 2010, Kallemeijn et al. 2012 
α-galactosidases Willems et al. 2014, Kytidou et al. 2017 
α-fucosidases Jiang et al. 2015 
α-iduronidases Artola et al. 2018 
α-glucosidases Jiang et al. 2016 
β-glucuronidases Wu et al. 2017 
β-galactosidases Marques et al. 2016b, not published 
α-mannosidases Not published 
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Figure 3. Activity-based probe (ABP) technology. A. ABP approach. B. ABP library.  
C. Reaction mechanism of epoxide and aziridine activity-based probes.  
 
        Several applications for glycosidase ABPs in both fundamental research 
and diagnosis of lysosomal diseases have meanwhile been developed (Kuo et al. 
2018). Firstly, the ABPs can be used to label active enzyme molecules and 
visualize these upon SDS-PAGE by fluorescence scanning. Thus, the MW of the 
target enzyme is detected and maturation by proteolytic processing or 
modification of N-glycans can be observed (Witte et al. 2010; Jiang et al. 2016). 
Secondly, the amphiphilicity of ABPs allows passage of membranes and the 
labeling of active enzymes in situ (Witte et al. 2010; Kallemeijn et al. 2012). 
Recently, correlative light electron microscopy (CLEM) was successfully used 
to visualize the location of active GBA molecules in individual lysosomes and 
the delivery of exogenous therapeutic enzyme to these organelles in cultured 
cells expressing mannose receptor (Van Meel et al. 2019). Infusion of ABPs in 
mice has allowed the detection of active enzyme molecules in various visceral 
tissues (Kallemeijn et al. 2012). The fluorophore in the ABP prevents effective 
passage across the blood-brain barrier. Labeling of GBA in the brain was 
accomplished by i.c.v. administration of ABP in rodents (Herrera Moro Chao et 
al. 2015). Another application concerns the convenient screening of libraries for 
inhibitors of the target glycosidases (Lahav et al. 2017). This method is based 
on detecting the competition of ABP labeling of a target enzyme by an inhibitory 
compound blocking the active site. Along the same line, the in-situ target 
engagement of cyclophellitol and conduritol B-epoxide (CBE), two suicide 
inhibitors of GBA, was recently determined (Kuo et al. 2019). Analyzed was 
possible interaction of cyclophellitol (CP) and CBE with the off-target enzymes 
Gba2, β-glucuronidase and retaining a-glucosidases GAA and GANAB after 
C.  Mechanism 
Aziridine ABP mechanism Epoxide ABP mechanism 




administration of the inhibitors to cultured cells or zebrafish larvae. The 
investigation revealed that CP inhibits GBA2 on a par with GBA and is 
therefore not suitable to generate a genuine GD model. Examination of mice 
exposed to relative low dose CBE administrations showed that GBA was 
selectively inhibited under these conditions (Kuo et al. 2019).  
        A great advantage of ABPs is that they label retaining glycosidases cross-
species as the result of conservation of catalytic pockets. This enables the use 
of such inhibitors not only for the detection of human hydrolases but also for 
the study of plant, bacterial and fungal enzymes. A recent study revealed the 
successful use of ABPs in detection and identification of β-xylosidases and endo-
β-1,4-xylanases in secretome of Asperigillus niger, for research of biomass 
breakdown (Schröder et al. 2019). Comparable examples are reported regarding 
use of ABPs in plant science. The van den Hoorn laboratory used β- and α-
glucosyl configured cyclophellitol ABPs in several plant species to identify 
various enzymes (Chandrasekar et al. 2014; Husaini et al. 2018). The β-glucosyl 
configured ABPs epoxide and aziridine were also used in plants during these 
experiments, data presented at chapter 6.  In addition, the use of α 
galactosidase ABPs in plants is described in this thesis chapters 3 and 4.   
        Together with the enormous progress in the use of ABPs in cells and 
organisms, the cyclophellitol-type inhibitors have proved to be valuable in 
biochemical investigations and crystallography, providing further 
understanding of mechanism of the glycosidases (Jiang et al. 2015; Ben Bdira 
et al. 2016, 2018; Wu et al. 2017). Finally, the application of ABPs for diagnosis 
of corresponding lysosomal diseases holds great promise (Aerts et al. 2011, this 







Scope of the thesis  
 
This thesis reports the study of retaining glycosidases in humans and plants. 
The major goal of the performed investigations has been to increase 
fundamental knowledge on the enzymes to contribute to translation into 
improved diagnosis and treatment of LSDs caused by deficiencies in lysosomal 
glycosidases. The first part of this thesis pays special attention to plants as 
platform for the production of recombinant enzymes for use in human 
glycosidases as well as source of endogenous enzymes with potential medical 
application. The second section is focused on the diagnostic value of the activity-
based probes as used towards urine and cultured cell materials.  
        At chapter 1 a brief introduction on the lysosomal storage disorders and 
glycosidases, both in human and plants, is presented. Chapter 2 reviews 
glycosylated metabolites from plants and their metabolizing enzymes. 
Discussed are the medical applications of plant glycoconjugates, with special 
emphasis to glycosylated lipids. The features of metabolizing plant β-
glucosidases and glucosyltransferases are described. The reaction mechanisms 
of glycosidases are discussed in detail and new chemical biology tools employed 
to investigate retaining glucosidases, so-called activity-based probes (ABPs) are 
introduced. The emerging use of plants as production platforms for therapeutic 
glycosidases is described.  
        Recombinant human glycosidases are presently used to treat patients with 
corresponding enzyme deficiencies. Traditionally, therapeutic enzymes 
employed in ERT were produced with cDNA technology in cultured Chinese 
hamster ovary (CHO) cells. More recently, alternative production platforms, 
including plants, have been used. Chapter 3 reports an investigation on the use 
of Nicotiana benthamiana as production platform (Figure 4) of three 
recombinant human α-galactosidases: α-galactosidase A (deficient in the 
lysosomal storage disorder Fabry disease), α-N-acetyl-galactosaminidase and a 
modified α-N-acetyl-galactosaminidase with increased α-galactosidase activity. 
The feasibility of production of human α-galactosidases in planta was studied 
and the efficacy of the recombinant enzymes to correct cultured fibroblasts of 
Fabry patients was examined.  




 Figure 4. Overview of transient overexpression of proteins in N.benthamiana leaves.  
 
        The abundant presence of endogenous α-galactosidase in Nicotiana 
benthamiana was observed with activity-based probe labeling. Chapter 4 
concerns an investigation on a novel α-galactosidase, named A1.1, from 
Nicotiana benthamiana. It was studied to which extent the enzyme resembles 
the human counterparts. In this analysis use was made of N-glycan detection 
and crystallography. The potential value of plant A1.1 to Fabry disease was 
examined by studying correction of stored glycolipids in cultured fibroblasts of 
Fabry patients.   
        Knowledge on the reaction itinerary led to the design of a new close mimic 
of the transition state, cyclosulfamidate. In chapter 5, the design of the 
cyclophellitol cyclosulfamidate is described and the outcome of studies on the 
ability of the compound to stabilize human and plant α-galactosidases in human 
serum and culture media is described. The findings with cyclosulfamidate are 
compared to those with deoxy-galactonojirimycin, a registered chaperone for 
human α-galactosidase A and the treatment of amenable Fabry patients. 
        In the last decade ABPs labeling various glycosidases have been designed 
and applied. The first ones involved cyclophellitol scaffold modified to 
fluorescently label retaining β-glucosidases. Since ABPs can be applied cross 
species to identify target glycosidases, the thesis reports a pilot investigation 
on plant β-glucosidase and the fungal α-galactosidase from Beano supplement. 
Chapter 6, reports the visualization of retaining β-glucosidases in tobacco BY2 
cell cultures via the use of activity-based probes. The identified enzymes 
belonged to GH families, 5, 3 and 17. Interestingly, some of the identified 
candidates showed activity towards the human lipid accumulated in Gaucher 
disease, Glccer. Further, the presence of the fungal (Asperigillus niger) α-
galactosidase in the dietary supplement Beano was detected via the use of 
activity-based probes. The dietary enzyme which is used to improve the 








infiltrated leaves  













        The ability to visualize active glycosidase molecules with fluorescent ABPs 
has potential diagnostic applications regarding inherited defects in enzymes 
underlying lysosomal storage diseases. Urine is known to contain considerable 
amounts of lysosomal glycosidases and to be a useful source for diagnosis of 
lysosomal glycosidase deficiencies. Chapter 7 concerns an investigation with 
cultured cells and urine samples regarding the diagnostic potential of ABPs 
visualizing distinct glycosidases. The findings of this thesis investigation are 
discussed in view of the literature and future research prospects are put 
forward in the discussion (chapter 8). Further, in chapter 8, the urinary 
activity-based protein profiling of patients experiencing kidney failures, such 
as diabetes, is being described. In more detail, detection of urinary heparanase 
in relation to kidney failure diseases is also discussed.  
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Plants contain numerous glycoconjugates that are metabolized by specific 
glucosyltransferases and hydrolyzed by specific glycosidases, some also 
catalyzing synthetic transglycosylation reactions. The documented value of 
plant-derived glycoconjugates to beneficially modulate metabolism is first 
addressed. Next, focus is given to glycosidases, the central theme of the review. 
The therapeutic value of plant glycosidases is discussed as well as the present 
production in plant platforms of therapeutic human glycosidases used in 
enzyme replacement therapies. The increasing knowledge on glycosidases, 
including structure and catalytic mechanism, is described. The novel insights 
have allowed the design of functionalized highly specific suicide inhibitors of 
glycosidases. These so-called activity-based probes allow unprecedented 
visualization of glycosidases cross-species. Here special attention is paid on the 
use of such probes in plant science that promote the discovery of novel enzymes 





















Plant metabolites and their glycosylation. Plants provide nutrition and the 
human body has evolved to thrive optimally on this nourishment. Besides the 
nutritional value, plant-derived food influences the microbiome in the 
gastrointestinal tract with physiological effects (Theilmann et al., 2017). Plants 
produce a huge variety of secondary metabolites that can be decorated with 
sugars, i.e. glycosylated (Jones and Vogt 2001; Gachon et al., 2005; Wink, 2015). 
Specific plant glycosyltransferases using nucleotide-sugars as donors can 
attach specific sugar moieties to an acceptor molecule (Henrissat and Davies, 
2000; Jones and Vogt, 2001). Glycosyl hydrolases, so-called glycosidases, 
remove specific sugar moieties. Most of these enzymes are retaining exo-
glycosidases (Coutinho et al., 2003). Some of these glycosidases are also able to 
synthetically transglycosylate in the presence of high concentrations of an 
acceptor molecule, a reaction implying the transfer of a sugar moiety from a 
substrate to an acceptor molecule (Morant et al., 2008).   
        Glycosylation of metabolites in plants serves multiple purposes. Upon 
glycosylation, hydrophobic metabolites become more water-soluble which 
improves their bio-distribution and metabolism (Kren and Martinkova, 2001; 
Pandey et al., 2014). Increased solubility and amphiphilicity of glycosylated 
metabolites may assist their transport across cell membranes (Vetter, 2000). 
The attachment of sugars to small metabolites raises their molecular weight 
and melting point. This allows synthesis and storage of precursors of volatile 
compounds that can be released on demand after hydrolysis (Ohgami et al., 
2015). The stability of glycosylated metabolites may depend on the position 
where the sugar moiety is attached, for example the 6-O-glucosides of ascorbic 
acid are chemically less stable than the 2-O-glucoside form or non-glycosylated 
ascorbic acid (Jones and Vogt, 2001). Furthermore, detoxification of harmful 
molecules can take place through glycosylation. Glycosylation may generate a 
non-toxic agent that later can be re-activated and used as aglycone in defense 
against parasites and plant-eating organisms such as herbivores. Examples are 
cyanogenic glycosides produced by plants. These consist of an α-hydroxynitrile 
group attached to a sugar moiety, often a D-glucose (Vetter, 2000). Release of 
cyanohydrin aglycone leads to spontaneous transformation to the 
corresponding ketone or aldehyde and release of hydrogen cyanide (prussic 
acid) (Cressey and Reeve, 2019). Hydrolysis of cyanogenic glycosides can be 
mediated by endogenous β-glucosidases when brought into contact with the 
substrate upon damaging of plant cells (Cressey and Reeve 2019). Additionally, 
hydrolysis may take place by the gut microbiome during digestion of plant 
material. The first identified cyanogenic glycoside was amygdalin isolated from 




almonds in 1830 (Robiquet and Bourtron-Charland, 1830). Cyanogenic 
glycosides are ubiquitous in plants, being identified in more than 2500 species 
(Vetter, 2000). The sugars attached to the aglycone may vary from a 
disaccharide to monosaccharide, usually glucose (Vetter, 2000; Haque and 
Bradbury, 2002; Cressey and Reeve, 2019). Cassava, M. esculenta, produces the 
cyanogenic glycosides linamarin and lotaustralin and consumption may cause 
severe pathology (Kamalu, 1991; Kamula, 1993). Finally, another example of 
regulating biological activity by glycosylation is provided by glycosylated 
phytohormones such as abscisic acid (ABA), auxin (IAA), cytokinins (CKs), 
brassinosteroids (BRs), salicylic acid and gibberellin that regulate growth, 
development, and responses to environmental stresses (Gachon et al., 2005). 
Glycosylation of phytohormones usually leads to inactive storage forms of plant 
hormones that can be hydrolyzed for activation, allowing rapid responses and 
maintaining the hormonal homeostasis (Kren and Martinkova, 2001; Stupp et 
al., 2013; Pandey et al., 2014).  
         In this review we pay attention to the natural occurrence of glycosides in 
plants with emphasis to glycolipids and touch upon their metabolizing 
enzymes. We address the use of plant lipids for therapeutic purposes as well as 
their potential harmful effects. Described is the increasing use of plants as 
production platforms for therapeutic enzymes, in particular glycosidases for the 
treatment of lysosomal storage disorders. Finally, we discuss the recent design 
of unprecedented tools to study glycosidases, cross-species. These so-called 
activity-based probes (ABPs) are modified cyclophellitols that allow in situ 
visualization of their target glycosidases. ABPs label glycosidases cross-species 
due to the highly conserved catalytic pockets and find many applications like 
discovery of glycosidases in several organisms, diagnosis of inherited lysosomal 
glycosidase deficiencies, visualization of tissue distribution and subcellular 
localization of endogenous and exogenous (therapeutic) glycosidases and the 
identification of therapeutic inhibitors and chaperones. 
 
Beneficial glycosylated plant metabolites 
 
Plant-derived agents and human health. Balanced consumption of vegetables 
is nowadays in the center of attention, particularly prompted by the worldwide 
epidemic of obesity and associated health problems. There is considerable 
interest in plant products from practitioners of regular medicine and 
pharmaceutical industry. Of note, the first generation of pharmaceuticals 
largely consisted of plant-derived products or minor chemical modifications 





with alternative medicine advocates stems in many cases from ancient use of 
such materials in traditional medicine.  
        The chemical structure of plant glycosides determines their biological 
action(s) and bioavailability (uptake). In this respect, attention is first paid to 
glycosylated flavonoids.  
        Glycosylated flavonoids. The predominant polyphenols in food (i.e. fruits, 
vegetables, nuts) and beverages (i.e. tea, wine) are flavonoids (Pandey and 
Rizvi, 2009; Pan et al., 2010). Plant flavonoids can be categorized into 
subclasses: flavonols, isoflavonols, flavones, flavanones, flavanols (catechins) 
and anthocyanidins (Ross and Kasum, 2002; Xiao et al., 2014). Daily 
consumption of several milligrams of flavonoids (25 mg to 1 g/day) is common 
(Hertog et al., 1993; Tsuda et al., 1999; Ross and Kasum, 2002). 
        Many plant flavonoids (see Figure 1 for general structures) are 
glycosylated (Day et al., 1998; Tohge et al., 2017). Glycosides are linked to the 
phenolic hydroxyls, via α- or β-D-glycosidic linkages (Murota and Terao, 2003). 
This type of modification may involve a single oligosaccharide or in some cases 
a polysaccharide moiety (Xiao et al., 2014). Commonly reported benefits of 
flavonoid glycosides are anti-oxidants and anti-inflammatory activities which 
find application in prevention and disease management (Lin and Harnly, 2007; 
Xiao et al., 2014). To illustrate this, some examples of each subclass are here 
discussed.  
        Flavonols are characterized by a phenolic substitution at position 2 of its 
3-hydroxyflavone backbone. Quercitin is a flavonol present in plants, fruits and 
vegetables. It can occur as diverse glucosylated forms: for example quercetin-
4’-O-β-D-glucoside or quercetin-3,4’-O-β-D-glucoside are predominant in onion 
with the glucose attached at the 3 or/and 4’ position of the phenol respectively 
(Murota and Terao, 2003) (Figure 1A). It has been suggested that phenolic 
hydroxyl groups contribute to the free radical scavenging activity of the 
molecules (Bors et al., 1990). The health benefits of quercetin are generally 
attributable to its anti-oxidant action positively impacting on glutathione and 
reactive oxygen species (Xu et al., 2019). The anti-oxidant action is in part 
mediated by the modulation of enzymes associated with oxidative stress like 
acetylcholinesterase and butyrylcholinesterase (Xu et al, 2019). Kaempferol, 
present in broccoli, apples, tea, strawberries and beans, is another flavonol with 
reported antioxidant and anti-inflammatory properties (Chen and Chen, 2013).  
        Whereas flavonols have an OH group at C-3, the flavones bear a hydrogen 
in that position (Figure 1B). Apigenin and luteolin are flavones found in plant 
food. Apigenin occurs in a wide variety of vegetables and fruits such as parsley, 
celery, chamomile, oranges, thyme, onions, honey and spices, as well as 
beverages derived from plants such as tea, beer and wine. It exists largely as 




C-glycosylated form, being more stable and reactive than the O-glycosylated 
counterparts. Apigenin is found to be absorbed as glycosylated structure and to 
exert antioxidant, anti-inflammatory and anti-cancer effects. For instance, 
glycosylated forms of apigenin with various pharmacological activities are 
apigenin 6-C-glucoside (isovitexin), apigenin 8-C-glucoside (vitexin), apigenin 
7-O-glucoside and apigenin 7-O-neohesperidoside (rhoifolin) (He et al., 2016). 
Luteolin, present in carrots, peppers, celery, olive oil, peppermint, thyme, 
rosemary and oregano, is reported to have antioxidant effects and it is assumed 
to inhibit angiogenesis, induce apoptosis and thereby prevent carcinogenesis in 
vivo (Lin et al., 2008). Well known glycosylated forms of luteolin in citrus fruits 
are luteolin 7-O-rutinoside and lucenin-2 (luteolin 6,8-di-C-glucoside). 
Furthermore, cynaroside, the 7-O-glucoside derivative of luteolin, is found in 
Lonicera japonica Thunb. and Angelica keiskei. and also shows anti-oxidant 
and anti-inflammatory activity (Lin et al., 2008; Lopez-Lazaro, 2009; Chen et 
al., 2012; Nho et al., 2018).  
        Isoflavones bear a phenolic moiety at position 3 instead of 2 (Figure 1C). 
Genistein, an isoflavone found predominantly in soy, and together with its 
glycosylated form genistin, is reported to provide multiple health benefits. 
Several studies demonstrated that genistein has anti-diabetic effects, in 
particular through direct positive effects on β-cells and glucose-stimulated 
insulin secretion. In addition, protection against apoptosis is reported, 
independent of its function as an estrogen receptor agonist, antioxidant action, 
and inhibition of tyrosine kinase activity (Fotsis et al., 1993; Record et al., 1995; 
Allred et al., 2001; Pandey et al., 2014).  
        Flavanones are characterized by a saturated C2-C3 bond in the C ring and 
normally occur as a racemic mixture (Figure 1D). Hesperidin, a 7-O-rutinoside 
flavone, is a natural product with a wide range of biological effects, in particular 
it presents inhibitory effect against the development of neurodegenerative 
diseases (Hajialyani, 2019). Hesperidin, a dietary flavanone, and its aglycone 
hesperetin, are found predominantly in citrus fruits such as oranges and 
lemons. These compounds are considered to exert beneficial anti-inflammatory 
and anti-oxidative action (De Souza et al., 2016).  
        Flavanols (a.k.a. catechins) have a 2-phenyl-3,4-dihydro-2H-chromen-3-ol 
skeleton and are mainly found in tea. Contrary to other flavonoids, flavanols 
are often not glycosylated and their glycosylation normally decreases anti-
oxidant activity (Plumb et al., 1998). The beneficial effects of green tea have 
been attributed to its high content of polyphenolic catechins, including catechin 
(C), (−)-epicatechin (EC), (−)-epigallocatechin (EGC), (−)-epicatechin-3-gallate 
(ECG), and (−)-epigallocatechin-3-gallate (EGCG) (Figure 1E). Among them, 





reactive oxygen species (ROS) scavenger and metal ion chelator, and it finds 
application in prevention of disease caused by oxidative stress, such as cancer, 
cardiovascular diseases, neurodegenerative disease, neuropathic pain and 
diabetes (Roghani and Baluchnejadmojarad, 2009; Xifró et al., 2015).  
        Anthocyanidins possess a 2-phenylchromenylium ion backbone and are 
the deglycosylated version of anthocyanins (Figure 1F). Anthocyanins are 
abundant pigments in many red berries with documented antioxidant action. 
Examples are cyanidin-3-O-rutinoside and cyanidin-3,5-O-diglucoside (Feng et 
al., 2016). Likewise, anti-inflammatory properties are reported for the 
anthocyanidin malvidin-3’-O-β-D-glucoside and malvidin-3’-O-β-D-galactoside 
in blueberries by blocking the NF-κB pathway mechanism (Huang et al., 2014). 
        To which extent glycosylation of flavonoids contributes to their beneficial 
action is not always well understood. Glycosylation of flavonoids might favor 
bioavailability and uptake into the body. One advantage of glycosylation is that 
it can stabilize the molecules, preserving their structural integrity and 
therefore enabling their accumulation. In addition, glycosylation serves as a 
transport signal among the different compartments of the plant cell. For 
example, cyanogenic glucosides are transported only in their glycosylated form 
(Jones and Vogt, 2001). Flavonoid glycosides may be converted to their aglycons 
prior to absorption by intestinal epithelial cells. However, some glycosylated 
flavanoids are apparently also absorbed as such (for example, cyanidin-3-O-β-
D-glucoside and glycosylated apigenin) (Murota and Terao, 2003; Xiao et al., 
2014; Xio et al,. 2016). The linked sugar moiety, the type of linkage (O- versus 
C-) and the position of the glycoside attachment may influence the bioactivity 
of a flavanoid. An example of the latter forms the inferior free radical 
scavenging of quercetin-4’-O- β-D-glucoside compared to quercetin-3-O-β-D-
glucoside (Yamamoto et al., 1999). This difference is due to the fact that the 
flavonoids’ free radical scavenging activity depends on phenolic hydroxyl 
groups which act as electron donors. In particular, a catechol moiety with two 
neighboring hydroxyls has high electron donation ability (Murota and Terao, 
2003). The antioxidant activities of glycosylated flavonoids can partly be also 
attributed to their chelation action, with the catechol group also playing a key 
role in the process (Murota and Terao, 2003). Interestingly, C-glycosylation 
enhances some of the beneficial traits of flavonoids such as their antioxidant 
and anti-diabetic activities. O-glycosylation is reported to reduce flavonoid 
bioactivity and absorption (Hostetler et al., 2012; Xiao et al., 2014).    
        The anti-inflammatory effects of flavonoids can be attributed to reduction 
of cytokine-induced inflammation by the inhibition of tumor necrosis factor-α 
(TNF-α) signalling and reduced expression of pro-inflammatory genes by down-
regulation of NF-κB (Ramos, 2007; Pan et al., 2010; Huang et al., 2014). An 




example is provided by the anti-inflammatory flavonol kaempferol which is 
present in broccoli, tea and vegetables. During osteoporosis, pro-inflammatory 
cytokines, e.g. TNF-α, are expressed and cause bone disruption and further 
cytokine production. Kaempferol antagonizes the TNF-α induced production of 
interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP1a), as well as 
the RANKL triggered osteoclast precursor cell differentiation (Pang et al., 2006; 
Pan et al., 2010). Another example is the anti-inflammatory effect of 
glycosylated anthocyanins present in blueberries, malvidin-3-O-glucoside and 
malvidin-3-O-β-D-galactoside. These molecules reduce the levels of MCP1, 
intercellular adhesion and vascular cell adhesion molecule-1 at protein and 
mRNA level in endothelial cells through the inhibition of TNF-α. In addition, 
they block the NF-κB pathway by affecting IκBα degradation and the nuclear 
translocation of p65 (Huang et al., 2014). 
        For many flavonoids miscellaneous anti-cancer effects have been reported. 
The presumed modes of action of flavonoids as anti-cancer agents are diverse 
and the role of glycosylation in such anti-tumor effect is often not well 
understood. Examples of flavonoids with reported anti-tumor action are 
kaempferol (Ramos, 2007; Chen and Chen, 2013), peonidin 3-O-β-D-glucoside, 
genistein, genistin and EGCG (Fotsis et al., 1993; Record et al., 1995; Allred et 
al., 2001; Pandey et al., 2014; Xifró et al., 2015). Genistein and genistin are 
however also reported to stimulate breast cancer cells in vivo at very low 
concentrations (nM range), acting as estrogen agonists in mice mammary 
glands (Allred et al., 2001). Daidzin of soybeans is another well-studied 
isoflavone 7-O-β-D-glucoside with similar anti-cancer properties as genistein. 
Anti-cancer action has also been documented during the last decades for 
apigenin, hesperidin and its aglycone hesperetin (Madunić et al., 2018). 
        Plant-derived cardiac glucosides are secondary metabolites consisting of a 
steroid backbone functionalized with a lactone ring at the 17-β position and a 
sugar moiety at the 3-β position (Figure 1G). Cardiac glycosides can be 
classified as cardenolides or bufadienolides depending on the 5- or 6-membered 
lactone ring, respectively. Cardenolides are known since ancient times for their 
positive effects on cardiac arrhythmia, congestive heart failure and atrial 
fibrillation (Nesher et al., 2007). Their main role as antiarrhythmic agents is 
based on their ability to inhibit the Na+/K+ ATPase ion pump, thus increasing 
intracellular potassium concentrations (Kelly, 1990; Kepp et al., 2012; Patel, 
2016). In response to this, intracellular calcium increases which promotes more 
efficient myocardial contraction and improves cardiac pump activity (Newman 
et al., 2008). Well known examples of therapeutic cardiac glycosides are digoxin 
and digitoxin from the foxglove plant Digitalis. Even though the positive effects 





issue (Ehle et al., 2011). Bufadienolides are present in very low amounts in 
plants and are prominent in animals such as the toad (Bufo), fireflies (Photinus) 




Figure 1. Glycosylated plant metabolites beneficial for humans. Flavonoids and some of their 
glycoside metabolites: flavonols (A), flavones (B), isoflavones (C), flavanones (D), flavanols (E) and 





Diacylglycerols. Plants contain diverse glycosylated lipids. Galactosylated 
diacylglycerols are ubiquitous glycolipids in plants. They are predominantly 




found in photosynthetic tissues, such as the leaf. In particular, chloroplast 
thylakoid membranes contain high quantities of monogalactosyldiacylglycerol 
(MGDG) and digalactosyldiacylglycerol (DGDG) (see figure 2A for the chemical 
structure and cellular localization) (Hölzl and Dörmann, 2019). For instance, 
MGDG and DGDG account to 36% and 20%, respectively, of spinach chloroplast 
glycerolipids. Less abundant are the acidic sulfoquinovosyldiacylglycerol (5%), 
and other glycerophospholipids (Wintermans, 1960). Of note, the existence of 
acylated MGDG (acylMGDG) has also been documented by Nilsson et al. 
(Nilsson et al., 2015) and their concentration is increased during environmental 
stresses such as frost. Glucosylated diacylglycerols are far rarer than 
galactosylated counterparts in plants and animals. 1,2-Di-O-acyl-3-O-β-D-
glucopyranosyl-sn-glycerol has however been found in rice bran (Holst, 2008). 
        Sphingolipids. Glycosylated sphingolipids (glycosphingolipids) in which 
sugar(s) are attached to ceramide are very abundant in animal cells. Distinct 
sphingolipids exist in plants (see figure 2B for the chemical structure and 
cellular localization). Plants produce, like animals, the simple 
glycosphingolipid glucosylceramide (GlcCer) where glucose is β-linked to a 
phytoceramide that differs from animal ceramide in the composition of the 
sphingosine moiety (also referred as long-chain base (LCB)) (Spassieva and 
Hille, 2003; Pata et al., 2010; Ali et al., 2018; Huby et al., 2019). Another 
glycosylated sphingolipid in plants is glucosylinositol phosphoryl ceramide 
(GIPC) (Ali et al., 2018). Whereas in animals the major sphingosine base is C18 
LCB, in plants over 9 different LCBs have been identified. In addition, the 
presence of dienes in the plant sphingosine bases is rather common (Pruett et 
al., 2008; Ali et al., 2018). Plant LCBs can occur in very low concentrations in 
cells, but they are mainly present as backbones of ceramides that further 
contain linked fatty acid chains (C16-C26). The ceramides are next glycosylated 
forming GlcCer and/or glucosylinositol phosphoryl ceramides (GIPC) (Ali et al., 
2018). In plants, elongation of glucosylceramide to oligoglycosylceramides 
occurs with either mannosyl or galactosyl units (Lynch and Dunn, 2004). In the 
common mannosyl series in higher plants, up to four mannosyl units may be 
added via β1→4 linkages. Oligoglycosylceramides are present in the 
endoplasmic reticulum (ER), Golgi apparatus, vacuole membrane and plasma 
membrane. Sphingolipids and their glycosylated forms together with plant 
sterols are important constituents of the lipid rafts of the plasma membrane 
(Msanne et al., 2015). The complex GCIPC are considered as the equivalents of 
complex glycosphingolipids like gangliosides in animal cells (Gronnier et al., 
2016; Cacas et al., 2016). They play important roles in regulation of cellular 
processes, such as cell wall formation, programmed cell death, drought and salt 





        Phytosterols (plant sterols and stanols). Phytosterols, also known as 
xenosterols, are essential components of plant cells that are predominantly 
found in cell membranes (Hartmann, 1998). They include plant sterols and 
stanols (saturated sterols without double bonds in the sterol ring) (see figure 
2C for chemical structure and cellular localization). Their chemical structure 
consists of a sterol body; a cyclopentano-perhydro-phenanthrene ring system 
(formed by four rigid rings) with a hydroxyl group at position C-3 and a side 
chain attached to the carbon C-17 (Figure 2C). Differences in the nature of the 
side chain gives a plethora of diverse sterols in plants, accounting to more than 
260 different ones, as described over the last decades (Vanmierlo et al., 2015). 
The most abundant phytosterols in human diet are β-sitosterol, campesterol, 
campestanol and stigmasterol. Their structure is similar to the structure of the 
mammalian sterol, cholesterol. Phytosterols structurally differ from cholesterol 
only at the length and saturation of their aliphatic side chain. For instance, 
campesterol has an additional methyl group at its side chain, at C-24 position 
(Mamode Cassim et al., 2019). It is important to mention that plants also 
contain small amounts of cholesterol (Hartmann, 1998).         Phytosterols are 
mainly found in vegetable oils, seeds and nuts and in less extent in fruits and 
vegetables (Amiot et al., 2011). Phytosterols play important roles in several 
biological processes. For instance, campesterol is found to act as a precursor at 
the biosynthesis of brassinosteroids, hormones that regulate plant growth, 
development and morphogenesis. In addition, β-sitosterol and stigmasterol are 
mainly involved in the maintenance of cell membranes, and together with 
sphingolipids, form the lipid rafts (Amiot et al., 2011; Ferrer et al., 2017). 
Phytosterols are also involved in responses to biotic and abiotic stresses (Ferrer 
et al., 2017). A characteristic example is the formation of stigmasterol in 
Arabidopsis leaves after inoculation with specific bacteria. In general, plant 
sterols play a key role in the innate immunity of plants against bacterial 
infections via regulating the nutrient efflux in the apoplast (Griebel and Zeier, 
2010; Wang et al., 2012). In addition, tolerance to aluminum is shown to be 
influenced positively by the high sterol and low phospholipid contents in the 
root tip of plants. This results in a less negatively charged plasma membranes, 
tolerating better aluminum (Wagatsuma et al., 2014). At last, drought tolerance 
is also associated with sterol composition of the plants as studied via using the 
drought hypersensitive/squalene epoxidase 1‐ 5 mutants in Arabidopsis (Posé 
et al., 2009). 
        Glucosylated phytosterols and medicinal properties. Conjugated forms of 
phytosterols occur. Examples are the steryl glycosides (SG) (sometimes referred 
to as sterolins) and their acylated forms; the acyl steryl glycosides (ASG). In 
plant SG, the sugar moiety, often a glucose, is attached at the C-3 hydroxyl 




group of the sterol. When the sugar moiety is further acylated with a fatty acid 
at the primary alcohol (C-6 carbohydrate numbering), ASG is formed (Grille et 
al., 2010; Nyström et al., 2012) (Figure 2C). The first glycosylated plant sterol 
to be purified was ipuranol from the olive tree in 1908. A few years later it was 
identified as β-sitosteryl-D-glycoside. ASGs were next discovered in lipid 
extracts of soybean seeds and potato tubers (Grille et al., 2010). Plant 
glycolipids occur in different amounts and in different composition among plant 
species even in different tissues from the same plant. High levels of SG and 
ASG occur in Solanum species, accounting to more than 50 % of the total sterol 
levels (Nyström et al., 2012; Ferrer et al., 2017). SG and ASG levels are high in 
fruit, vegetable juices, beer, wine as well as in tomatoes and potatoes (Decloedt 
et al., 2018).   
        SGs and ASGs play important roles in biological processes such as 
maintenance of the plasma membrane organization and they allow adaptive 
responses to environmental changes (Mamode Cassim et al., 2019). Several 
studies using forward and reverse genetic approaches have revealed the import 
role of SGs and ASGs in plants during different environmental stresses. An 
example is provided by transgenic Arabidopsis and tobacco plants, 
overexpressing a sterol glycosyltransferase from W. somnifera, showing 
increased tolerance towards salt, heat and cold. Furthermore, downregulation 
of the same gene product results in increased susceptibility to plant pathogens 
(reviewed in Ferrer et al. 2017). SGs and ASGs are also present in pollen and 
phloem sap of Arabidopsis. It has been hypothesized that SGs act as primers of 
cellulose synthesis (Ferrer et al., 2017). The attached sugar to the sterol 
increases drastically the hydrophilicity of phytosterols and might increase the 
ability to interact with proteins embedded in membranes as well as with other 
glycolipids in lipid rafts. The same has been proposed for the amphiphilic 
cardiac glycosides ouabain and digitalin (Tabata et al., 2008). 
        Phytosterols are nowadays widely used as food additives aiming to lower 
plasma LDL cholesterol and reduce cholesterol absorption in humans. Already 
in the early 1950s, intake of plant sterols was reported to reduce the total 
plasma cholesterol and LDL-cholesterol and cholesterol absorption efficiency 
(Peterson, 1951). After this, a vast number of studies and clinical trials 
demonstrated cholesterol-lowering effects of a phytosterol-rich diet. This led to 
the industrial production of phytosterol enriched food products such as 
margarines and yogurts (Abumweis and Jones, 2008; Amiot et al., 2011; 
Trautwein et al., 2018; Nakano et al., 2019). It is generally accepted that 1-3 g 
of a daily dose of phytosterols leads to a 10-15% decrease of total cholesterol 
levels and also decreases plasma LDL-cholesterol (Patel et al., 2018; Nakano et 





        The metabolic response to phytosterols varies among individuals (Jones, 
2015). This can be due to genetic differences, for example in genes encoding 
ApoE and CyP7A1. Of particular interest in this connection are also ATP-
binding cassette (ABC) subfamily G member 5 (ABCG5) and member 8 
(ABCG8), which are proteins involved in phytosterol transport. Mutations in 
ABCG5 or ABCG8 cause sitosterolemia, a devastating disease first described 
by Bhattacharyya and Connor in 1974 (Bhattacharyya and Connor, 1974; Tada 
et al., 2018; Plat et al., 2019). The ABCG5 and ABCG8 proteins act as 
heterodimers, forming together with other proteins a functional sterol 
transport complex, and are expressed in hepatocytes, gallbladder epithelium, 
and enterocytes. ABCG5/ABCG8 excretes phytosterols and other xenosterols 
from cells, even better than cholesterol. Impaired ABCG5/ABCG8 leads to 
accumulation of phytosterols in the body causing macrothrombocytopenia, 
platelet dysfunction, liver disease, cholesterol accumulation with xanthoma 
formation and atherosclerosis (Silbernagel et al., 2013; Patel et al., 2018). 
        Little is still known on the impact of SGs and ASGs on the human body. 
The β-sitosterol-β-D-glycoside (BSSG) is relatively abundant in the human diet 
(Decloedt et al., 2018). Both β-sitosterol (BSS) and its glycosylated form are 
found in human plasma and tissues in very low levels, at 800-1000 less 
compared to endogenous cholesterol (Pegel, 1997). It has been shown that upon 
chronic high intake plant sterols accumulate in the brain (Vanmierlo et al., 
2012; Saeed et al., 2015). Even though the mammalian blood brain barrier 
(BBB) is not, or very poorly, permeable to cholesterol, studies have shown that 
phytosterols like sitosterol and campesterol are able to cross the BBB in mice.  
        BSS and BSSG are proposed to exert beneficial anti-inflammatory actions 
and to reduce mild hypercholesterolemia (Bouic et al., 1999). Bouic et al. 
observed that administering a mixture of BSS/BSSGs to marathon runners had 
a positive effect on the immune system under physical stress conditions (Bouic 
et al., 1999). On the other hand, BSSGs were also found to be toxic to motor 
neurons in vitro (Tabata et al., 2008). The exposure to high amounts of BSSGs 
amounts present in the seed of the cycad tree (Cycas micronesica) has been 
speculated to underly the historical high prevalence of the neurodegenerative 
disease amyotrophic lateral sclerosis–parkinsonism dementia complex (ALS–
PDC) at the island of Guam (Tabata et al., 2008). Indeed, feeding of BSSGs to 
rats is found to cause several neurological signs and defects resembling those 
occurring in Parkinson disease patients, such as α-synuclein aggregates, motor 
abnormalities and striatal dopamine loss (Shen et al., 2010; Van Kampen et al., 
2014; Kampen et al., 2015; Franco et al., 2018). Van Kampen and co-workers 
successfully induced Parkinsonism in Sprague Dawley rats by feeding them 
with BSSG for 4 months (Van Kampen et al., 2014).  





Figure 2. Different classes of plant lipids and their localization in the plant cell. A. Chemical 
structures of plant glycosylated lipids: monogalactosyldiacylglycerol (MGDG) and 
digalactosyldiacylglycerol (DGDG). B. Chemical structures of plant (glycosyl)sphingolipids: long-chain 
base (LCB) 4,8-sphingadienine, ceramide (Cer), glucosylceramide (GlcCer), glucosylinositol phosphoryl 
ceramides (GIPC) and oligoglycosylceramide. C. Chemical structures of plant sterols (green) versus the 
animal counterparts (blue). Plant cell image illustrating the localization of lipid classes: A. stands for 





Absorption and metabolism of plant glycoconjugates 
 
Knowledge on the absorption and metabolism of individual plant 
glycoconjugates is warranted to better understand their mechanism of action. 
It appears that upon ingestion the fate of individual glycoconjugates may 
fundamentally differ.  
        Uptake of glycosylated flavonoids. For decades it was widely believed that 
prior to uptake in the body glycosylated flavonoids, such as quercitrin, rutin 
and robinin, common components of human diets, were first deglycosylated by 
intestinal glycosidases and bacterial enzymes in the intestine (Griffiths and 
Barrow, 1972; Bokkenheuser et al., 1987). Only the produced aglycones would 
be partially absorbed in the large intestine (Walle, 2004). Following uptake, 
flavonoids are glucuronidated, O-methylated or sulphated in the liver. Part of 
them are subsequently excreted into the bile and undergo enterohepatic cycling 
to finally being eliminated by renal excretion (Murota and Terao, 2003). An 
example of such metabolism is that of the flavanone hesperidin, mainly found 
in citrus fruits such as oranges and lemons. Hesperidin (hesperetin with a 
linked rutinoside moiety) is absorbed as the aglycone hesperetin, after removal 
of the glycose moiety by intestinal bacteria. However, rapid absorption of α-
glucosylated hesperidin (G-hesperidin) containing an additional linked α-
glucosyl moiety has been observed, possibly due to its high-water solubility (De 
Souza et al., 2016). It has become apparent that deglycosylation of some 
flavonoids may not depend on intestinal bacteria. Saliva has been also 
suggested to play a role in the hydrolysis of the dietary flavonoids. Browning et 
al. in 2005 performed a study on different glycosylated flavonoids like 
quercitrin, rutin, isoquercitrin, spiraeoside, genistin, naringin and phloridzin 
(Browning et al., 2005). Their findings suggest that saliva enzymes may 
hydrolyze the glycosylated flavonoids, in particular, glucosides. For instance, 
quercetin 4-glucoside and genistein 7-glucoside, found in high amounts in 
dietary products, are rapidly hydrolyzed in the oral cavity. Saliva is also 
suggested to already hydrolyze quercetin glucosides (Hirota et al., 2001).  
        Dietary glycosylated anthocyanins, such as cyanidin-3-glucoside and 
cyanidin-3,5-diglucoside, are absorbed in intact form (Miyazawa et al., 1999). 
Quercetin glycosides are known to be taken up in the small intestine via the 
sodium dependent glucose transporter SGLT1 (Hollman et al., 1995; Walgren 
et al., 1998; Walgren et al., 2000). Phloridzin, the glucoside of the flavonoid 
phloretin, was also found to be transported by SGLT1 (Walle and Walle, 2003). 
Takahashi et al. recently observed that intestinal absorption of galactosylated-
cyanidin is inferior to that of the glucosylated one (Takahashi et al., 2019). Of 
note, absorbed glycosylated anthocyanins may pass the BBB and reach 




different brain regions like the cortex and hippocampus (Milbury et al., 2002; 
Milbury and Kalt, 2010; Zhang et al., 2019).  Phloridzin and other flavonoid 
glycosides (quercetin and genistein) have also been identified as substrates for 
efflux by the multidrug resistance-associated protein transporters MRP1 and 
MRP2 (Walle and Walle, 2003). Thus, dietary glycosylated anthocyanins seem 
to manage to reach visceral tissues and the brain by hijacking glucose 
transporters and are actively removed by MRPs. 
        Uptake of (glycosylated) phytosterols. In the lumen of the intestine the 
poorly water-soluble phytosterols are incorporated into micelles that allow close 
contact with the surface of enterocytes (Gylling et al., 2014). Next, phytosterols 
are thought to be internalized by the mucosal intestinal cells via the Niemann–
Pick C1-Like1 (NPC1L1)-transporter. Subsequently, plant sterols are re-
secreted into the lumen of the intestine via ABCG5/ABCG8 transporter 
complex (as discussed in section 3). In the liver, the ABCG5/ABCG8 complex 
mediates efflux of plant sterols into bile (Gylling et al., 2014). Plant sterols 
manage to pass the BBB and therefore potentially may influence brain function 
(Jansen et al., 2006; Vanmierlo et al., 2012). This notion raises considerations 
regarding excessive consumption of olive oil containing high amounts of plant 
sterols.  The poor solubility of phytosterol in both water and oil limits 
absorption. Esterification of phytosterols increases their solubility in oil and 
margarine (Ostlund, 2004). Regarding glycosylated phytosterols it is clear that 
these reach tissues, including the brain (see section 3). Relatively little is 
however known with respect to transporter proteins involved in the uptake 
glycosylated sterols. They have been reported to be absorbed intact and exert 
as such their effects (Lin et al., 2009; Lin et al., 2011). 
 
Plant β-glucosidases and glucosyltransferases  
 
Classification of glycosidases. All domains of living organisms contain multiple 
glycoside hydrolases (GHs, glycosidases). These enzymes play a variety of 
functions, including the lysosomal metabolism of glycolipids in animals, the 
catabolism of cell wall polysaccharides in plants and biomass conversion in 
microorganisms (Leah et al., 1995; Ketudat Cairns and Esen, 2010). More than 
160 GH families have been listed in the Carbohydrate Active EnZymes (CAZy) 
database using a classification system based on amino acid sequence and 
secondary structure similarities (Henrissat, 1991; Ben Bdira et al., 2018). This 
classification system is regularly updated and new families are continuously 
discovered. Additionally, the enzymes are classified based on their reaction 
mechanism, according to the stereochemical outcome of the hydrolytic reaction, 





glycosidases are also classified as exo- or endo-enzymes, depending on their 
ability to cleave at the end or in the middle of a carbohydrate chain.  
        Plants contain numerous carbohydrate active enzyme-encoding genes, 
more than any other organism. For instance, Arabidopsis contains over 400 
different genes encoding glycosidases (Husaini et al., 2018). This complexity 
stems from gene duplications and has likely been promoted by the increasingly 
complex plant cell wall structure, as described for Arabidopsis by Bowers et al. 
(Bowers et al., 2003). Some proteins, based on homology designated as 
glycosidases or glycosyltranferases might have further evolved to act on 
different types of substrates or to fulfill other non-enzymatic functions 
(Coutinho et al., 2003). An example is the soybean hydroxyisourate hydrolase. 
Even though the enzyme has a highly conserved retaining β-glucosidase active 
site, it catalyzes the hydrolysis of 5-hydroxyisourate (Raychaudhuri and Tipton, 
2003). Therefore, caution when talking about plant glycosidases and 
glycosyltransferases is necessary.  
        Particularly ubiquitous in plants are β-glucosidases. Most plant β-
glucosidases (E.C.3.2.1.21) are mainly classified in the glycoside hydrolase 
family 1 (GH1) of the CAZy database. However, some plant β-glucosidases are 
grouped in GH families 5 and 30. They all fall in GH Clan A, and contain similar 
(β/α)8-barrel structures. They consistently share an active site with two 
catalytic residues (Morant et al., 2008; Ketudat Cairns and Esen, 2010). Their 
main activity, even though it is not restricted, accounts to the hydrolysis of the 
β-glucosidic bond between carbohydrates or between a sugar and an aglycone 
moiety.  
        Plant β-glucosidases play a number of important biological roles. For 
instance, they are involved in cell wall degradation during endosperm 
germination (Leah et al., 1995). The enzymes together with other plant and 
microbial glycosidases and glycanases degrade the plant cell wall, leading to 
formation of intermediates for cell wall lignification (Dharmawardhana et al., 
1995; Escamilla-Treviño et al., 2006). Over different enzymes have been 
reported taking a part in this process (Mohnen, 2008). Furthermore, β-
glucosidases are involved in activation of phytohormones (Kristoffersen et al. 
2000; Lee et al. 2006). They participate in plant defence mechanisms via 
activating several chemical defence compounds, like phytohormones, flavonoids 
and cyanogenic glucosides (Nisius, 1988; Poulton, 1990; Suzuki et al., 2006; 
Morant et al., 2008). For instance, a cyanogenic glucosidase (linamarase) from 
cassava and white clove is able to cleave glucosides from glucosylated 
cyanosides releasing toxic HCN as a defence mechanism (Oxtoby et al., 1991; 
Hughes et al., 1992). In addition, a β-glucosidase from maize was found to be 
active towards cytokinin-O-glucosides and kinetin-N3-glucoside, releasing 




active cytokinin (Brzobohaty et al. 1993). Furthermore, they are reported to 
release volatiles like flower scents from their glycoside storage forms (Sarry and 
Günata, 2004). Due to the high number of different plant glucosides, it is very 
likely that plant glucosidases play other roles that are yet to be discovered.  
        Catalytic mechanism of glucosidases. Two carboxyl-exposing residues in 
the active site of both inverting and retaining β-glucosidases enzymes take part 
in the hydrolysis of the glycosidic bond (Koshland, 1953). In the case of 
inverting enzymes, these two groups are separated at a distance of 6-12 Å, 
whereas in retaining enzymes, this is ~5 Å. The inverting reaction is a single 
step reaction; a direct displacement of the aglycone, where one carboxylic group 
is acting as the base and it activates a water molecule that hydrolyses the 
glycosidic bond through a nucleophilic attack at the anomeric centre (Guce et 
al., 2010) and at the same time, the second carboxylic acid facilitates the 
departure of the leaving group via acid catalysis. On the contrary, retaining 
glycosidases employ a double displacement mechanism (Koshland, 1953). The 
reaction initiates with the nucleophilic attack to the anomeric center, resulting 
in a glycosyl-enzyme covalent intermediate. Then, the deprotonated 
carboxylate acts as a base and deprotonates a water molecule, that now plays 
the role of a nucleophile, to hydrolyze the covalent intermediate giving the 
reaction product. The transfer of a released sugar from a substrate to an 
acceptor other than a water molecule is called transglycosylation, and has been 
observed for several retaining glycosidases (Hehre, 2001; Sinnott, 1990). The 
acceptor molecules can be sugars, as in the case of chitotriosidase (Aguilera et 
al., 2003), but also retinol or sterol in the case of glucocerebrosidase, the human 
β-glucosidase (Vanderjagt et al., 1994). Akiyama and Marques reported the use 
of glucosylceramide as sugar donor in the formation of cholesterol glucoside via 
β-glucosidase mediated transglucosylation (Akiyama et al., 2013; Marques et 
al. 2016a). Several examples of transglycosylation activity of plant and 
bacterial glycosidases have also been reported (Crout and Vic, 1998; Morant et 
al., 2008).  
        Glycosyltransferases. The carbohydrate active enzyme (CAZy) database 
currently contains 110 glycosyltransferases (GTs). In plants, GTs have many 
functions, for example in the biosynthesis of glycosylated metabolites, 
oligosaccharides, polysaccharides (cellulose, hemicelluloses, and pectins among 
others) and glycoproteins in the plant cell membrane (Hansen et al., 2012). The 
polysaccharides and other glycans are mainly synthesized by 
glycosyltransferases (GTs; EC 2.4.x.y). Most GTs (Leloir GTS) transfer a sugar 
residue from an activated nucleotide sugar to a specific acceptor molecule, with 
high specificity for the sugar donor and the acceptor substrates (Breton et al., 





glycosylation results in net retention or inversion of stereochemistry at the 
anomeric carbon of the donor substrate. GTs are classified in the CAZy 
database into families on the basis of amino acid sequence similarities 
(Cantarel et al., 2009). Two major folds of structures of nucleotide–sugar-
dependent GTs solved to date are observed, termed GT-A and GT-B (Hansen et 
al., 2010). Many GT-Bs are independent of a metal ion for catalysis, whereas 
most GT-A enzymes contains a conserved DxD motif that coordinates the 
phosphate atoms of the nucleotide donors via coordination of a divalent cation, 
usually Mn2+ or Mg2+ (Breton et al., 2005). Besides glycosyltransferases using 
sugar mono- or diphosphonucleotide donors, known as Leloir type GTs, two 
additional group of glucosyltransferases occur: non-Leloir-type GTs which 
employ sugar lipid phosphates, pyrophosphates or polyprenol phosphates as 
donors, and non-activated acyl-glucose dependent glucosyltransferases. This 
last group of enzymes are transglucosidases related to GH1 family hydrolases. 
One example of this is the rice β-glucosidase Os9BGlu31 that uses 
glucopyranosides as well 1-O-acyl glucose esters as sugar donors in synthetic 
reactions (Luang et al., 2013; Komvongsa et al., 2015).  
 
New tools to explore “plant” glycosidases; Activity based 
probes (ABPs) for retaining glycosidases 
 
Detailed knowledge on the reaction mechanism of retaining glycosidases has 
allowed the generation of ABPs, a new class of versatile research tools (for a 
recent review see Wu, 2009).   
        ABPs, principles and applications through time. The idea to exploit 
covalent inhibitors of active enzymes as ABPs was firstly put forward for 
esterases by Ostrowski et al. in 1961 (Ostrowski and Barnard, 1961). The 
concept was further pioneered by Cravatt and co-workers for several enzyme 
classes. Now, ABPs have been designed for kinases, proteases, serine 
hydrolases, lipases and glycosidases (Cravatt et al., 2008; Witte et al., 2010; 
Witte et al., 2011; Serim et al., 2012; Baggelaar et al. 2013).  
        In the case of retaining glycosidases, the use of irreversible inhibitors 
optimally mimicking the oxocarbenium ion-like transition state of the target 
enzyme has promoted the design of diverse ABPs. Withers et al. first proposed 
the use of fluorinated inhibitors for targeting human β-glucosidase (Wicki et al., 
2002; Goddard-Borger et al., 2010). Chauvigné-Hines and co-workers generated 
difluoromethylphenyl aglycone, N-halogenated glycosylamine, and 2-deoxy-2-
fluoroglucoside activity-based probes to identify reactive glycosidases in the 
cellulosomal secretome of Clostridium thermocellum (Chauvigné-Hines et al., 




2012). Their study identified a wide number of cellulases, xylanases, 
hemicellulases and carbohydrate active enzymes. More specific, they were able 
to identify both inverting and retaining enzymes that were listed in different 
GH families. Some of them play an important role in the degradation of 
cellulose: GH9 (inverting) cellulase enzymes, a number of GH5 (retaining) 
endoglucanases, and GH10 and GH11 (retaining) xylanases (Chauvigné-Hines 
et al., 2012).  
        The first retaining β-glucosidase for which a high affinity and highly 
selective ABP was designed has been human glucocerebrosidase. A decade ago, 
Witte et al. demonstrated that cyclophellitol based ABPs irreversibly bind and 
enable identification of GBA (human lysosomal β-glucosidase; 
glucocerebrosidase) in complex biological samples, such as cell lysates, cell 
cultures and laboratory animals (Witte et al., 2010). This ABP has meanwhile 
found important applications in studies on Gaucher disease, an inherited 
lysosomal storage disorder caused by GBA deficiency. Its use for diagnostic 
purposes holds great promise (Aerts et al., 2011). The glucosyl-configured 
cyclophellitol ABP binds covalently to the catalytic nucleophile, Glu-340, of the 
human GBA enzyme (Figure 3A). In addition to the cyclophellitol sugar, the 
probes contain a reporter group, that can be a fluorophore and/or biotin, 
attached via a linker to the C-6 position of the functionalized cyclophellitol, 
enabling the visualization and/or identification of active enzyme molecules 
(Witte et al., 2010).  
        Next, a different class of ABPs was designed by Overkleeft for retaining β-
glucosidases based on the use of cyclophellitol-aziridine scaffolds (Kallemeijn et 
al., 2012) (Figure 3A and B). Subsequently, by variation of the configuration of 
cyclophellitol-aziridine a series of new probes were developed for other 
retaining glycosidases. Detection of active α-D-galactosidase (Willems et al., 
2014a), β-D-galactosidase (Marques et al., 2016b), α-L-fucosidase (Jiang et al., 
2015), α-D-glucosidases (Jiang et al., 2016), β-D-glucuronidase (Wu et al., 2017), 
α-L-iduronidase (Artola et al., 2018) and α-L-arabinofuranosidases (McGregor 
et al., 2020) was achieved with these types of ABPs. Through changing the 
reporter group into a biotin, the probes can be used for streptavidin-mediated 
enrichment, followed by proteomics identification of labelled proteins using LC-
MS/MS (Jiang et al., 2016). Meanwhile, many research applications for 
glycosidase ABPs have been found. The amphiphilic nature of glycosidase ABPs 
enables them to penetrate cells and organisms, allowing in situ labelling of 
active enzyme molecules in lysosomes. Intravenous infusion of mice with ABPs 
resulted in specific labeling of GBA in various tissues (Kallemeijn et al., 2012). 
More recently, the same ABPs were employed to very sensitively visualize 





microscopy (CLEM) (Van Meel et al., 2019). Visualization of GBA in the brain 
of mice was also achieved after intracerebroventricular administration of the 
ABP (Herrera Moro Chao et al., 2015). Application of ABPs in studies with 
zebrafish models of GBA enzyme deficiency have been recently described 
(Artola et al., 2019; Lelieveld et al. 2019). In addition, β-D-glucuronidase ABPs 
have recently been employed in fecal samples to study the anticancer Irinotecan 
drug toxicity driven by gut microbial enzymes (Jariwala, et al. 2020). 
        ABPs in plant science. Plant scientists interested in hydrolases have to 
deal with a huge number of genes encoding potential glycosidases. Moreover, 
transcript expression levels do not always correlate with actual active enzyme 
levels. Therefore, methods for conveniently monitoring distinct active 
glycosidases are in great demand to establish the functional proteome of 
different plant species. ABPs provide a novel toolbox for this purpose which has 
been successfully applied in plant science during the last decade (van der Hoorn 
and Morimoto, 2016). Enzymes of several families have been identified and 
functionally characterized using ABPs, such as serine hydrolases (Kaschani et 
al., 2009), papain-like cysteine proteases (Richau et al., 2012) and cysteine 
proteases (Lu et al., 2015). In addition, retaining glycosidases of different plant 
species have been characterized and identified (Chandrasekar et al., 2014; 
Husaini et al., 2018; Kytidou et al., 2018-chapter 4). The use of ABPs as 
functional tool for studying retaining glycosidases in plants was first reported 
by the group of van der Hoorn in 2014. The chemical structures of ABPs used 
in this research are depicted in Figure 3B. An overview is provided in Figure 
3C of key publications describing specific applications of ABPs in research using 
several plant species. 
        The β-D-glucose configured cyclophellitol-aziridines JJB70 conjugated 
with a BODIPY green fluorophore and JJB111 conjugated with a biotin was 
combined with proteomic analysis of targeted protein to study glycosidases in 
Arabidopsis thaliana total leaf samples and in N. benthamiana apoplast 
samples (Chandrasekar et al., 2014). KY371 probe, which does not contain any 
reporter group, was applied as competitor to ensure that protein labeling was 
specific. The investigation revealed that the aziridine type β-glucosidase ABPs 
present a broad activity, enabling identification of not only β-glucosidases but 
also myrosinases, xylosidases, and galactosidases. Importantly, very high 
(micromolar) concentrations of ABP were used in the study which favors 
detection of different classes of glycosidases. The identified proteins are 
members of seven different retaining glycosidase families (Chandrasekar et al., 
2014). Of note, no cellulases were identified. The main identified proteins were 
the β-thioglucoside glucohydrolase TGG2 (68-kDa signal) and TGG1 (75-kDa 
signal). Both enzymes are myrosinases and catalyze the conversion of 




glucosinolates during attack of invaders. Interestingly, yet uncharacterized 
glycosidases, one of which was previously classified as pseudogene (TGG3), 
were identified in the study. An investigation with the ABP of secreted proteins 
by N. benthamiana cells led to the identification a wide range of putative 
xylosidases, galactosidases, glucanases, and heparanase. In addition, in situ 
labeling of active glycosidases present in Arabidopsis cell cultures revealed that 
ABPs (KY371 and JJB70) can penetrate living plant cells and therefore can be 
fortuitously also used to generate knock out models. Furthermore, van Hoorn 
and colleagues explored the presence of glycosidases in different (tissues of) 
plant species like Brassica napus, Brassica oleracea, Brassica rapa, Brassica 
pekinensis, Triticum monococcum, Zea mays, Avena sativa and Nicotiana 
benthamiana via in-gel imaging (Chandrasekar et al. 2014) (see Figure 3C).  
        Next, Daneri-Castro et al. used ABPs to identify and characterize enzymes 
that are secreted by the aleurone layer during barley germination and are 
induced or not by gibberellic acid (GA). They employed different ABP classes 
and thus were able to identify putative aleurains, cathepsin-B-like proteases 
and serine hydrolases. JJB70 ABP, targeting active retaining glycosidases, was 
used to demonstrate the presence of a putative xylanase in barley aleurone by 
competing the labeling with xylose (Daneri-Castro et al., 2016). More recent, 
ABPs targeting α-glucosidases have been used in investigations on Arabidopsis 
and saffron crocus (Crocus sativus) (Husaini et al. 2018). Interestingly, using 
the α-glucosidase ABP (JJB383) evidence was obtained that during stigma 
development in saffron glycosidases are involved in the conversion of 
picrocrocin into safranal. Furthermore, during Fox infection the enzyme 
AGLU1 was detected to be present in the apoplast. In the same study, parallel 
analysis of both α- and β-glucosidases was performed, enabling simultaneous 
identification of different enzyme classes (Husaini et al., 2018). In conclusion, 
ABPs find very broad applications in investigations on plant metabolism and 
physiology.  
        ABPs have also already been successfully used to monitor recombinant 
active enzyme during transient expressions in N. benthamiana plants. Human 
α-galactosidases have been produced in N. benthamiana leaves and in HEK293 
cell cultures (Kytidou et al., 2017-chapter 3). Recombinant protein was detected 
and quantified using the α-galactosyl configured cyclophellitol-aziridine TB474 
containing a Cy5 fluorophore (Kytidou et al., 2017). This detection method is 
superior to western-blot since it allows selective detection of active enzyme 
molecules. Based on previous investigations, it might be concluded that ABPs 
can be applied as an easy quantitative method to follow the production of 
biopharmaceuticals in recombinant systems. In addition, the use of the 





galactosidase, named A1.1. The enzyme was then overexpressed in N. 
benthamiana leaves, purified and further biochemically characterized. One of 
the most important findings was that A1.1 proves to be able to hydrolyze human 
glycosphingolipids in vitro and in situ and might find applications in the 
treatment of Fabry disease, caused by deficiency of the human α-galactosidase 
(Kytidou et al., 2018, chapter 4). Therapeutic application of a plant enzyme, 
discovered with an ABP, for treatment of a human metabolic disease can be 
thus be envisioned (Figure 3B and C).  
        The specificity of ABP labeling of glycosidases can be fine-tuned by the 
assay conditions (e.g. variation of pH), concentration of probe and use of 
competitive inhibitors. The ABPs can in principle be used to visualize 
glycosidases during physiological processes of interest such as plant 
development, seed germination, cell wall formation and different responses to 











Figure 3. Activity based probes mechanism and use in plant science. A. Mechanism of aziridine 
and epoxide activity-based probes. B. Structures of ABPs used in plant science. C. Summary of 
published ABPs used in plant research. Presented are key publications describing specific applications 
in plant species. 
 
Production of therapeutic (human) glycosidases in 
plants  
 
History. Production of biopharmaceutical proteins in plants is undertaken since 
the early 2000s. It gained great attention due to the advantages in economy, 
safety and scalability with several examples of in planta recombinant protein 
productions over the last decades (Westerhof et al., 2014; Wilbers et al., 2017). 
The first plant-produced protein was the human growth hormone, in 1986, in 
tobacco cell cultures (Fischer et al., 2004). After that, a vast number of different 
proteins have been produced in planta, demonstrating the viability of such 
methods for industrial and pharmaceutical uses (Hidalgo et al., 2018; 
Kopertekh and Schiemann, 2019). A recent example is the large-scale 





virus (Yao et al., 2015). This review focuses on the production of therapeutic 
human glycosidases in plants for the treatment of lysosomal diseases.  
        Lysosomal enzymes and their production in plants. Lysosomal diseases 
are inherited metabolic diseases caused by dysfunction of lysosomal hydrolases. 
A possible therapy for these diseases involves replacement of deficient enzymes 
by their normal equivalents. Supplementation of patient cells is envisioned 
following intravenous administration (infusion) of recombinant enzyme. This 
concept was developed and pioneered by Brady and is known as enzyme 
replacement therapy (ERT) (Brady, 2003; Desnick and Schuchman, 2012; Aerts 
and Cox, 2018). The uptake of the recombinant enzyme preparations is usually 
mediated by mannose receptors (MR) which are present in the surface of the 
targeted cells and also via mannose-6-phosphate receptors (M6PR) and the 
asialoglycoprotein receptor (Ashwell-Morell receptor; AMR) (Figure 4) 
(Coutinho et al., 2012; Shen et al., 2016; Tian et al., 2019). Examples of such 
disorders and their corresponding impaired glycosidase are Gaucher disease 
and β-glucocerebrosidase (GBA), Fabry disease and α-galactosidase (αGAL), 
Pompe disease and α-glucosidase (GAA) and Krabbe disease and β-
galactocerebrosidase (GALC).  
        The production of the lysosomal human GBA enzyme in carrot cells by 
Shaaltiel and colleages in 2007 can be considered as a hallmark in the 
production of pharmaceutical glycosidases in plants for the treatment of 
lysosomal diseases (Shaaltiel et al., 2007). The plant produced enzyme, 
ELELYSO (taliglucerase alfa) (Protalix BioTherapeutics), was approved by the 
FDA in May 2012. The enzyme is targeted to the vacuoles of carrot cells via the 
insertion of a chitinase (“GLLVDTM”) vacuole signal peptide. The recombinant 
enzyme has high mannose terminal N-glycans that mediate uptake by 
macrophages (Shaaltiel et al., 2007). It was firstly demonstrated that the plant 
specific N-glycans on the plant produced recombinant GBA are not 
immunogenic, a crucial finding. Production of human GBA enzyme in 
transgenic, complex-glycan-deficient, Arabidopsis seeds, has also been achieved 
(He et al., 2011). The produced enzyme in the latter case does not contain any 
targeting signal to the vacuole. Active GBA has recently also been produced in 
root cultures of Nicotiana tobacco (Naphatsamon et al., 2018). Finally, GBA 
enzyme with high mannose N-glycans (gnt1-GBA) was produced in mutant rice 
(Jung et al., 2019).  
        Another human lysosomal hydrolase produced in plants is α-galactosidase 
A. The production of this enzyme for therapy of Fabry disease was firstly 
accomplished in tobacco cell cultures in 2015 (Kizhner et al., 2015; Ruderfer et 
al., 2018; Schiffmann et al., 2019). The protein, pegunidalsidase alfa, PRX-102 
(Protalix BioTherapeutics), is currently in clinical trials and it is produced in 




large scale at ProCellEx plant cell-based protein expression platform (Ruderfer 
et al., 2018). Interestingly, the recombinant protein is chemically modified with 
a bifunctional PEG polymer to form stable dimers. Such modification improves 
the enzyme’s stability in plasma and its pharmacokinetic properties (Ruderfer 
et al., 2018). PRX-102 is found superior in stability than the current available 
recombinant enzymes for treatment of Fabry disease (agalasidase beta, 
Fabrazyme and agalsidase alpha, Replagal) which are both produced in 
mammalian cell culture systems. Of note, no M6P residues are present in the 
N-linked glycans of pegunidalsidase alfa. A mannose enriched human α-
galactosidase A was produced in 2016 in moss cell cultures (Shen et al., 2016). 
The enzyme was found to be effectively targeted through the MR pathway to 
defective organs such as heart and kidney. α-Galactosidase was also produced 
transiently in N. benthamiana leaves for research purposes (Kytidou et al., 
2017). In parallel, in the same platform human α-N-acetylgalactosaminidase 
and a mutated form with increase α-galactosidase activity was generated 
(Tajima et al., 2009; Kytidou et al., 2017). Finally, a modified fragment of 
human α-glucosidase (GAA) has been produced in plant chloroplasts to induce 
tolerance against human GAA in Pompe disease patients receiving ERT (Su et 
al., 2015). Future investigations will demonstrate clinical benefit of this 
approach. 
        N-glycoengineering. The feasibility to manipulate and humanize the N-
glycosylation pathway of plants offers a great advantage in the production of 
biopharmaceuticals (Castilho and Steinkellner, 2012; Bosch et al., 2013). N-
glycosylation of glycoproteins in plants and mammals is identical up to the 
formation of the vital intermediate “GlcNAc2Man3GlcNAc2” N-glycan (GnGn 
structure) in medial-Golgi apparatus (Figure 4A) (Gomord et al., 2010). Further 
modification of the GnGn structure takes place in mammals in trans-Golgi 
apparatus, resulting in complex and highly heterogenic N-glycan structures 
whereas in plants further modifications are not as frequent and mainly include 
the addition of β (1,2)-xylose and α (1,3)-fucose residues at core GnGn structure 
(Gomord and Faye, 2004). Additionally, high mannose, paucimannosidic 
structures and also Lewis-X- epitopes are frequently observed in N-glycans of 
plant glycoproteins. Even though core fucosylation may occur in mammals this 
involves addition of α(1,6)-linked fucose residues (Bosch et al., 2013). Several 
examples of N-glycoengineering plants to reach a human like N-glycan profile 
have been reported and reviewed (Castilho and Steinkellner, 2012; Bosch et al., 
2013). Using reverse genetics (CRISPR/cas9 knock out, RNAi methods), plants 
were generated lacking endogenous activities such as the ones of β (1,2)-
xylosyltransferase and core α (1,3)-fucosyltransferase responsible for attaching 





first accomplished in Arabidopsis thaliana plants followed by Nicotiana 
benthamiana, Lemna minor, and the moss Physcomitrella patens and rice cells 
(Strasser et al., 2004; Schähs et al., 2007; Loos et al., 2011; Castilho and 
Steinkellner, 2012; Bosch et al., 2013). 
        During ERT of patients suffering from glycosidase deficiencies, 
intravenously infused recombinant enzymes are endocytosed via lectin-
mediated pathways. In the case of Gaucher disease, ERT is highly successful 
since the recombinant enzyme is targeted efficiently to macrophages (the 
primary storage cells) via MR-mediated uptake (see above and Figure 4B). In 
other LSDs however, several cell types are affected and need to be 
supplemented with therapeutic enzyme. For this reason, use of the ubiquitous 
M6PR uptake is envisioned and recombinant enzyme with a high M6P content 
in their N-glycans are produced (Schiffmann et al., 2001; Eng et al., 2001; Kroos 
et al., 2012; Ferraz et al., 2014). Thus, the N-glycan profile of the therapeutic 
enzyme plays a key role in its availability, targeting and bioactivity. The α-
galactosidase produced in moss by Shen et al. is claimed to be endocytosed by 
many cell types via mannose-lectin mediated uptake. The enzyme has high 
mannose N-glycans that lack the plant specific α (1,3)-fucose and β (1,2)-xylose 
residues (Shen et al., 2016).  
 






Figure 4. Plant and human N-glycosylation pathways: importance in production of 
pharmaceuticals. A. N-linked glycosylation pathway of proteins produced in plants and humans. B. The 






ABPs: linking retaining glycosidases with small 
compound interactors of their catalytic pockets.  
 
The previous sections of this review largely focused on glycosylated metabolites 
on the one hand and retaining glycosidases on the other hand. In addition, the 
design and application of ABP reacting in a mechanism-based manner with the 
catalytic nucleophile of specific glycosidases was introduced. In this section, the 
use of ABPs to ‘bridge’ glycosidases with interacting small compounds is 
discussed. 
        The great value of ABPs to identify, purify and characterize glycosidases 
from various plants has been addressed in the previous sections. Some of these 
enzymes might find future applications as drugs or in industrial processes. 
Another application for ABPs warrants discussion. By virtue, ABPs can be also 
used to identify small compounds that interact with the catalytic pocket of the 
reactive glycosidase. Such interactors, (substrates, inhibitors), will compete 
with the ABP for occupancy of the pocket and the subsequent labeling of the 
enzyme (Figure 5). This concept can for example be exploited to screen different 
plant extracts or selected compounds (glycosylated plant sterols and flavonoids) 
for interaction with (plant or human) glycosidases as revealed by the 
competition of labeling of the glycosidase with the corresponding ABP. Proof of 
principle for such screens has already been obtained. In this manner, inhibitors 
have been identified for the human non-lysosomal glucosylceramidase GBA2, 
an enzyme that is difficult to purify to homogeneity in active form. Lahav et al. 
used a fluorescent polarization activity-based protein profiling (ABPP) assay 
where they successfully screened a library of 350+ iminosugars for potential 
GBA2 inhibitors using a lysate of cells over-expressing GBA2 and the 
appropriate glucosidase ABP (Lahav et al., 2017). In the same manner, complex 
biological samples can be screened on the presence of potential substrates for a 
glycosidase competing with ABP labelling. One further application along the 
same line is the use of cell-permeable ABP labeling of a glycosidase to identify 
the in-situ inhibition of a target glycosidase by an administered inhibitor. An 
example of such application is provided by a recent study identifying in intact 
cells and zebrafish the β-glucosidase target engagement of conduritol B-epoxide 
and cyclophellitol analogues (Kuo et al., 2019; Artola et al., 2019).  
        In conclusion, ABPs will not only be of value to study their target 
glycosidases but also interactors of their catalytic pockets.  
 






Figure 5. Principle of activity-based protein profiling for target identification and competitive 
activity-based protein profiling for the screening of glycosidase inhibitors. The competition of ABP 
labelling of a glycosidase by agents interacting with its pocket (inhibitors, substrates) can be 
conveniently and sensitively assessed. Note: there is no need for a pure enzyme, when visualizing 
labelled glycosidase using SDS-PAGE and fluorescence scanning. 
 
Summary and Perspectives 
 
Natural plant–derived glycosides are used for various therapeutic purposes. 
Increased knowledge of beneficial/toxic effects is warranted. This is particularly 
relevant for plant sterols for which beneficial and potentially harmful effects 
have been reported. Better insight is needed regarding the biological effects, 
bioavailability and metabolism of glycosylated sterols prior to any clinical use 
in prevention/treatment of diseases. This may also hold for other plant 
metabolites. The therapeutic value of infusion of glycosidases in treatment of 
inherited deficiencies in man has been demonstrated for a number of diseases. 
In recent years, production of such glycosidase increasingly occurs in plant 
platforms that offer several advantages. Importantly, the N-glycan composition 
of plant-produced recombinant enzymes can be very well controlled using 
genetically modified plants. The ubiquitous plant glycosidases themselves 
might conceivably find therapeutic applications in humans and might have 
potential to treat inherited glycosidase deficiencies in man (Kytidou et al., 2018-
chapter 4). Overall, activity-based probes may help to identify plant 
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Deficiency of α-galactosidase A (α-GAL) causes Fabry disease (FD), an X-linked 
storage disease of the glycosphingolipid globtriaosylcerammide (Gb3) in 
lysosomes of various cells and elevated plasma globotriaosylsphingosine (Lyso-
Gb3) toxic for podocytes and nociceptive neurons. Enzyme replacement therapy 
is used to treat the disease, but clinical efficacy is limited in many male FD 
patients due to development of neutralizing antibodies (Ab). Therapeutic use of 
modified lysosomal α-N-acetyl-galactosaminidase (α-NAGAL) with increased α-
galactosidase activity (α-NAGALEL) has therefore been suggested. We 
transiently produced in Nicotiana benthamiana leaves functional α-GAL, α-
NAGAL and α-NAGALEL enzymes for research purposes. All enzymes could be 
visualized with activity-based probes covalently binding in their catalytic 
pocket. Characterization of purified proteins indicated that α-NAGALEL is 
improved in activity towards artificial 4MU-α-galactopyranoside. Recombinant 
α-NAGALEL and α-NAGAL are not neutralized by Ab-positive FD serum tested 
and are more stable in human plasma than α-GAL. Both enzymes hydrolyze 
the lipid substrates Gb3 and Lyso-Gb3 accumulating in Fabry patients. The 
addition to FD sera of α-NAGALEL, and to a lesser extent that of α-NAGAL, 
results in a reduction of the toxic Lyso-Gb3.  
        In conclusion, our study suggests that modified α-NAGALEL might reduce 
excessive Lyso-Gb3 in FD serum. This neo-enzyme can be produced in 
Nicotiana benthamiana and might be further developed for the treatment of 


















Deficiencies in lysosomal enzymes are the cause of various inherited lysosomal 
storage disorders in humans (Futerman and van Meer, 2004). Examples are 
Gaucher disease (GD), Pompe disease and Fabry disease (FD) with deficiencies 
of acid beta-glucosidase (glucocerebrosidase, GBA), acid alpha-glucosidase and 
acid alpha-galactosidase (α-GAL) respectively. For each of these diseases, 
enzyme replacement therapy (ERT) approaches have been designed and are 
applied with variable success. Highly efficient is ERT for Gaucher disease 
resulting in reversal and /or prevention of organomegaly and haematological 
abnormalities in non-neuropathic type 1 patients (Barton et al., 1990). ERT of 
Pompe disease has been shown to increase the life expectancy in patients 
suffering from the infantile form of the disorder (Van den Hout et al., 2000). 
Two similar approaches were also developed for Fabry disease using human α-
GAL produced in Chinese hamster ovary cells, (agalsidase beta; Fabrazyme™; 
Sanofi-Genzyme) or human fibroblasts (agalsidase alfa; Replagal™; Shire) (Eng  
et al., 2001;Schiffmann et al., 2001). Both enzyme preparations were registered 
in August 2001 as orphan drug in Europe, but only Fabrazyme was approved 
by the FDA in the U.S.A. (Desnick, 2004).  
        α-Galactosidase A (α-GAL; E.C. 3.2.1.22) is encoded by the GLA (ID: 2717) 
gene at locus Xq22 (Desnick, 2001). The enzyme is synthesized as 429 amino 
acid precursor from which the signal peptide is removed to yield a 398 amino 
acid glycoprotein forming a homodimer (Brady 1967; Hamers, 1977;Bishop et 
al., 1988;Desnick, 2001). Formation of mannose-6-moieties (M6P) in the 3 N-
linked glycans of α-GAL allows transport to lysosomes by mannose-6-phosphate 
receptors (M6PR) (Sakuraba et al., 2005). The natural substrates of α-GAL are 
glycosphingolipids with terminal α-galactosyl moieties, including 
globotriaosylceramide (Gb3; ceramidetrihexoside: CTH), galabiosylceramide, 
and blood group B, B1, and P1 antigens (Sweeley, 1963; Desnick, 2001). In 
various cell types of classic male FD patients Gb3 accumulates in 
intralysosomal lipid deposits. Both Fabrazyme and Replagal are aimed to be 
delivered to lysosomes of cells by M6PR mediated endocytosis (Sakuraba et al., 
2005). Unfortunately, the evaluation of long-term ERT of FD patients indicates 
that clinical efficacy is relatively poor (Schuller et al., 2015). ERT treatments 
result in the case of some FD patients in stabilization of disease, but 
progression of symptoms has also been observed (Blom et al., 2003;Lin et al., 
2009). The poor response to ERT of classic FD males, usually completely lacking 
α-GAL protein, is partially explained by the common induction in these 




individuals of neutralizing antibodies (Ab) against the therapeutic enzyme 
(Linthorst et al., 2004).  
        A recent important insight on pathogenesis of FD stems from the notion 
that the storage lipid Gb3 is partly actively converted to its sphingoid base 
globotriaosylsphingosine (Lyso-Gb3) in lysosomes (Aerts et al., 2008;Ferraz et 
al., 2016a). In symptomatic FD males plasma Lyso-Gb3 is chronically several 
hundred fold increased, and symptomatic female FD patients also show 
increased levels of the sphingoid base (Gold et al., 2013;Ferraz et al., 2016a). 
Excessive circulating Lyso-Gb3 seems a culprit, contributing to renal 
complications and neuropathic pain in FD patients as the results of toxicity for 
podocytes and nociceptive neurons respectively (Choi et al., 2015;Sanchez-Niño 
et al., 2015). In line with this, FD patients with Abs show a relapse of plasma 
Lyso-Gb3 to pre-treatment values (Ohashi et al., 2007;van Breemen et al., 
2011;Rombach et al., 2012). In view of the toxicity of Lyso-Gb3 a treatment 
based on enzyme supplementation aiming to specifically reduce this lipid might 
be considered. Ideally, such therapeutic enzyme should not induce neutralizing 
antibodies in FD males as occurs with Fabrazyme and Replagal.  
        Plants, among others Nicotiana benthamiana (N. benthamiana), have 
been shown to be excellent production platforms of therapeutic enzymes 
(Fischer et al., 2004;Gomord and Faye, 2004). Besides the amply reviewed 
advantages such as associated low costs, feasibility of large-scale production 
and reduced risk for contaminating animal viruses and prions, plants may be 
engineered to process recombinant proteins with all post-translational 
modifications required for desired bioactivity and pharmacokinetics. Shaaltiel 
and colleagues were among the first to develop the production of a lysosomal 
hydrolase in plant cells for therapeutic use in humans (Shaaltiel et al., 2007). 
They generated recombinant glucocerebrosidase in carrot cells for the 
treatment of type 1 GD. Clinical investigations with GD patients demonstrated 
that the therapeutic efficacy of the plant-produced enzyme preparation is on a 
par with recombinant enzyme conventionally produced in mammalian cells. 
Moreover, no significant immune responses to the plant-produced glycoprotein 
as such were noted. These findings promoted swift registration of taliglucerase 
(Uplyso™; Protalix) as drug for type 1 GD in Europe, Israel and the U.S.A. (van 
Dussen et al., 2013). Another recent example forms the production in tobacco 
of acid alpha glucosidase for treatment of Pompe disease (Su et al., 2015). 
Furthermore, in Nicotiana tabacum cells a PEGylated human α-Galactosidase 
A enzyme has been produced for treatment of FD (Kizhner et al., 2014). Human 
α-Galactosidase A was also recombinantly produced in an engineered moss cell 
line by Jin-Song Shen and colleagues and shown to undergo mannose receptor 





        The unfortunate detrimental immune response to infused human α-GAL’s 
in most FD males, leading to neutralizing antibodies, inspired Sakubara and 
colleagues to propose the use of a modified enzyme (Tajima et al., 2009). Their 
alternative approach elegantly exploits the existence of a homologous lysosomal 
enzyme named α-galactosidase B or α-N-acetyl-galactosaminidase (α-NAGAL). 
It is encoded by the NAGA gene (ID: 4668) (22q13.2) arisen by gene duplication 
of the GLA gene. Until the late 70’s both enzymes were actually considered as 
different isoforms of the same protein (Schram et al., 1977). Mature α-NAGAL, 
a 411 amino acid glycoprotein with 4 N-linked glycans still shows considerably 
structural similarity to α-GAL. The enzyme α-NAGAL exerts α-N-acetyl-
galactosaminidase activity, but also hydrolyses at low rate artificial α-
galactosides like 4-methylumbelliferyl-α-galactopyranoside (4MU-α-GAL) or p-
nitrophenyl-α-galactopyranoside (pNP-α-GAL). The similarity of α-GAL and α-
NAGAL  is also revealed by recently developed activity-based probes (ABP) that 
bind covalently to the  catalytic nucleophile of both retaining glycosidases 
(Willems et al., 2014). In the present study we used a similar alpha-galactosyl 
configured cyclophellitol-aziridine ABP equipped with a Cy5 fluorophore, again 
labeling both α-GAL and α-NAGAL. X-ray crystallography of α-GAL and α-
NAGAL provided a structural basis for the specificity of both proteins for 
substrates (Tomasic et al., 2010). The introduction of two amino acid 
substitutions in the catalytic pocket of α-NAGAL, Ser188Glu and Ala191Leu, 
suffices to increase about 40 times the ability of the neo-enzyme (α-NAGALEL) 
to hydrolyse 4MU-α-GAL (Tajima et al., 2009). Furthermore, it was described 
that α-NAGALEL reduces Gb3 in cultured fibroblasts from a FD patient. 
Intravenous administration of α-NAGALEL in FD mice  partially reduced Gb3 
storage in liver, kidney, and heart (Tajima et al., 2009). Garman recapitulated 
some of the findings by demonstration of about 4.5 fold increased activity of α-
NAGALEL towards pNP-α-GAL (Tomasic et al., 2010). The enzymes α-GAL and 
α-NAGAL differ not only in affinity for the sugar-moiety of natural substrates, 
but also their aglycon moieties (Clark and Garman, 2009;Guce et al., 2010). 
Whereas α-GAL degrades glycosphingolipids, α-NAGAL degrades glycopeptides 
and oligosaccharides as indicated by storage materials in Schindler disease 
(inherited α-NAGAL deficiency).   
        In our present study we investigated whether it is feasible to produce in 
N. benthamiana leaves α-GAL, α-NAGAL and α-NAGALEL. All plant-produced 
enzymes were active and could be labelled by the Cy5 equipped ABP. The 
glycosidases were purified to homogeneity and characterized regarding 
enzymatic activity towards artificial alpha-galactoside and alpha-N-
acetylgalactosiminide substrates, and their N-glycan composition. In addition, 
we produced the same enzymes in HEK293 cells, showing no difference in 




specific activities to the ones produced in the N. benthamiana leaves. Moreover, 
we established whether the enzymes cross react with antibodies in serum of an 
FD patient with neutralizing activity (Linthorst et al., 2004). Next, we studied 
the activity of the various enzymes towards lipid substrates, in particular Gb3 
and Lyso-Gb3. Finally, we examined the stability of various enzymes in plasma 
and their ability to degrade excessive Lyso-Gb3 in FD sera using LC-MS/MS 
and isotope-encoded internal standards (Gold et al., 2013;Ferraz et al., 2016a). 
From the results obtained we conclude that it seems feasible to produce a 
modified α-NAGALEL that is more stable in human plasma than α-GAL and is 
better able to degrade excessive Lyso-Gb3 in FD serum. Further tailoring of an 
enzyme to optimally degrade circulating Lyso-Gb3 in the blood of FD patients 
is a therapeutic avenue to be considered, and plants might be used as a protein 























Transient production of human α-galactosidases in N. benthamiana leaves  
We first established the optimal conditions for production of α-galactosidases α-
GAL, α-NAGAL and α-NAGALEL in a transient expression system in N. 
benthamiana. In the constructs the sequences of mature α-galactosidases were 
preceded by that of the Arabidopsis thaliana chitinase signal peptide. 
Agrobacterium tumefaciens infiltrated leaves of 5-6 weeks old N. benthamiana 
plants were collected at 1, 3 and 5 days post-infiltration (dpi), lysates were 
prepared and enzymatic activities of α-galactosidases were measured using the 
respective 4MU substrate (Figure 1A). For each enzyme an optimal yield was 
observed at 5 dpi, while co-expressing the p19 silencing suppressor of tomato 
bushy stunt virus. This time point was used throughout all later experiments 
for harvesting. The amounts of active recombinant α-GAL, α-NAGAL and α-
NAGALEL at 5 dpi was 71, 5 and 7 nmol/h/μg total protein, respectively, as 
measured with 4MU-α-GAL substrate. No 4MU-α-NAGAL activity was 
detected for the α-NAGALEL enzyme, whereas the wild type reached 33 
nmol/h/μg at 5 dpi (Figure 1A). The amount of enzyme activity was proportional 
to the amount of active enzyme molecules detected with the fluorescent activity-
based probe (Figure 1B) and that detected with western blotting using anti-α-
GAL and α-NAGAL antibodies (Figure 1C). The molecular weight of α-GAL was 
about 44 kDa. Those of the two α-NAGALs were about 49 kDa, the higher mass 
being due to the known presence of one extra N-glycan (Clark and Garman, 
2009).  
 
























Figure 1. Production of α-galactosidases α-GAL, α-NAGAL and α-NAGALEL in transiently 
transformed N. benthamiana leaves. Samples were harvested 1, 3 and 5 days post infiltration (dpi) 
either or not co-expressed with P19 silencing inhibitor. (A) Enzymatic activity was measured with 
corresponding 4MU-substrate.  (Represented in black the 4MU activity of lysates harvested in 1st Dpi, 
light grey 3rd Dpi, dark grey 5th Dpi) (n=4, error bars indicate mean ± standard deviation). Asterisk(s) 
indicate significant differences as measured by a two-way ANOVA corrected using Bonferroni post-hoc 








plant lysates. As controls an empty vector sample (E.V) and an untreated plant leaf (P.L). The gels were 
stained with Coomassie Brilliant Blue staining (CBB) as a loading control. (C) Western blot analysis of 
the plant produced α-galactosidases using anti-α-GAL and anti-NAGA polyclonal rabbit antibodies 
raised against the human homologue. As control an empty vector sample (E). Black asterisk indicating 
the α-NAGALs and red asterisk the α-GAL. 
 
 
Purification and biochemical characterization of plant produced α-
galactosidases  
Recombinant α-galactosidases were purified from lysates of N. benthamiana 
leaves by sequential chromatography during which the presence of enzymes 
was monitored by measurement of enzymatic activities with 4MU-substrates. 
As generic first step we used Concanavalin A-Sepharose chromatography 
exploiting the presence of mannose-containing N- glycans in the recombinant 
α-galactosidases ensuring high affinity binding to the immobilized lectin 
(Yasuda et al., 2004). The recovery in this step was high (> 40 %) for each 
enzyme and led to > 50-fold purification (Table 1). The next step in purification 
was ion exchange chromatography performed at pH 5.0 for α-GAL and at pH 
6.3 for α-NAGAL and α-NAGALEL as described in experimental procedures. 
This led for each enzyme to considerable further purification with acceptable 
recovery (Table 1). The final purification step for all enzymes was gel filtration, 
resulting in an apparently pure protein as judged by silver staining of protein 
resolved by SDS-PAGE (Figure 2A). About 1 μg α-GAL, α-NAGAL and α-
NAGALEL was purified from 1 mg of soluble lysate protein. 









Figure 2. Overview of enzyme purifications: activity based probe detection, Immunoblotting and 
Coomassie Brilliant Blue, staining of the plant produced pure enzymes. (A) SDS-PAGE and silver 
staining of fractions obtained during purification. Four μg of total protein per lane was loaded for all 
unpurified samples and 1-2 μg for all pure protein fractions (α-NAGAL, α-NAGALEL and α-GAL). Shown 
are: starting material/ Lysate (L), bound protein to Concanavalin A (C), pooled collected eluate of ion 
exchange (I), and the final pooled gel filtration fraction (GL) with highest enzyme specific activity. For 
comparison is shown recombinant α-galactosidase A, Fabrazyme (Fz). Black asterisk indicating the α-
NAGALs and red asterisk the α-GAL. (B) Before electrophoresis, 1μg of each pure enzyme was treated 
with 0.25μM of Cy5 α-galactosidase activity-based probe, ABP. NEL = α-NAGALEL, N = α-NAGAL, A = 
α-GAL. The gels were scanned λexc=635nm, then immunoblotted with anti-α-GAL or anti-NAGAL rabbit 
polyclonal antibodies, following Coomassie Brilliant blue, CBB, staining of the blots. The same gel had 
to be repeated since anti-α-GAL and anti-NAGA antibodies were both polyclonal anti-rabbit. 
 
        The apparent molecular weights of all three α-galactosidases as 
determined by gel filtration coincided with dimers (113 kDa for α-GAL, 134 kDa 
for α-NAGAL, and 132kDa for α-NAGALEL) (Figure S2A and B). Of note, the 
specific activity of plant-produced α-GAL (2.35 mmol/h/mg) was quite 
comparable to that of Fabrazyme (2.18 mmol/h/mg) (Table 2) (Tajima et al., 
2009). After purification, further enzyme characterization was performed. 
Equal μg amounts of pure enzymes were incubated with fluorescent ABP 
followed by SDS-PAGE and fluorescence scanning analysis (Figure 2B). The 
intensity of the fluorescently labeled bands was the same for the three enzymes, 
revealing similar amounts of active enzyme molecules in each purified protein 
preparation. Western blotting using anti-α-GAL and anti-α-NAGAL antibodies 








N-glycan profile of the plant produced enzymes 
Next, the N-glycan composition of the purified α-galactosidases was examined 
using deglycosylation with Endo H and PNGase F endoglycosidases following 
SDS-PAGE analysis. Fabrazyme, produced in CHO cells, was used as a control. 
Consistent with literature reports, PNGase F led to conversion of Fabrazyme 
to a molecular mass of 39 kDa (Figure 3A). In the case of plant produced 
enzymes the reductions in molecular mass with EndoH or PNGase F were less 
pronounced (Figure 3A). This difference can be attributed to the presence of α1-
3 core fucose residues, attached to most of the N-acetyl-glucosamine backbones 
(GlcNAc), inhibiting digestion by the endoglycosidases. The higher molecular 
weight of Fabrazyme compared to the plant produced enzymes could be due to 
the different N-glycan composition of this enzyme, mainly consisting of complex 
N-glycan structures, with additional mannose 6 phosphate residues (Sakuraba 
et al., 2005). To get more insight in the N-glycan composition of the plant 
produced enzymes, all N-linked glycans were released with PNGase A (not 
inhibited by the presence of α1-3 fucose) and subjected to MALDI-TOF MS 
(Figure 3B, C, D). The most prominent N-glycan type of α-GAL recombinant 
protein was paucimannose structure (Man3GlcNAc2) with α1-3 fucose attached 
on the core GlcNAc and β1-2 xylose on the first mannose. Conceivably, the 
enzyme was secreted to the apoplastic fluid and hexosaminidases cleave the 
GlcNAc molecules yielding the pausimanosidic structure. On the other hand, 
both α-NAGALs have oligo-mannose type N-glycans (Man7GlcNAc2) as the most 
abundant N-glycan type, suggesting their retention in Golgi and /or ER 
compartments.  
 


























Figure 3. N-glycans of α-galactosidases. (A) SDS-PAGE analysis followed by Coomassie Brilliant 
Blue staining of 1 μg pure plant produced proteins and 3μg of Fabrazyme. E = protein treated with Endo 
H, F = protein treated with PNGase F, C = untreated protein. (B, C, D) N-glycosylation profiles were 
determined by MALDI-TOF MS analysis of 2-aminobenzoic acid derivatised PNGase-A released N-
glycans of plant produced galactosidases. Glycan structures depicted were deduced from the measured 
m/z values. Blue square, N-acetylglucosamine; red triangle, fucose; open star, xylose; green circle, 




Cross reactivity with antibodies (Ab) in Fabry serum and stability tests  
We next examined the cross reactivity of recombinant α-galactosidases towards 
neutralizing antibodies in the serum of an Ab-positive male FD patient 
receiving ERT for six years (T=1). As a control, serum was used of the same 
patient before ERT (T=0) and still lacking antibodies against therapeutic α-
GAL. Inhibition of enzymatic activity by presence of Ab-positive serum was 
determined (Figure 4A). Activity of plant produced α-GAL and Fabrazyme was 
clearly inhibited, but activities of α-NAGALs, as determined with 4MU-α-GAL 
and/or 4MU-α-NAGAL substrates were not significantly influenced. The 
stability of the plant-produced galactosidases and Fabrazyme in human plasma 
was next studied by incubating enzymes at 37 oC for different time periods and 
detection of residual enzymatic 4MU-α-GAL activity (Figure 4B). Alpha-






















Figure 4. Inhibition of activity of α-galactosidases by Ab-positive Fabry serum. (A) Percentage 
inhibition by FD serum, obtained after six years ERT (T=1), of enzymatic activity measured with 4MU-
α-GAL and 4MU-α-NAGAL. As negative control, serum of FD patient pre-ERT (T=0), was used. 
Asterisk(s) indicate significant difference as measured by a two-way ANOVA, **** =P<0.0001. (B) 










Enzymatic activities of plant produced α-GAL, α-NAGAL and α-NAGALEL 
towards artificial substrate(s) and their comparison with the same enzymes 
produced in HEK293 cells 
We next studied the substrate specificity of the various recombinant α-
galactosidases. First, activity was measured towards artificial 4MU-α-GAL and 
4MU-α-NAGAL substrates. The amino acid substitutions Ser188Glu and 
Ala191Leu in the catalytic pocket of α-NAGAL (α-NAGALEL) abolished activity 
towards 4MU-α-NAGAL as earlier reported (Tajima et al., 2009;Tomasic et al., 
2010) (Table 2). The noted increase in hydrolytic specific activity towards 4MU-
α-GAL (about a doubling) was less prominent as earlier reported by Tajima et 
al. The kinetic parameters kcat and Km determined with 4MU-α-GAL as 
substrate were improved by the amino acid substitutions in α-NAGALEL (Table 
3). The plant produced α-GAL showed comparable kinetic parameters to 
Fabrazyme (Table 3) (Hopkin et al., 2003;Lee et al., 2003). To determine 
whether production in N. benthamiana leaves influences kinetic features, the 
various recombinant enzymes were also generated in human HEK293 cells as 
described in experimental procedures (Figure 5A). ABP-labeling showed that 
similar proteins were produced in N. benthamiana and HEK293 cells (Figure 
5B). The specific activity towards 4MU-α-GAL was also comparable, being 
relatively low for α-NAGAL and increased (3-fold) by the amino substitutions 
in α-NAGALEL (Figure 5C). 
 


















Figure 5. Comparison of the biochemical properties of recombinant galactosidases produced in 
plants and HEK293 cells. (A) Overexpression of human galactosidases in HEK293 cells was estimated 
via SDS-PAGE analysis. 20ug of total soluble protein were incubated with 0.5uM of Cy5 ABP, following 
Western blot analysis and Coomassie Brilliant Blue, CBB, staining of the blot. (B) ABP labelling of active 
enzyme molecules present in HEK293 and plant lysates overexpressing the proteins α-NAGALEL, α-
NAGAL and α-GAL. Different total protein content was loaded in each lane. (C) The 4MU-α-GAL specific 












Activity of recombinant enzymes towards (semi) natural substrates  
The activity of plant produced galactosidases towards lipid substrates was next 
determined. NBD-Gb3 was found to be degraded by Fabrazyme and plant-
produced α-GAL on a par (Figure 6A). Of note, significant degradation of NBD-
Gb3 to NBD-Lac Cer by α-NAGAL and α-NAGALEL was detected (Figure 6A). 
To further substantiate the findings, we incubated wild type and mutant α-
NAGALs with NBD-Gb3 in the absence or presence of 2.5mM N-
acetylgalactosamine, a potent inhibitor of α-NAGAL activity (Figure 6B). The 
wild type α-NAGAL was inhibited, resulting in loss of NDB-Lac Cer formation, 
whereas α-NAGALEL was not. Next, activity towards 5 μM of natural Gb3 and 
its deacetylated form Lyso-Gb3, was determined using detection of metabolites 
with LC-MS/MS. The analysis revealed a 2-5-fold increased activity of α-
NAGALEL compared to α-NAGAL with both substrates (Figure 6C). The pH 
optimum was pH 4.2 for α-GALs and pH 5.2 for both α-NAGALs (Figure S3).  
        Finally, serum of male FD patients, containing high amount of Lyso-Gb3, 
was incubated overnight with recombinant galactosidases (at a concentration 
of 8 μmol/h/ml activity mimicking levels reached during ERT). Of note, the rate 
of degradation of Lyso-Gb3 in the serum sample was highest with α-NAGALEL 
(Figure 6D). Likely this reflects the greater stability and ongoing activity of α-



























Figure 6. Activity of α-galactosidases towards semi-natural and natural lipid substrates. (A) Pure 
recombinant proteins were incubated with 5 μM of NBD-C12-Gb3. detection of formation of NBD-
C12Lactosylceramide, Lac Cer detected by HPTLC. (B) Pure α-NAGALs (wild type and modified) were 
incubated with 5μM of NBD-C12-Gb3 in presence/absence of 2.5 mM N-acetyl-galactosamine. 
Formation of NBD-C12-Lactosylceramide detected by HPLC. (C) Pure plant produced galactosidases 
and Fabrazyme were incubated with 5 μM of C18-Gb3, and Lyso-Gb3. Formation of Lac Cer and Lyso-
Lac Cer (pmol/h/μg) detected by LC-MS/MS. Data represent the mean ± S.D, n=2. (D) Correction of 
Lyso-Gb3 in FD serum of 2 different Fabry patients pre-ERT after incubation with pure plant produced 
enzymes (each 8 μmol artificial 4MU-substrate hydrolysis/h) overnight at 37°C. Lyso-Gb3 levels 
measured by LC-MS/MS. Data represent as mean ± S.D, n=2. Asterisk(s) indicate significant difference 













The combined challenges of high costs, immunogenicity and poor efficacy posed 
by present Fabry ERT’s prompted us to consider an examination of wildtype 
and mutant recombinant human α-galactosidases. We used N. benthamiana 
leaves as production system for this purpose. All enzymes could be expressed 
at substantial amounts, 0.1-0.2 % of total soluble protein, in N. benthamiana. 
The expressed α-GAL in N. benthamiana seems most likely to be secreted or 
transported to the vacuole as based on its N-glycan composition consisting 
largely of Man3GlcNAc2 with α1-3 fucose attached to the core GlcNAc and β1-
2 xylose to the first mannose (Castilho and Steinkellner, 2012).  In contrast, the 
transiently expressed α-NAGALs show prominent Man7GlcNAc2 N-glycans, 
more consistent with retention in the cis Golgi or ER (Castilho and 
Steinkellner, 2012).    
        Purification of all enzymes to homogeneity could be achieved by three 
relatively simple chromatographic steps. The observed specific activities of the 
purified enzymes were in the range of single digit nanomole substrate 
hydrolysis/μg pure protein per hour, being comparable to that of Fabrazyme. 
Recombinant, plant produced galactosidases were all labeled by fluorescent α-
galactosyl cyclophellitol-aziridine ABP. The intensity of ABP labeling per 
protein amount was identical for all galactosidases, substantiating further that 
in all cases the majority of purified protein is enzymatically active. 
        The observed specific activities of the produced α-galactosidases warrant 
discussion. The specific activity of pure α-NAGALEL (0.55 mmol/h/mg) as 
measured with 4MU-α-GAL was 2-3-fold increased to that of wild type α-
NAGAL (0.19 mmol/h/mg). The Km of α-NAGALEL (3 mM) was lower compared 
to that of α-NAGAL (6 mM). Almost the same specific activity for α-NAGALEL 
(0.5 mmol hydrolysis/h/mg) was reported by Sakuraba and co-workers (Tajima 
et al., 2009). They related this to that of wild type α-NAGAL from a different 
source, resulting in an apparent 43 fold improved α-galactosidase activity 
imposed by the introduction of the S188E and A191L in α-NAGAL (Tajima et 
al., 2009). Our results are in closer alignment with those of Garman and co-
workers (Tomasic et al., 2010). Using p-nitrophenyl-α-Gal as substrate the 
kcat/Km value of α-NAGALEL was found to be 4.6-fold higher than that of α-
NAGAL, similar to the 4-fold increase of kcat/Km value with 4MU-α-GAL 
substrate observed by us (Tomasic et al., 2010). Comparison of plant produced 
α-GAL with Fabrazyme revealed that their specific activities towards 4MU-α-
GAL, as well as Gb3, are almost identical. We also produced the various 
recombinant α-galactosidases in mammalian HEK293 cells showing similar 




kinetic parameters as the plant-produced enzymes, indicating that these are 
not influenced by the production platforms.  
        Fabrazyme produced in CHO cell line contains the sialic acid N-
glycolylneuraminic which does not occur in humans and therefore is potentially 
immunogenic (Bekri, 2006;Castilho and Steinkellner, 2012;Kizhner et al., 
2014). The plant-produced recombinant enzymes of the current study do not 
contain N-glycolylneuraminic acid in their N-glycans. The N-glycan profiles of 
all plant-produced recombinant enzymes were relatively homogenous, but 
differences were seen in N-glycans among the various enzymes. Most 
importantly, the majority of N-glycans of all recombinant enzymes were found 
to be core α1-3 fucosylated and β1-2 xylosylated. The same modifications occur 
in N-glycans of carrot-produced taliglucerase (human glucocerebrosidase) 
(Shaaltiel et al., 2007). Of note, there is no evidence that these modifications  
induce immune responses in Gaucher disease patients (Shaaltiel et al., 2007). 
A priori this does not exclude immunogenicity in FD patients however.  
        The recombinant enzymes produced in N. benthamiana lack M6P residues. 
In theory, the glycans may be swapped for other structures through the 
chemoenzymatic methodology developed by Fairbanks and colleagues 
(Priyanka et al., 2016). However, given the limited success of existing Fabry 
ERT aiming at M6P receptor mediated delivery of therapeutic enzyme to 
lysosomes it might be considered to refrain from this type of enzyme targeting. 
We earlier demonstrated that deacylated Gb3, Lyso-Gb3, is extremely elevated 
in FD patients and α-galactosidase A deficient mice (Aerts et al., 2008;Ferraz 
et al., 2016b). Excessive Lyso-Gb3 has been shown to be toxic for nociceptive 
peripheral neurons and podocytes in FD patients (Choi et al., 2015;Sanchez-
Niño et al., 2015). Reduction of Lyso-Gb3 in FD patients therefore seems 
therefore a valid therapeutic goal. In view of this consideration above, our 
finding that not only α-GAL but also α-NAGALs are able to degrade Gb3 and 
Lyso-Gb3 is of interest. The amino acid substitutions in α-NAGALEL improve ~ 
2-fold the capacity of the enzyme to degrade Lyso-Gb3 and ~5 fold that for Gb3. 
The relative efficacy of α-NAGALEL compared to α-GAL in ability to degrade 
Lyso-Gb3 in FD serum is even better. The greatest reduction of Lyso-Gb3 is 
detected with α-NAGALEL added to FD serum at 37 oC. The superior action of 
α-NAGALEL is likely due to its stability at neutral pH. This remarkable finding 
suggests that the use of non-antigenic, (modified) α-NAGAL might be a way to 
reach desired reductions in circulating Lyso-Gb3. The use of (modified) α-
NAGALs benefits from the higher stability and activity of the enzyme at 
neutral pH as compared to α-GAL. PEGylation could be employed to increase 
the presence of (modified) α-NAGAL in the blood. Of note, endogenous α-





low (Aerts, unpublished observations) and therefore likely does not contribute 
significantly to metabolism of the glycosphingoid base in the blood.  
        In conclusion, we here demonstrate that production of substantial 
amounts of wild-type human α-GAL, α-NAGAL and modified α-NAGALEL is 
feasible in N. benthamiana, resulting in enzymes with comparable kinetic 
properties to those produced in mammalian cell production systems. The 
introduction of two amino acid substitutions in α-NAGAL improves its α-
galactosidase activity as measured with artificial fluorogenic substrate and 
natural lipids. A significant difference between α-GAL and α-NAGAL is the 
greater stability and activity at neutral pH of the latter enzyme. Furthermore 
α-NAGAL is not inhibited by existing Ab in male FD patients by present ERTs. 
Modifications in the catalytic pocket of α-NAGAL can improve its capacity to 
degrade Gb3 and Lyso-Gb3. The kinetic properties of modified α-NAGAL and 
its greater stability at neutral pH could be further exploited for treatment of 
FD. In particular, use of modified α-NAGAL to reduce circulating Lyso-Gb3 in 


















Materials and Methods 
 
Plants. Nicotiana benthamiana plants were grown at 21 oC and 60-70 % 
humidity in the Unifarm greenhouses of Wageningen University (Westerhof et 
al., 2014).  
Chemicals. All chemicals were obtained from Sigma (Germany) if not indicated 
otherwise. Fluorescent NBD-lipids and pure lipids were purchased from Avanti 
(Alabama, USA). Antibodies purchased from Abcam (Cambridge, MA, USA). 
Activity based probes. The fluorescent ABP directed against α-galactosidases 
was produced based on previously described synthesis (Willems et al., 2014). 
Alpha-Galactopyranose configured cyclophellitol-aziridine was grafted with 
Cy5 as fluorophore as described in detail in the supplementary material 
(Scheme 1). The newly synthesized probe was examined on reactivity with 
human recombinant α-GAL (Fabrazyme, Sanofi-Genzyme, Cambridge, USA) 
(Figure S1A and B).  
Preparation of human α-GAL, α-NAGAL and α-NAGALEL (S188E; A191L) plant 
expression vectors. Both GLA (ID: 2717) and NAGA (ID: 4668) were amplified 
from MegaMan Human Transcriptome cDNA library (Stratagene). The coding 
region of genes was amplified by Phusion ® HighFidelity PCR MasterMix 
(BioLabs) using the following primers: GLA sense: 5'-
CTCATGAGTGCCAAGACCAACCTCTTCCTCTTCCTCATCTTCTCCCTCCTG
CTCTCCCTC TCCTCCGCCCTGGACAATGGATTGGCAAG-3', GLA antisense: 
5'- CCCGTACGTTAAAG TAAGTCT-3', NAGA sense: 5'-
CTCATGAGTGCCAAGACCAACCTCTTCCTCTTCCTCATC 
TTCTCCCTCCTGCTCTCCCTCTCCTCCGCC-3', NAGA antisense: 5'-
CCGTACGTCACTGCT GGGACA-3'. The genes were amplified between BspHI 
and BsiWI restriction sites, lacking the sequence encoding for their native 
signal peptide. Instead, the native signal peptide of Arabidopsis thaliana 
chitinase was added at primer sequences. Insertion of mutations S188E and 
A191L in NAGA gene was achieved via overlap extension PCR. PCR reactions 
were performed using the following primers: NAGA mutant antisense: 5'-
CCTTCATAGAGTGGCCACTCGCAGGAG AAGGC-3', NAGA mutant sense: 5'-
GCCTTCTCCTGCGAGTGGCCACTCTATGAAGG-3'. The elements were 
cloned into pGEM ®-T Easy Vector System (Promega), following 
electroporation of DH5α E. coli cells. After clone selection and confirmation of 
sequences by sequencing (Macrogen), the complete open reading frames (ORFs) 
of GLA, NAGA and NAGAEL were inserted in plant expression vectors. A 





2012), was used as the main plant expression vector during all experiments. 
The vector was digested with Acc65I and NcoI, leaving compatible overhangs 
for ligation of the elements flanked between BspHI and BsiWI restriction sites. 
All constructs were under the control of cauliflower mosaic virus 35S 
constitutive promoter, with duplicate enhancer (d35S) and the nopaline 
synthase terminator (Tnos) derived from Agrobacterium tumefaciens (A.tum). 
The pHYG vectors harboring the genes were used for transformation of A.tum 
strain MOG101, following N. benthamiana plant leaf infiltrations. 
Agrobacterium tumefaciens transient transformation assay. A.tum cultures 
were grown as previously described (Westerhof et al., 2012;Westerhof et al., 
2014). The constructs were co-expressed or not with the tomato bushy stunt 
virus silencing inhibitor p19 (Voinnet et al., 2003), by mixing  A.tum cultures 
1:1 following 1-2 hours incubation at room temperature. 
Infiltration of plants, harvesting and lysate preparation. The inoculated 
bacterial cultures were used for infiltration of the two youngest leaves of 5-6 
weeks old N. benthamiana plants. Whole leaves and leaf disks (50 mm) were 
harvested at different days post-infiltration (dpi), snap-frozen and homogenized 
in liquid nitrogen. Homogenization was performed with a tissue lyser (AKA 
Qiagen TissueLyser II) at 30 rounds/sec for 1 min. Extraction of total soluble 
proteins of samples was achieved using 2-3 ml per leaf gram of extraction buffer 
(30 mM citric acid /sodium phosphate buffer, pH 6.3, containing 2% (w/v) 
polyvinylpolypyrrolidone, 0.1% (v/v) Tween20, 0.5 M NaCl, and protease 
inhibitor by Roche, EDTA free) following homogenization at same tissue lyser 
program. When whole leaves were used, homogenization was performed by 
grounding with a mortar and pestle. Samples were next centrifuged for 15 min 
at 15000 g, (F13S 14x50 cy, Sorvall rotor), at 4 oC. The supernatant was 
collected and used for further analysis or it was stored at -80 oC upon desalting 
at G25-Sephadex column.  
Enzyme purification. As first step in the purification of all enzymes, a 5 ml 
column of Concanavalin-A-Sepharose (GE healthcare Bio-Sciences) was used. 
The column was equilibrated with 40 ml washing buffer (0.1 M sodium acetate, 
0.1 M NaCl, 1 mM MgCl2, 1 mM CaCl2, 1 mM MnCl2, pH 6.0). Then, protein 
sample (lysate) was applied to the column, 1:1 diluted in washing buffer (0.5 
ml/min loading conditions). For α-GAL 49ml of protein lysate was applied on 
the column, for α-NAGAL 38 ml and α-NAGALEL 25 ml. Proteins were eluted 
with 30 ml elution buffer (washing buffer supplemented with 0.9 M methyl-α-
mannoside and 0.9 M methyl-α-glucoside). Ten fractions of 1 ml showing 
highest levels of enzymatic activity were pooled (post-ConA). Next, for α-GAL 




purification, 10 ml of post-ConA was loaded on an ultrafiltration device 
(Centricon Plus-20, 15 ml with 10 kDa molecular cutoff, Millipore, Bedford, MA) 
to remove methyl-monosaccharides and buffer exchanged to 20 mM sodium 
acetate, pH 5.0, until obtaining a volume of 3 ml. Dialysis of the sample was 
continued in 20 mM sodium acetate buffer, pH 5.0, 4 oC, overnight. A HiTrap 
SP HP column (1 ml; GE healthcare Bio-Sciences) was equilibrated with 15 ml 
binding buffer: 20 mM sodium acetate buffer, pH 5.0. The sample, 3 ml, was 
applied on the column which was extensively washed with 10 ml binding buffer 
afterwards. Then, protein was eluted using a gradient of 0 to 300 mM NaCl, 15 
ml. Enzyme eluted in 0.5 ml fractions 2-4, which were pooled. For wild type α-
NAGAL and modified α-NAGALEL, post-ConA, 2-3 ml, was buffer exchanged via 
ultrafiltration to 10 mM potassium phosphate buffer, KPi (pH 6.3) with 10 mM 
NaCl. Next, sample was dialyzed in the same buffer to further remove any 
methyl-monosaccharides. After this, sample was applied on a HiTrap Q HP 
column (1ml; GE healthcare Bio-Sciences). Anion exchange chromatography 
was performed using a gradient of 10 to 600 mM NaCl in 10 mM Kpi (pH 6.3). 
Enzymes eluted in 0.5 ml fractions 2-4, which were pooled. As final purification 
step for all enzymes gel filtration was used. A Superdex™ 200 Increase 10/300 
GL (GE healthcare Bio-Sciences) column was prior equilibrated with 50 ml of 
20 mM sodium acetate buffer with 150mM NaCl, pH 5.0. Samples were applied 
and chromatography performed at a flow 0.75 ml/min. 0.2 ml fractions were 
collected and analyzed on enzymatic activity. The final material was snap 
frozen in liquid nitrogen and stored at -80 oC until further use.  
Overproduction of α-GAL, α-NAGAL and α-NAGALEL in HEK293 cells. Vectors 
for human cell line HEK293 were produced as follows: The complete open 
reading frames of human α-GAL, α-NAGAL and α-NAGALEL were amplified 
from previous pGEMt easy vectors harboring the genes with their native signal 
peptide, via PFX50 high fidelity DNA polymerase (Invitrogen), using the 
primers below. GLA sense: 5’-
GGGGACAAGTTTGTACAAAAAAGCAGGCTACCACCATGCA GCTGAGGAA 
CCCAGA-3’, GLA antisense: 5’-GGGGACCACTTTGTACAAGAAAGCTGGGTC 
TTAAAGTAAGTCTTTTAATGACATC-3’, NAGA sense: 5’-GGGGACAAGT 
TTGTACA AAAA AGCAGGCTACCACCATGCTGCTGAAGACAGTGCTC-3’, 
NAGA antisense: 5’-GGGGACCA 
CTTTGTACAAGAAAGCTGGGTCTCACTGCTGGGACATCTCCAG-3’. The 
elements were cloned via Gateway cloning into the donor vector pDONR221 
(BP reaction), following transformation of DH5α E. coli strain. Clones were 
collected upon kanamycin selection and their sequences were confirmed. Next, 





forming the final construct to transfect HEK293 cells. The HEK293 cells were 
cultured in 6 well plates in 2.5 ml Dulbecco's Modified Eagles Medium (DMEM, 
Sigma) supplemented with 10% fetal calf serum, 1% penicillin/streptomycin 
and glutamax at 37 oC, at 7% CO2. Three µgram of pcdna-DEST40-zeo DNA 
was transfected into cultured HEK293 cells using polyethylenimine, primarily 
mixed with serum free DMEM medium. After 2 days of cell culture, 200 μg/μl 
of zeocin was added to the culture media for selection of clones harboring the 
gene of interest. The cells grew for 3 weeks at 37 oC, at 7% CO2 in the presence 
of antibiotics and lysed in 20 mM potassium phosphate buffer (pH 6.5), 0.1% 
Triton with additional protease inhibitor by Roche. The cells were stored at -
150 oC in DMEM, 20% fetal calf serum, 10% DMSO until further use.  
Enzymatic activity measurements. Both α-galactosidase A and α-N-acetyl-
galactosaminidase activities of samples were examined with corresponding 4-
methylumbelliferyl (4MU) substrates. For α-galactosidase activity 
measurement samples were incubated for 1hr at 37 oC with a final 
concentration of 1.2 mg/ml 4MU-α-D-galactosylpyranoside (4MU-α-GAL) in 150 
mM McIlvaine pH 4.6, supplemented with 0.1% (w/v) BSA and released 4MU 
was quantified as described earlier (Blom et al., 2003).  
        Activity of plant produced recombinant enzymes and Fabrazyme towards 
5 μM of NBD-C12-Gb3 substrate was measured for 3 hrs at 37 oC in 150 mM 
McIlvaine buffer (pH 4.6) containing 0.05% (v/v) Triton X-100 and 0.2% (w/v) 
sodium taurocholate, pH 4.6. Lipids were extracted with the Bligh and Dyer 
procedure, applied to HPTLC. The plate was scanned for fluorescent lipids with 
a Typhoon FLA 9500. Protein concentrations in assay were for Fabrazyme 3.8 
μg/ml, α-GAL 3.2 μg/ml, α-NAGAL 40 μg/ml, and α-NAGALEL 16 μg/ml. Activity 
of recombinant enzymes towards natural C18: Gb3 was measured using 500 
pmol of lipid in (100 μl total volume) 150 mM McIlvaine buffer with 0.05% (v/v) 
Triton X-100 and 0.2% (w/v) sodium taurocholate for 3 hrs at 37 oC. The pH was 
4.2 for α-GALs and 5.2 for α-NAGALs. After incubation, neutral lipids were 
extracted by the Folch method. Deacetylation of lipids was performed as 
described earlier (Ferraz et al., 2016b). After deacetylation, samples were dried 
and further cleaned by adding 1:1 butanol: water. The butanol phase was 
collected, dried and lipids were dissolved in 200 μl methanol, ready for LC-
MS/MS injection. The conversion of Gb3 to lactosylceramide (Lac Cer) was 
measured in LC-MS/MS using C17-Gb3 and C17-Lac Cer as controls and C17-
Sphinganine as internal standard. The same assay conditions were used when 
applying natural Lyso-Gb3 as substrate. Lipids were extracted according to 
Bligh and Dyer and subjected to LC-MS/MS injection as above. Isotope 13C-
Lyso-Gb3 was used as an internal standard for monitoring the conversion of 




Lyso-Gb3 into Lyso-Lac Cer. Protein concentrations in assays were for 
Fabrazyme 1.9 μg/ml, α-GAL 1.6 μg/ml, α-NAGAL 20 μg/ml and α-NAGALEL 8 
μg/ml.  
Determination of kinetic parameters. Km, Vmax and kcat values were determined 
using 4MU substrates. Reactions were performed for 1hr or 30min at 37 oC at 
10 different 4MU-α-GAL and 4MU-α-NAGAL concentrations in 150 mM 
McIlvaine pH 4.6 supplemented with 0.1% (w/v) BSA. The 4MU-α-GAL 
concentrations in the assays ranged from 0.074 to 4.72 mM; for 4MU-α-NAGAL 
from 0.022 to 0.91 mM. Protein concentrations in the assays were: for α-GAL 7 
ng/ml, Fabrazyme 2 ng/ml, α-NAGAL 16 ng/ml, when using 4MU-α-NAGAL 
substrate and 100 ng/ml, when using 4MU-α-GAL substrate, and for α-
NAGALEL 16 ng/ml. Parameters were calculated using GraphPad Prism6.  
N-glycan analysis of plant produced α-galactosidases. Proteins were 
deglycosylated with EndoH and PNGase F (Wilbers et al., 2016). MALDI-TOF 
analysis performed as previously described (Wilbers et al., 2016). 
SDS-PAGE and Western blotting. To examine purity and molecular mass of 
recombinant α-galactosidases, sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS- PAGE) (10 % polyacrylamide) was used (Witte et al., 
2010). Samples were run under reduced conditions. After SDS-PAGE analysis, 
gels were stained with Coomassie Brilliant Blue staining or silver stain using 
the PhastSystem system (GE Healthcare). Western blotting and fluorescence 
scanning for ABP-labeled protein was performed exactly as described earlier 
(Willems et al., 2014).  
Protein determination. Protein concentrations were determined with a Micro 
BCA Protein Assay Reagent Kit (PIERCE), and bovine serum albumin was 
used as a standard according to the supplier’s protocol. In addition, pure protein 
concentrations were measured in NanoDrop 2000c (Thermo Scientific) via 
adjusting the molecular weight and extinction coefficient parameteres.  
Detection of cross reactivity with Antibody (Ab) -positive FD serum. Samples 
were incubated for 1hr 4 oC while rolling, with 2 μl Ab+ FD serum or normal 
serum of an FD patient and α-galactosidase activity was measured with 4MU-
α-GAL and 4MU-α-NAGAL substrate (Linthorst et al., 2004).  
Degradation of Lyso-Gb3 in FD serum. To serum from 2 different FD patients 
pre-ERT, recombinant enzymes (8 μmol artificial substrate hydrolysis/h/ml) 
were added and incubated overnight at 37 oC. Then, lipids were extracted as 
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Supplementary material  
 
Synthesis and characterization of activity-based probe α-galactopyranose-
configured cyclophellitol aziridine tagged with fluorescent Cy-5. 
 
Synthesis  
All chemicals were purchased from Acros, Sigma Aldrich, Biosolve, VWR, 
Fluka, Merck and Fisher Scientific and used as received unless stated 
otherwise. Dichloromethane (DCM), N,N-dimethylformamide (DMF) and 
toluene were stored over flame-dried 4 Å molecular sieves before use. Traces of 
water from reagents were removed by co-evaporation with toluene in reactions 
that require anhydrous conditions. All reactions were performed under an 
argon atmosphere unless stated otherwise. TLC analysis was conducted using 
Merck aluminium sheets (Silica gel 60 F254) with detection by UV absorption 
(254 nm), by spraying with a solution of (NH4)6Mo7O24·4H2O (25 g/L)  and 
(NH4)4Ce(SO4)4·2H2O (10 g/L) in 10% sulfuric acid, a solution of KMnO4 (20 g/L) 
and K2CO3 (10 g/L) in water or ninhydrin (0.75 g/L), followed by charring at 
150 ˚C. Column chromatography was performed using Screening Device b.v. 
Silica Gel (particle size of 40 – 63 µm, pore diameter of 60 Å) in the indicated 
solvents. For reversed-phase HPLC purifications an Agilent Technologies 1200 
series instrument equipped with a semiprep column (Gemini C18, 250x10 mm, 
5 µm particle size, Phenomenex) was used. LC/MS analysis was performed on 
a Surveyor HPLC system (Thermo Finnigan) equipped with a C18 column 
(Gemini, 4.6 mm x 50 mm, 5 μm particle size, Phenomenex), coupled to a LCQ 
Adventage Max (Thermo Finnigan) ion-trap spectrometer (ESI+). The applied 
buffers were H2O, MeCN and 1% aqueous TFA. 1H NMR and 13C NMR spectra 
were recorded on a Brüker AV-400 (400 and 101 MHz respectively) or a Bruker 
AV-850 (850 and 214 MHz respectively) spectrometer in the given solvent. 
Chemical shifts are given in ppm (δ) relative to the residual solvent peak as 
internal standard. Coupling constants are given in Hz. High-resolution mass 
spectrometry (HRMS) analysis was performed with a LTQ Orbitrap mass 
spectrometer (Thermo Finnigan), equipped with an electronspray ion source in 
positive mode (source voltage 3.5 kV, sheath gas flow 10 mL/min, capillary 
temperature 250 °C) with resolution R = 60000 at m/z 400 (mass range m/z = 
150–2000) and dioctyl phthalate (m/z = 391.28428) as a “lock mass”. The high-
resolution mass spectrometer was calibrated prior to measurements with a 









Cy5 OSu ester 1(Kvach et al., 2008) (3.10 g, 5.0 mmol) and propargylamine (0.35 
mL, 5.5 mmol) were dissolved in CH2Cl2 (25 mL). After addition of Et3N (6.0 
mmol, 0.84 mL), the reaction mixture was stirred for 2.5 h at room temperature. 
The reaction mixture was concentrated in vacuo and purification by column 
chromatography (1% MeOH in CH2Cl2 → 4% MeOH in CH2Cl2) gave Cy5-
alkyne 2 (690 mg, 1.24 mmol, 25%) as a dark-blue foam. 1H NMR (400 MHz, 
MeOD): δ 8.26 (t, J = 13.1 Hz, 2H), 7.48 (d, J = 7.4 Hz, 2H), 7.44 – 7.35 (m, 2H), 
7.29 (d, J = 7.9 Hz, 2H), 7.24 (t, J = 7.4 Hz, 2H), 6.71 (t, J = 12.4 Hz, 1H), 6.31 
(t, J = 13.5 Hz, 2H), 4.12 (t, J = 7.4 Hz, 2H), 3.92 (d, J = 2.5 Hz, 2H), 3.63 (s, 
3H), 2.57 (t, J = 2.6 Hz, 1H), 2.23 (t, J = 7.3 Hz, 2H), 1.84 (dt, J = 14.9, 6.3 Hz, 
2H), 1.75 – 1.66 (m, 14H), 1.51 – 1.46 (m, 2H). 13C NMR (101 MHz, MeOD): δ 
175.4, 175.2, 174.5, 155.4, 144.2, 143.5, 142.6, 142.5, 129.7, 129.6, 126.8, 126.1, 
123.4, 123.3, 112.0, 111.8, 104.4, 55.9, 50.5, 44.8, 36.4, 31.8, 29.4, 28.2, 28.0, 






To a solution of 8-azidooctanoic acid (David et al., 2003) (94 mg, 0.50 mmol) in 
DMF (4 mL) was added Cy5-alkyne 2 (282 mg, 0.50 mmol) at room temperature. 
After addition of copper (II)sulfate pentahydrate (500 µL, 1 M in H2O) and 
sodium ascorbate (700 µL, 1 M in H2O) the reaction mixture was heated up to 
80 °C and stirred overnight. The reaction mixture was concentrated in vacuo, 
redissolved in CH2Cl2 and washed with HCl (0.1 M, 3 x) and brine (1 x). The 




organic layer was dried over MgSO4 and concentrated in vacuo to obtain Cy5 
acid 3 (0.43 mmol, 0.32 g, 86%) which was used without further purification. 
LC/MS analysis: Rt 7.27 min linear gradient 10% -> 90% B in 12.5 min, m/z 
705.33 [M]+. HRMS: calculated for [C43H57N6O3]+ 705.44867, found 705.44892. 
To a solution of crude Cy5 acid 3 (111 mg, 0.12 mmol) in DMF (0.8 mL) was 
added EEDQ (30 mg, 0.12 mmol) and stirred for 2 h at room temperature to 
obtain a pre-activated mixed anhydride solution. Aziridine 5 (17.4 mg, 0.1 
mmol) was dissolved in DMF (0.4 mL) and pre-activated mixed anhydride 
solution (0.5 eq.) was added at 0 °C. After stirring for 30 min additional pre-
activated mixed anhydride solution (0.5 eq.) was added. The reaction mixture 
was stirred for 30 min after which additional EEDQ (25 mg, 0.10 mmol) was 
added. After stirring overnight at 4 °C, the reaction mixture was quenched with 
MeOH at 0 °C and concentrated in vacuo. Purification by semi preparative 
reversed phase HPLC at neutral conditions (A: 50 mM NH4HCO3 in H2O, B: 
MeCN; linear gradient: 44% → 50% B in 12 min) gave compound 4 (4.39 mg, 
4.88 µmol, 5%) as a blue powder. LC/MS analysis: Rt 6.13 min and 6.37 min, 
linear gradient 10% -> 90% B in 12.5 min, m/z 862.40 [M]+. 1H NMR (850 MHz, 
MeOD): δ 8.24 (td, J = 13.2, 3.5 Hz, 2H), 7.84 (d, J = 4.7 Hz, 1H), 7.49 (d, J = 7.3 
Hz, 2H), 7.44 – 7.39 (m, 2H), 7.32 – 7.24 (m, 4H), 6.62 (t, J = 12.3 Hz, 1H), 6.30 
– 6.25 (m, 2H), 4.41 (d, J = 7.2 Hz, 2H), 4.38 – 4.34 (m, 2H), 4.11 – 4.06 (m, 3H), 
3.87 – 3.84 (m, 1H), 3.63 (s, 3H), 3.59 – 3.55 (m, 2H), 3.53 (dd, J = 10.7, 6.3 Hz, 
1H), 3.44 (dd, J = 10.7, 6.0 Hz, 1H), 3.36 (dd, J = 8.9, 1.9 Hz, 1H), 2.95 (dd, J = 
6.0, 4.0 Hz, 1H), 2.60 (d, J = 6.0 Hz, 1H), 2.25 (t, J = 7.3 Hz, 2H), 2.01 (td, J = 
7.4, 3.8 Hz, 1H), 1.88 – 1.86 (m, 2H), 1.84 – 1.79 (m, 2H), 1.74 – 1.71 (m, 13H), 
1.62 – 1.55 (m, 2H), 1.48 – 1.45 (m, 2H), 1.36 – 1.27 (m, 6H). 13C NMR (214 
MHz, MeOD): δ 187.2, 174.3, 174.0, 173.2, 154.1, 154.0, 144.7, 142.8, 142.1, 
141.2, 141.1, 128.3, 128.3, 125.2, 124.9, 124.8, 122.7, 122.0, 121.8, 110.6, 110.4, 
103.0, 102.8, 72.9, 71.7, 68.1, 64.2, 61.4, 61.4, 49.7, 43.3, 43.1, 41.8, 38.0, 35.0, 
34.2, 29.7, 28.7, 28.5, 28.2, 26.7, 26.5, 26.4, 25.9, 25.8, 24.9. HRMS: calculated 
for [C50H68N7O6]+ 863.53038, found 863.52566. 
        The synthetic strategy towards α-galactopyranose-configured 
cyclophellitol aziridine ABP 4 is depicted in Scheme 1. It was envisioned that 
coupling of Cy5-functionalized spacer 3 with reported aziridine 5 (Willems et 
al., 2014) using 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (EEDQ) as the 
coupling reagent, would result in ABP 4. Hence, Cy5-functionalized spacer 3 
was synthesized in 2 steps from Cy5-OSu ester 1 (Kvach et al., 2008).  
Propargylamine was reacted with Cy5-OSu ester 1 to obtain compound 2 with 
an alkyne moiety. Copper(I)-catalyzed click reaction of 2 with 8-azidooctanoic 
acid gave Cy5-functionalized spacer 3, which in turn was coupled to aziridine 5 







Scheme 1. Overview of synthesis. Reagent and conditions: a) propargylamine, Et3N, CH2Cl2, 2.5 h, 
room temperature, 25%; b) 8-azidooctanoic acid, CuSO4·5H2O, sodium ascorbate, DMF, 80 °C, 
overnight; c) 5 (Willems et al., 2014),EEDQ, 0 °C to 4 °C, overnight, DMF, 5% over 2 steps. 
 
 






Figure S1. Characterization of ABP. (A) Inhibition of 4MU-α-GAL activity of Fabrazyme, after 
incubation with different ABP concentrations for different time periods. (B) In vitro labeling of human 







Figure S2. Gel filtration chromatograms of plant produced enzymes and calibration curve. (A) 
Chromatograms of all recombinant α-galactosidases after their application in Superdex™ 200 Increase 
10/300 GL. (B) Gel filtration chromatography calibration curve of proteins with known molecular weight, 
fitting the results of the plant produced enzymes. Proteins used for the calibration curve were β-amylase, 
alcohol dehydrogenase, albumin, carbonic anhydrase, cytochrome c from horse heart and Dextran. 





Figure S3. pH optimum of recombinant galactosidases towards Gb3. Different amounts of 
recombinant proteins, α-NAGALEL, α-NAGAL, α-GAL and Fabrazyme were incubated with 100pmol of 
C18:Gb3 overnight at 37 oC. For detection of Lac Cer formation, lipids extracted and subjected to LC-
MS/MS. 
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α-Galactosidases (EC 3.2.1.22) are retaining glycosidases that cleave terminal α-
linked galactose residues from glycoconjugate substrates. α-Galactosidases 
take part in the turnover of cell wall–associated galactomannans in plants and 
in the lysosomal degradation of glycosphingolipids in animals. Deficiency of human 
α-galactosidase A (α-Gal A) causes Fabry disease (FD), a heritable, X-linked 
lysosomal storage disorder, characterized by accumulation of 
globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3). Current 
management of FD involves enzyme-replacement therapy (ERT). An activity- 
based probe (ABP) covalently labeling the catalytic nucleophile of α-Gal A has 
been previously designed to study α-galactosidases for use in FD therapy. Here, 
we report that this ABP labels proteins in Nicotiana benthamiana leaf extracts, 
enabling the identification and biochemical characterization of an N. 
benthamiana α-galactosidase we name here A1.1 (gene accession ID GJZM-
1660). The transiently overexpressed and purified enzyme was a monomer 
lacking N-glycans and was active toward 4-methylumbelliferyl-α-D-
galactopyranoside substrate (Km = 0.17 mM) over a broad pH range. A1.1 
structural analysis by X-ray crystallography revealed marked similarities with 
human α-Gal A, even including A1.1’s ability to hydrolyze Gb3 and lyso-Gb3, 
which are not endogenous in plants. Of note, A1.1 uptake into FD fibroblasts 
reduced the elevated lyso-Gb3 levels in these cells, consistent with A1.1 delivery 
to lysosomes as revealed by confocal microscopy. The ease of production and the 
features of A1.1, such as stability over a broad pH range, combined with its 
capacity to degrade glycosphingolipid substrates, warrant further examination 















α-Galactosidases (EC 3.2.1.22) occur widely in plants, animals, and 
microorganisms. Based on primary and secondary structures, they are 
classified into the three glycoside hydrolase families 4, 27, and 36. Family 
27 contains mainly eukaryotic α-galactosidases removing terminal α-
galactosyl moieties from glycoconjugates (Henrissat and Romeu 1995; 
Maranville and Zhu 2000; Carmi et al. 2003). Plant α-galactosidases are so far 
known to participate in the catabolism of galactosyl-sucrose oligosaccharides, 
raffinose family of oligosaccharides, and cell wall galactomannans primarily 
during germination of seeds (Murali et al. 1994; Gao and Schaffer 1999; Kim 
et al. 2002; Carmi et al. 2003; Fujimoto et al. 2003). In man, a single α-
galactosidase occurs in lysosomes, α-galactosidase A (α-Gal A), and is primarily 
responsible for the metabolism of glycosphingolipids (Desnick 1995; Toumi et 
al. 2012). 
        A well-established classification of the plant enzymes is based on their 
pH optimum for enzymatic activity: acidic ones with broad pH optima from 
4.5 to 6.5, and alkaline ones with pH optimum between 7.0 and 7.5 (Carchon 
and DeBruyne 1975; Carmi et al. 2003). These two classes of plant α-
galactosidases might differ in localization. The acidic α-galactosidases most 
likely locate inside the vacuoles and apoplast, whereas alkaline α-
galactosidases act in the cytoplasm with a neutral pH, where they might 
catalyze removal of terminal galactose residues of substrates (Carchon and 
DeBruyne 1975; Carmi et al. 2003). One of the first plant α-galactosidases to be 
cloned and biochemically characterized was an enzyme from coffee beans 
(Marraccini Pierre et al. 2005). It occurs as two different isoforms with molecular 
masses of 28 and 36.5 kDa showing slightly different pH optima (pH 5.3 
and 6.3) and isoelectric points (Haibach et al. 1991; Ioannou et al. 2001). 
Similar heterogeneity of α-galactosidases exists in other plant species, for 
example in rice (Kim et al. 2002). Interestingly, the acidic plant α-
galactosidases are most homologous to the human enzyme (Carmi et al. 
2003). For example, rice α-galactosidase shows 37% homology in amino acid 
sequence to human α-Gal A (Fujimoto et al. 2003). 
        The human α-Gal A enzyme is able to cleave α-1,4-linked galactosyl 
moieties from glycosphingolipids such as globotriaosylceramide (Gb3; 
ceramide trihexoside) and galabiosylceramide and from blood groups B, B1, 
and P1 antigens. The hydrolase is encoded by the GLA gene (gene ID, 2717) 
at locus Xq22 (Ioannou et al. 2001). Its mature form lacking the signal 
sequence contains 398  amino  acids  with  three  N-glycans,  naturally  
forming homodimers (Hamers et al. 1977; Bishop et al. 1988; Ioannou et al. 
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2001; Schiffmann et al. 2001). Mannose 6-phosphate moieties (Man-6-P) on the 
three N-linked glycans of α-Gal A mediate the transport of newly formed 
enzyme to lysosomes by Man-6-P receptors (MPRs). Alternative sorting via the 
mannose receptor pathway was suggested by Sakuraba et al. (Sakuraba et al. 
2005) and Shen et al. (Shen et al. 2016). 
        Dysfunction or absence of α-Gal A leads to Fabry disease (FD), an X-
linked lysosomal disorder characterized by accumulation of 
glycosphingolipids with terminal galactosyl moieties in tissues and body 
fluids of FD patients (Charles C. Sweeley and Bernard Klionsky 1963; 
Desnick 1995). The classic manifestation of FD in males involves 
development of acroparasthesias, corneal clouding, and neuronopathic 
pain followed by later-onset renal and cardiac disease and strokes. Female 
carriers may develop an attenuated disease. In so-called atypical 
manifestations of FD, associated with missense mutations in α-Gal A, 
pathology is to a single organ like heart or kidney and only develops late in 
life (Desnick 1995). 
        Enzyme-replacement therapy (ERT) with an MPR-targeted 
recombinant enzyme is used to treat FD (Schiffmann et al. 2001; Eng et al. 
2007). Two therapeutic enzymes (agalsidase α, Replagal®, and agalsidase 
β, Fabrazyme®) produced in mammalian cells are in use, and a plant-
produced enzyme is being developed (Sakuraba et al. 2005; Kizhner et al. 
2015). The efficacy of present ERT interventions is considered to be poor 
(Arends et al. 2017). Unfortunately, most male FD patients lack the α-Gal 
A protein and consequently develop neutralizing antibodies against the 
therapeutic recombinant enzymes that might contribute to the noted poor 
responses to current treatments (Linthorst et al. 2004). Indeed, it was recently 
reported that compared with agalsidase inhibition-negative men, agalsidase 
inhibition-positive men showed greater left ventricular mass and 
substantially lower renal function (Lenders and Brand 2018). Additionally, 
these patients presented more often with symptoms such as diarrhea, 
fatigue, and neuropathic pain. Despite the lack of residual α-Gal A, even in 
classic male FD patients, Gb3 accumulation is leveling with age. In Fabry 
patients, accumulating Gb3 is alternatively metabolized in lysosomes by 
acid ceramidase to globotriaosylsphingosine (lyso-Gb3) (Ferraz et al. 2016). 
In plasma of male FD patients and mice, lyso-Gb3 is several hundred-fold 
elevated, an abnormality that can be exploited for diagnosis and monitoring 
of disease progression and therapeutic correction (Aerts et al. 2008; Gold et 
al. 2013; Mirzaian et al. 2016, 2017). Excessive lyso-Gb3 is toxic for nociceptive 
neurons and podocytes, which might explain the development of 
neuronopathic pain and renal failure in FD patients (Choi et al. 2015; 
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Sanchez-Niño et al. 2015). Again, the formation of neutralizing antibodies in 
male FD patients receiving ERT is reported to impair reduction in plasma 
lyso-Gb3 (Linthorst et al. 2004). 
        Recently, novel chemical tools have been developed to study different 
retaining glycosidases, including α-galactosidases (Witte et al. 2011; Willems et 
al. 2014a). These activity-based probes (ABPs) are mechanism-based 
irreversible inhibitors functionalized with a bio-orthogonal tag such as a 
fluorophore or biotin. The first of these, ABPs, was developed for retaining 
β-glucosidases such as the human lys- osomal glucocerebrosidase (GBA). 
The natural glucosyl-configured suicide inhibitor cyclophellitol covalently 
binds the catalytic nucleophile residue, Glu-340, in the enzymatic pocket of 
GBA (Witte et al. 2010). Equipped with a fluorescent reporter, the C-6 
functionalized cyclophellitol permits specific and sensitive visualization of 
active enzyme molecules. Their amphiphilic nature renders the fluorescent 
ABPs membrane-permeable and allows in situ detection of active 
glucocerebrosidase in cells and organ- isms. Subsequently, cyclophellitol 
aziridine–type probes were developed to label, again in a mechanism-based 
manner, a broad range of β-glucosidases (Kallemeijn et al. 2014, 2017). 
Next, the approach was extended to other retaining glycosidases by 
variation of the cyclophellitol configuration, yielding ABPs for α-
galactosidases, β-galactosidases, α-fucosidases, and β-glucuronidases 
(Willems et al. 2014b, a; Jiang et al. 2015; Wu et al. 2017). Equipping the 
cyclophellitol scaffold with a biotin allows streptavidin-mediated 
enrichment and subsequent chemical proteomics experiments using LC-
MS/MS. The successful application of biotin-tagged ABPs in proteomics 
profiling of β-glucosidases from different plant species was demonstrated 
(Chandrasekar et al. 2014). A potent fluorescent α-galactosyl– configured 
cyclophellitol aziridine ABP was developed and shown to label human α-Gal 
A as well as α-Gal B, the homologous N-acetyl galactosaminidase arisen by 
a gene duplication (Willems et al. 2014a). 
        In this study, we used fluorescent α-galactosyl-configured 
cyclophellitol-aziridine ABPs and synthesized a biotinylated cyclophellitol-
aziridine ABP to search for α-galactosidases in Nicotiana benthamiana. 
With these tools, we were able to identify an abundant apoplast α-
galactosidase. We successfully cloned the gene and transiently 
overexpressed the protein, which we named A1.1, in N. benthamiana 
leaves. The recombinant enzyme was purified, crystallized, and 
biochemically characterized. We here report on the outcome of the 
investigation, including a comparison of the plant α-galactosidase with the 
human enzyme, which is deficient in FD patients. 





Screening for α-galactosidases in N. benthamiana leaf extracts and 
apoplast fractions. 
N. benthamiana leaf extracts and apoplast samples thereof were prepared 
and examined for α-galactosidase activity using 4-methylumbelliferyl–α-D-
galactose (4MU–α-Gal) as substrate. Enzyme activity, with a broad pH 
optimum of 5.0 – 6.7, was detected in both samples (Fig. 1A). Next, we 
incubated the leaf and apoplast samples with Cy5-functionalized TB474 
ABP at different pH values. In the case of the leaf extract, Cy5-ABP– labeled 
proteins with apparent molecular mass of ~39 and 45 kDa were detected 
(Fig. 1B). The apoplast fraction contained mainly the ~39-kDa labeled 
protein (Fig. 1B). To assess whether the plant α-galactosidases of interest 
are glycosylated, their binding to concanavalin A (ConA)-Sepharose beads 
was examined (Fig. 1, C and D). After incubation of samples with the lectin 
beads, ABP labeling and 4MU–α-Gal activities were per- formed. The ~39-
kDa protein did not bind to the lectin beads, in contrast to the ~45 kDa 
protein (Fig. 1C). Approximately 50 –55% of the 45-kDa protein is bound 
to the lectin beads, as judged by quantification of the band intensity of Fig. 
1C. This band corresponds to 5–10% of the total 4-MU–α-Gal activity, 
suggesting that the 45-Da protein is not as active as the 39 kDa protein. 
More than 80% of the total 39-kDa labeled protein in both lysate and 














Figure 1. Screening for α-galactosidases in N. benthamiana. Plant leaf lysates and apoplast 
samples were tested on their α-galactosidase activity via 4MU–Gal assays and ABP in vitro labeling, 
following in-gel detection of the labeled proteins. A, 4MU–α-Gal activities present in plant leaf lysates and 
apoplast samples were first examined at different pH values of 3– 8. (n = 2, error bars indicate mean ± S.D.) B, 45 
µg of plant leaf lysate and 12 µg of apoplast sample were incubated with 0.25 µM TB474 for 30 min at pH 4 –7 at 
room temperature. Labeled proteins were detected via in-gel fluorescent scanning (ABP), and the gels were 
stained with Coomassie Brilliant Blue (CBB) to show equal total protein loading. C, plant leaf lysates and 
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apoplast samples were incubated with ConA- Sepharose beads for2h at4 °C. After incubation, the samples 
were centrifuged, and different fractions were tested for α-galactosidase activity via ABP labeling and (D, left 
panel) 4MU–α-Gal assays. (n = 2, error bars indicate mean ± S.D.) In addition, D, right panel, quantification 
of the band intensity of C is presented. Samples tested: starting material = sample prior to ConA-Sepharose 
bead incubation, containing all proteins. Unbound = supernatant after incubation with the beads and 
centrifugation. This sample contains all material not bound to the beads. Wash = wash of the beads. Beads 
= pellet after incubation with the beads and centrifugation, containing the proteins attached to the ConA-
Sepharose beads. 
 
Identification of potential N. benthamiana α-galactosidases. 
Newly designed biotinylated ABP ME741 (Fig. 2A) was found to completely 
compete labeling of plant α-galactosidase in the apoplast fraction and leaf 
extracts by the Cy5-TB474 ABP (Fig. 2B). Conversely, labeling of plant α-
galactosidase by biotinylated ME741 (visualized by Western blotting with 
streptavidin- HRP) is blocked by prior incubation with TB474 ABP. Thus, 
both probes recognize the same α-galactosidases. Next, we conducted 
large-scale pull downs of the α-galactosidases present in leaf and apoplast 
samples using biotinylated ME741. After the pulldown, the target proteins 
were bound to streptavidin beads following bead tryptic digestion. Tryptic 
peptides were analyzed by nanoscale LC coupled to tandem MS (nano-LC- 
MS/MS) (Jiang et al. 2016). Peak lists were then searched against the Swiss-Prot 
(version June, 2017) database, and the identified peptides were manually 
curated. In this manner, peptides from known, well-annotated plant α -
galactosidases, similar in sequence to potential N. benthamiana α-
galactosidases, were identified (Table S1). 
 
 




Figure 2. Pulldown of plant α-galactosidases using ME741 and their identification by proteomics. 
A, i, α-galactosidase-configured aziridine scaffold; ii, Cy5 ABP, TB474; iii, biotin ABP, ME741. B, to prove 
that the same α-galactosidases are recognized by both ABPs, ME741 and TB474, competition experiments 
were performed. α-Galactosidases present in apoplast and plant leaf lysates were incubated with 0.25 µM 
ME741, at pH 5.5, for 30 min at room temperature, with or without subsequent incubation with 0.25 µM TB474, 
under the same conditions. Similarly, the samples were incubated first with TB474 and then with ME741. The 
labeled proteins were detected via in-gel fluorescent scanning and Western blot analysis using streptavidin-
HRP (dilution 1:4000). The blot was then stained with CBB to show equal protein loading. The black arrow 
indicates the 45-kDa band; the open arrow indicates the 29-kDa protein, and the gray arrow indicates 
unspecific biotinylated plant proteins. 
 
       The identified peptides belonged to Coffea arabica α-galactosidase 
(protein accession code Q42656) and Arabidopsis thaliana α-galactosidase 1 
and 2 (protein accession codes Q9FT97 and Q8RX86, respectively). Next, we 
conducted alignment analysis of the cDNA sequence encoding for C. arabica 
α-galactosidase, as it is a well-characterized protein, known not to be N-
glycosylated, toward the cDNA sequence of N. benthamiana (Sol Genomics 
Network). Based on the alignment, we designed specific primers to amplify 
the gene encoding for that most similar to Coffee, N. benthamiana α-
galactosidase, which we named A1.1. An additional peptide search was 
then conducted, after the insertion to the Swiss-Prot database of this 
new potential N. benthamiana enzyme, and the results were even more 
prominent (Table S2). We could identify more pep- tides, with better scores 
and higher protein coverage, indicating that this is the protein we were 
looking for and not the homologues from the other organisms. 
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N. benthamiana A1.1 purification and characterization 
To verify that A1.1 is truly an active α-galactosidase, we transiently 
overexpressed the enzyme via the Agrobacterium tumefaciens infiltration of 
N. benthamiana leaves. The p19 RNAi silencing inhibitor was used to 
ensure optimum protein expression levels (Wilbers et al. 2017). Leaves were 
harvested at different days post- infiltration (dpi), and A1.1 expression in 
the total leaf as well as in apoplast fluid was detected by 4MU–α-Gal 
activities, TB474 ABP labeling, and Coomassie Brilliant Blue staining of 
SDS- polyacrylamide gels (Fig. 3, A and B). Optimal starting materials for 
purification were apoplast fractions, collected at 4 dpi, showing the highest 
4MU–α-Gal activity. The α-galactosidase activity per µg of protein in 
apoplast fractions was 20 – 40-fold higher in the case of leaves 
overexpressing A1.1, as compared with those treated with empty vector or 
nontreated plant leaves. A1.1 α-galactosidase was purified to homogeneity 
in three purification steps with high recovery (>30%) (Table 1). The presence 
of the enzyme in fractions was monitored by enzymatic assay with 4MU–α-
Gal substrate. As the first purification step, we used ConA column 
chromatography, collecting the unbound material (flow-through fraction). 
In this step, other α-galactosidases were removed by binding to the lectin 
column. Next, cation-exchange chromatography was applied, resulting in a 
further modest purification (recovery 40%). Finally, the sample was 
subjected to gel-filtration chromatography, revealing that A1.1 behaves as 
monomer of about 30 kDa (Fig. S1). The final preparation of A1.1 was 
apparently pure as judged by SDS-PAGE analysis following silver staining 
of the gel (see Fig. 3B for an overview of the entire purification). 
        A1.1 seems not to carry N-glycosyl groups as demonstrated by the 
lack of effect of PNGase and EndoH on its molecular weight (Fig. 3C). The 
molecular weight of A1.1, in contrast to that of Fabrazyme, is not influenced 
after the endoglycanase treatments (Fig. 3C). Consistently, following 
incubation of A1.1 with PNGase A, no released N-glycans were detected by 
MALDI-TOF MS analysis (Fig. S2). 
 
 









Figure 3. Overexpression and biochemical characterization of the newly identified N.  
benthamiana α-galactosidase, A1.1. A, transient overexpression    of A1.1 in N. benthamiana leaves 
via A. tumefaciens transformation assays. Infiltrated leaves and apoplast samples were harvested on 
different days post- infiltration (dpi): 2, 4, and 6. The expression levels of the enzyme were first tested via 4MU–
α-Gal activities in lysates and apoplast fractions of different dpi. n =2. (A1.1 = leaf overexpressing A1.1; E. = 
empty vector; N. = nontreated plant leaf.) B, next, the expression levels of active enzyme molecules were 
(C) 
(D) 
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tested via in-gel ABP labeling. CBB staining of the gels followed to ensure the presence of the overexpressed 
enzyme. (P. = plant lysate; A. = apoplast sample; E. = empty vector; N. = nontreated plant leaf.) C, purification 
overview. SDS-PAGE analysis following silver staining of fractions obtained during different purification steps. 
(St. M. = starting material; ConA = fraction not bound to concanavalin A column; D. = sample obtained after 48 
h of dialysis; C.E. = pooled collected eluate from cation-exchange chromatography; G.F. = final pooled 
fraction obtained after gel filtration.) 2 µg of total protein were loaded in each lane, except in G.F., where 1 µ,g 
was loaded. D, SDS-PAGE analysis following Coomassie Brilliant Blue staining of 1 µ,g of pure A1.1 and 
Fabrazyme after treatment with PNGase F and EndoH (C = untreated pure enzyme; P = enzyme treated with 
PNGase F; E = enzyme treated with EndoH), shows that A1.1 is not likely N-glycosylated, whereas Fabrazyme 




Structural features of A1.1 α-galactosidase determined by crystallography 
Pure N. benthamiana A1.1 was crystallized. The protein structure was 
determined at a resolution of 2.8 Å using the molecular replacement method 
with the rice α-Gal A (PDB code 1UAS) as search model. The statistics data 
of the collection and refinement are listed in Table 2. The protein model is 
a monomer, consisting of 363 amino acids (not including the first 57 amino 
acid signal-peptide sequence) and being separated into two domains. The 
N-terminal domain or catalytic domain (1–278) contains a TIM (β/α)8-barrel, 
a common motif among glycosidases (Fujimoto et al. 2003), and the C-
terminal domain (279 –363) contains eight β-strands forming a “Greek key” 
motif (Fig. 4A).  
        The active site of the enzyme is found by prediction as the final model 
obtained without a bound ligand, at the C-terminal end of the catalytic 
domain. Similar to other glycoside hydrolases of family 27, two aspartic acid 
residues (Asp-181 and Asp-236) were observed to serve as the catalytic 
amino acids, one acting as the nucleophile and the other as the acid/base, 
taking part in the double displacement reaction mechanism of α-
galactosidases (Guce et al. 2010). A1.1 is negatively charged at the site of its 
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active site and more neutral at the opposite site (Fig. 4B). The pI of the 
enzyme is at around 5.32. Amino acid sequence alignment of A1.1, human 
(protein accession code P06280), rice (protein accession code Q9FXT4), and 
coffee (protein accession code Q42656) α-Gals reveals great secondary 
structure identity of all enzymes (Fig. 4C). A1.1 share 42% amino acid 
identity with the human enzyme, showing overall highly conserved 
secondary structures at the catalytic domain and not as much at the C-ter- 
minal domain. No Asn-Xaa-(Ser/Thr/Cys) motifs are present in amino acid 
sequences of A1.1, revealing that the protein is most likely not N-
glycosylated. In contrast, four potential N-glycosylation sites are present in 
human enzyme. A common amino acid sequence pattern (CEW, at positions 
212–214 in Fig. 4C) occurs in all aligned galactosidases, as described 
previously by Motabar et al. (Motabar et al. 2010). 
The overall structure of A1.1 is very similar to that of human (PDB code 
3HG2) α-Gal A, as visualized by the superimposed models, consistent with 
their 42% sequence identity (Fig. 4D, left panel). In addition, a closer look 
at the active site of both enzymes shows great conservation of the majority 









Table 2. Data collection and refinement statistics. PBD: 6F4C. Table 3. Activity of A1.1 towards different 4MU substrates. 
 
  
Data collection and refinement statistics 








a, b, c, α, β, γ 
74.04Å, 74.04Å, 133.31Å 
90.00, 90.00, 90.00 
pH 5.2 
β-D-glucopyranoside 8 
Resolution (Å) 25.00  2.80 
24.77  2.80 
pH 5.8 
β-D-glucopyranoside 0 
% Data completeness 







< I=(I) > 2.53 (at 2.80Å) pH 4.6 
 
Refinement program REFMAC 5.8.0158 α-D-galactopyranoside 1645 
 pH 6  
R, Rfree 0.216 , 0.287   
0.225 , 0.282 β-D-galactopyranoside 8 
Rfree test set 486 reflections (5.30%) 
Fo,Fc correlation 0.88 
Total number of atoms 2861 
Average B, all atoms (Å2) 4.0 
Ramachandran plot (%) 
Prefered regions 96 
Allowed regions 3 
Outlayers 1 
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Figure 4. Structural similarities of α-galactosidases from different species. A, stereo view of the 
ribbon model of A1.1 (PDB code 6F4C). Catalytic domain contains a (β/α)8-barrel. C-terminal domain 
forms a Greek key. β-Strands are represented in green; α-helices are represented in pink; and loops are 
represented in light blue. B, electrostatic map of A1.1: red indicates the - charges; blue indicates the + 
charges. C, multiple amino acid sequence alignment of A1.1: human, rice, and coffee galactosidases. The 
sequence alignment showing structural details of A1.1 was achieved using ESPript3.0. α-Helices are 
shown as coils labeled a; β-strands are shown as arrows labeled β, and β-turns are labeled TT. Identical 
residues are shown on a red background; conserved residues are shown in red, and conserved regions 
are shown as blue boxes. The catalytic residues are indicated with an asterisk. D, right panel, stereo view 
of the superimposed models of A1.1 with the human α-galactosidase. 348 residues were aligned, 
having a root-mean-square deviation of 1.3358 Å of their C-α atoms. The A1.1 model (PDB code 6F4C) 
is shown in green; the human α-Gal model (PDB code 3HG2) is shown in gray. The backbone of a modeled 
galactose molecule is shown in white, and its oxygen atoms are shown in red. Left panel, a closer look at 
the amino acids around the active site of both enzymes, presented as fat bonds. 
 
Catalytic features of A1.1 
We first examined substrate specificity of pure A1.1 using artificial 4-
MU– glycoside substrates (Table 3). The enzyme hydrolyzes with 
considerable affinity 4MU–α-Gal substrate but is inactive toward β-D-
glucopyranoside, β-D-galactopyranoside, α-D-mannopyranoside, α-L-
fucopyranoside, N-acetyl-α-D-galac- tosaminide, and N-acetyl-β-D-
glucosaminide. The pH optimum of A1.1 with 4MU–α-Gal substrate is 
broad, ranging from pH 5.0 to 6.5 (Fig. 5A). The apparent Km with 4-MU–α-
Gal is 0.17 mM and kcat 81  s-1 (Fig.  5B).  Comparable kinetic values are also 
obtained with Fabrazyme, although its pH optimum toward 4MU–α-Gal 
substrate is rather acidic at pH 4.5 (Fig. 5, A and B). 
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        The structural resemblance of A1.1 with human α-Gal A prompted us 
to examine its activity toward glycosphingolipid substrates. First, we tested 
the activity of A1.1 toward artificial NBD-labeled Gb3. A1.1 was found to 
convert NBD-Gb3 to NBD- lactosylceramide by removal of the terminal a-
linked galactose. The activity of A1.1 toward NBD-Gb3 is in several aspects 
comparable with that of Fabrazyme (recombinant human α-Gal A). The pH 
optimum is similarly acidic at pH 4.5 (Fig. 5C). The affinity of A1.1 for NBD-
Gb3 is high with an apparent Km of 32 µ,M, similar again to that of 
Fabrazyme. However, the kcat value is ~4-fold lower than that of human α-




        Next, we tested natural glycosphingolipids as substrates. A1.1 
degrades natural C18-Gb3 by converting it to C18-LacCer as measured by 
HPLC analysis (47). Its activity is again comparable with that of human 
enzyme: 96.3% of C18-Gb3 is con- verted to LacCer upon overnight 
incubation with 3 µg of A1.1 at pH 4.5 versus 98.3% conversion with the 
same amount of Fabrazyme at the same condition. In addition, A1.1 
hydrolases best this lipid substrate (C18-Gb3) again at acidic conditions, 
pH 4.6, the same as for the human enzyme (Fig. S3, A and B). 
        Finally, we determined by LC-MS/MS the ability of A1.1 to degrade 
lyso-Gb3, the toxic base of Gb3, to lactosylsphingosine (Mirzaian et al. 2017). 
A1.1 degrades lyso-Gb3, showing a Km of 37 µM, quite comparable with that 
of Fabrazyme. Its kcat value, however, is ~2-fold lower than that of the 
human enzyme (Fig. 5B). The noted activity of A1.1 toward 
Table 2. Data collection and refinement statistics. PBD: 6F4C. Table 3. Activity of A1.1 towards different 4MU substrates. 
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glycosphingolipid substrates in vitro resembles the earlier observed ability 





Figure 5. Activity of N. benthamiana A1.1 and Fabrazyme toward 4MU-α-GAL and human 
glycosphingolipids. A, 4MU–α-Gal activities of pure A1.1 and Fabrazyme at different pH values (3.8 – 8). 
B, Michaelis-Menten kinetic values of both enzymes toward 4MU–α-Gal, NBD-Gb3, and lyso-Gb3 substrates. 
Data represent mean values, n > 2. C, degradation of 5 µM NBD-Gb3 to NBD-Lac Cer by 50 ng of A1.1 or 
Fabrazyme at varying pH values (4.5–7.5). Quantification of HPTLC plates were conducted more than once, 
showing one gel quantification. 
 
A1.1 reduces lyso-Gb3 in intact FD fibroblasts 
At first the uptake of A1.1 from lysosomes of two different FD patients’ 
fibroblasts was evaluated. Different amounts of pre-labeled enzyme with 
TB474 A1.1 were applied overnight to the cells. After extensive washing (Fig. 
S4), the cells were lysed, and the uptake of A1.1 was studied via SDS-PAGE 
analysis (Fig. 6A). The cells from both FD patients were able to uptake A1.1. 
An increase in the uptake depending on the concentration of the pre-labeled 
protein added to the culture media was observed. To estimate the amount of 
the internalized enzyme, 1% of the input using 150 and 300 µg/ml were loaded 
on gel, together with 13–17% of the total lysates after treatment with the 
prelabeled enzyme (Fig. 6B). The quantification of the gels revealed that 0.3– 
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0.6% of the 150 µg/ml entered the cells, and 0.5–1% of the 300 µg/ml (Fig. 6C). 
        In addition, the uptake of the enzyme was studied by confocal microscopy. 
For this, A1.1 was again labeled with TB474 and subsequently applied to 
the FD fibroblasts. After a 16-h uptake, punctate fluorescence was observed 
in some cells, which was reminiscent of a lysosomal pattern, possibly 
through fluid-phase endocytosis. Immunofluorescent staining of the late 
endosomal/lysosomal marker LAMP-1 occasionally showed co-localization 
with TB474-A1.1, indicating lysosomal delivery of the enzyme (Fig. 6D).  
        To examine whether A1.1 is also able to degrade glycosphingolipid in 
vivo, we incubated the same cultured FD fibroblasts the exposure to A1.1 
(Fig. 7A) with 300 µ,g/ml A1.1. After overnight incubation, the cells were first 
washed and lysed, and the levels of both lyso-Gb3 and Gb3 were determined 
by LC-MS/MS. In addition, the 4MU– α-GAL cellular activity was 
measured. The elevated lyso-Gb3 and Gb3 in both FD fibroblasts were found 
to be significantly reduced by the exposure to A1.1 (Fig. 7A). In addition, the 
4MU–α-Gal cellular activity was significantly increased after exposure to the 
recombinant protein (Fig. 7B). Activities were also measured at washing 
steps 1 and 5 to ensure that no protein remained out- side of the cells prior 
to lysis (Fig. S5).  
 
 






Figure 6. Internalization of TB474-labeled A1.1 from Fabry fibroblasts. A, Fabry fibroblasts from 
two different patients were grown in 12-well plates. The cells were incubated with different amounts pre-
labeled with TB474, A1.1 (0, 5, 10, 70, 150, and 300 µg per 1 ml of culture media). Lysis of the cells took place, 
and samples were measured for Cy5 signal, through SDS-PAGE. Left top panel, results were obtained when 
using patient 1 cell line, SDS-polyacrylamide gel image, following fluorescent scanning and quantification of 
signal, left bottom panel. Right panel, results obtained from patient 2 cell line. The gels were conducted 
more than once. The uptake is gradually increased while increasing the amount of pre-labeled protein in both 
cell lines. 10 µg of total fibroblast protein was added in each well. Coomassie staining of the cells took place to 
show equal loading. ABP = activity-based probe signal; CBB = Coomassie Brilliant Blue signal; P1 = patient 
1; P2 = patient 2. B, estimation of the % of the internalization of pre-labeled A1.1 (150 and 300 µg per ml of 
culture media) from the same FD fibroblasts. Loaded on gel, 1% of the pre-labeled A1.1 input, together with 
10 µg of total fibroblast protein, accounted for 13–17% of the total cell lysate. C, quantification of signal 
obtained in B. The uptake of 150 µg of A1.1 account to 0.3– 0.5% of the total input and 0.5–1% when using 300 
µg. ABP = activity-based probe signal; P1 = patient 1; P2 = patient 2. D, overnight uptake of A1.1, pre-
labeled with TB474, by FD fibroblasts monitored by confocal microscopy. Cells were grown overnight on 
glass coverslips and incubated with 150 µg of pre-labeled A1.1 per ml of culture medium (here shown cells 
from patient 1). Panel in red, visualization of the internalized TB474-labeled A1.1. Panel in green, lysosomal 
labeling using anti-LAMP-1 antibody. Panel in blue, cellular nuclei stained with DAPI. D, overlay image. The 
white arrowheads indicate examples of co-localization of internalized TB474-labeled A1.1 with the late 








We earlier used N. benthamiana for expression of WT and mutagenized 
human α-galactosidase and α-galactosaminidase (Chapter 3, Kytidou et al. 
2017). The N. benthamiana plant is a convenient production platform for 
recombinant proteins given the ease of cultivation and transfection with A. 
tumefaciens (Kytidou et al. 2017). In chapter 3, we employed a cyclophellitol-
type activity-based probe (TB474) to visualize the recombinant human α-
galactosidases. In the course of the experiments, we noted the presence of 
two endogenous enzymes (39 and 45 kDa) labeled by TB474. We focused 
attention to the 39-kDa enzyme (named A1.1) that is present in relatively 
high concentrations in the apoplast. Using biotin-containing ABP (ME741) 
and streptavidin pulldown, the identity of the 39 kDa protein in apoplast 
fluid was determined by proteomics. The corresponding gene (accession ID: 
GJZM- 1660) was cloned from a N. benthamiana cDNA library and 
transiently overexpressed in N. benthamiana leaves using infiltrations with 
A. tumefaciens harboring the appropriate expression vectors. A high yield 
of A1.1 in the apoplast fluid was protein and it was purified with 33% 
recovery to homogeneity by sequential ConA chromatography, cation-
exchange chromatography, and gel filtration. The molecular mass of 39 kDa 
of the purified enzyme is similar to that reported for rice and coffee α-
galactosidases (Maranville and Zhu 2000; Fujimoto et al. 2003; Chien et al. 
2008). 
        We characterized A1.1 regarding structural features. The mature 
form of the enzyme consists of 363 amino acids and has a molecular mass 
of 39 kDa. The purified enzyme is an active monomer, based on gel 
filtration behavior. This feature is common to rice α-galactosidase, but the 
human enzyme occurs as a homodimer (Kytidou et al. 2017). As predicted 
by the absence of appropriate Asn-Xaa-(Ser/Thr/Cys) motifs, A1.1 is not N-
glycosylated, and endoglycanase digestion points to no N-linked glycans. 
Similarly, rice and coffee α-galactosidases lack N-glycans (Zhu et al. 1995; 
Fujimoto et al. 2003). Based on amino acid sequence alignments, the 
enzyme has 82% identity with coffee α-galactosidase, 68% identity with 
rice α-galactosidase, and 42% identity with human α-galactosidase A, also 
revealing great secondary structural conservation. 
        Crystals of pure A1.1 were obtained, and the structure was resolved 
by X-ray diffraction at a resolution of 2.8 Å. The enzyme contains a C-
terminal domain with Greek key motif and N-terminal domain with a 
(β/α)8-barrel, the common catalytic domain among the hydrolases of family 
27 (Fujimoto et al. 2003). The active site of retaining α-galactosidases 
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contains a catalytic nucleophile and acid/base residue mediating double-
displacement as a catalytic mechanism (Mathew and Balasubramaniam 
1987; Garman et al. 2002). In the active site of A1.1, other amino acids 
appear involved in substrate recognition, such as Trp-67, Asp-102, Tyr-
144, and Lys-179. Two disulfide bonds occur close to the catalytic pocket, 
Cys-72/104 and Cys-152/183, as also present in human α-galactosidase A 
(Bishop et al. 1988; Garman et al. 2002). Notably, the existence of a second 
ligand-binding site in human α-galactosidase A, centered on Tyr-329, was 
postulated by Guce et al. (Guce et al. 2010). This putative site, speculated 
to bind β-galactose, is located between the two domains of the human 
monomer enzyme, being exposed at the surface. However, in A1.1, instead of 
the Tyr-329, a Lys-330 is present, and the overall second binding- site region 
is different from the human enzyme. The C-terminal domain of A1.1 contains 
eight β-strands forming a Greek key motif. The C-terminal amino acid 
sequences of human and A1.1 α-galactosidases are different. Coffee α-
galactosidase, however, contains a C-terminal domain that is similar to A1.1 
and is thought to essentially contribute to the overall structure of the enzyme, 
as its deletion results in loss of enzymatic activity (Maranville and Zhu 2000). 
        A1.1 shows strong specificity regarding the substrate sugar. It 
hydrolyzes 4MU–α-galactopyranoside liberating fluorescent 
methylumbelliferone, but it does not correspond to β-D-glucopyranoside, β-
D-galactopyranoside, α-D-mannopyranoside, α-L- fucopyranoside, N-acetyl-α-
D-galactosaminide, or N-acetyl-β- D-glucosaminide. The broad pH optimum 
of A1.1, pH 5.0 – 6.5, is also reported for coffee and rice enzymes (Marraccini 
Pierre et al. 2005; Chien et al. 2008). The activity of A1.1 toward 4MU–α-
galactopyranoside (Km of 0.17 mM) is quite comparable with that of human 
α-galactosidase A (Km of 2.4 mM). For the rice enzyme, a high affinity toward 
pNP–α-Gal substrate was earlier reported by Chien et al. (Chien et al. 2008) 
(Km of 0.47 mM). For coffee α-galactosidase, a pH optimum of 6.5 with a Km of 
0.29 mM toward 4MU–α-Gal substrate was observed by Maranville and Zhu 
(Maranville and Zhu 2000). 
        α-Galactosidases from rice and coffee have been shown to remove 
terminal α1–3-linked galactose residues from type B glycolipid antigens on 
red blood cells, converting them to type O structures (Mathew and 
Balasubramaniam 1987; Chien et al. 2008). The ability of A1.1 to hydrolyze 
terminal α-galactoses from artificial and natural glycosphingolipid 
substrates was therefore studied. A1.1 was found to be well able to hydrolyze 
NBD-Gb3, C18-Gb3, and lyso-Gb3 in vitro. Of note, the presence of Gb3 in 
N. benthamiana leaves has not been reported. We could not detect Gb3 with 
a regular sphingolipid base (data not shown). A similar observation was 
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earlier made for rice α-galactosidase; Gb3 was shown to be converted to 
LacCer, but kinetic parameters were not determined (Chien et al. 2008). We 
observed a considerable affinity of pure A1.1 for lipids as substrates (Km values 
of 32 µM for NBD-Gb3 and 38 µM for lyso-Gb3), almost equal to those observed 
for human α-galactosidase A. 
        Presently, two different recombinant human α-galactosidase A 
preparations are used to treat FD, an X-linked disorder with lysosomal Gb3 
accumulation in various cell types and affecting heart and kidney (Ferraz et 
al. 2014). The therapeutic enzymes use Man-6-P containing N-linked 
glycans that are aimed to correct the lysosomal enzyme deficiency in all cell 
types following uptake and delivery to lysosomes by the ubiquitous MPR at 
the surface of cells (Ferraz et al. 2014). Exposure of cultured fibroblasts to 
recombinant human α-galactosidase A (Fabrazyme) results in a reduction 
of excessive Gb3 and is deacylated metabolite lyso-Gb3 (Ferraz et al. 2014). 
We investigated whether recombinant A1.1 also manages to degrade the 
toxic lyso-Gb3 accumulating in cells of FD patients. Indeed, an overnight 
incubation of patient fibroblasts with 300 µg/ml A1.1 resulted in significant 
reduction of both lyso-Gb3 and Gb3 accumulating glycosphingolipids, 
reaching levels found in normal fibroblasts (~4 pmol/mg and ~15 nmol/mg 
for lyso-Gb3 and Gb3, respectively). It should be kept in mind that because 
A1.1 lacks glycans, no lectin-mediated uptake of the enzyme by cells occurs, 
in contrast to that of Man-6-P–rich Fabrazyme. The ability of the latter 
enzyme to correct lyso-Gb3 in cultured fibroblasts is therefore far superior 
than that of A1.1. A same reduction in cellular lyso-Gb3 of FD fibroblasts 
was obtained, reaching levels found in normal fibroblasts, with 60-fold less 
Fabrazyme than A1.1 (Fig. S6).  
        Unfortunately, the present enzyme replacement therapies meet 
limited clinical success. Although storage lipid is cleared from endothelial 
cells, complications in heart and kidney may nevertheless develop in FD 
patients, possibly due to the use of insufficient therapeutic enzyme to 
penetrate these organs. High costs of the present α-galactosidase A 
preparations hamper the use of significantly higher doses. The elevated 
circulating lyso-Gb3, considered to be toxic for podocytes and nociceptive 
neurons, is not completely corrected by present ERT (Choi et al. 2015; 
Mirzaian et al. 2017). Finally, a complicating factor with the present ERT 
of FD proves to be the antigenicity of recombinant human α-galactosidase A 
in the majority of male FD patients that lack any endogenous enzyme 
(Lenders et al. 2016). In these individuals, neutralizing antibodies against 
therapeutic enzyme develop quickly, resulting in a relapse in the reduction 
of circulating toxic lyso-Gb3 (Linthorst et al. 2004). The clinical outcome of 
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ERT in antibody-positive FD patients is reported to be poorer (Linthorst et 
al. 2004). In view of all this, the use of a plant α-galactosidase to treat male 
FD patients deserves consideration. First, plant α-galactosidase could be 
produced in N. benthamiana or other plant production platforms at 
considerably lower costs than the present human recombinant 
enzymes, allowing use of higher doses. Second, A1.1 is able to degrade toxic 
lyso-Gb3. The enzyme can in principle be further engineered to increase 
stability and desired enzymatic activity. The lack of N-glycans on a plant-
derived α-galactosidase might even be beneficial, preventing a lectin 
receptor-mediated sink in the endothelium and liver as observed with 
present therapeutic human glycoprotein enzymes. Finally, we observed 
that N. benthamiana A1.1 does not cross-react with neutralizing antibodies 
directed against human α-galactosidase A that are present in serum of 
male FD patients treated with therapeutic enzyme (Fig. S7). Antigenicity of 
a plant protein might be a concern, but it should be kept in mind that this 
also exists with the human enzyme preparations in most male FD patients. 
The considerable progress made in induction of tolerance against foreign 
proteins may be exploited (Rezende and Weiner 2017). It is presently unclear 
how antigenic a plant α-galactosidase will be: the absence of glycans might 
reduce C-type lectin receptor-mediated presentation by dendritic cells. 
        In conclusion, further research on the optimization of plant α-
galactosidases such as A1.1 to reduce toxic lyso-Gb3 in FD should be 
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Material and Methods  
 
Chemicals. All chemicals were obtained from Sigma (Germany) if not 
indicated otherwise. Fluorescent NBD-lipids and pure lipids were 
purchased from Avanti Polar Lipids (Alabaster, AL). Anti- bodies purchased 
from Abcam (Cambridge, MA). 
Plants. N. benthamiana plants were grown at 21 °C and 60–70% humidity in 
the Unifarm greenhouses of Wageningen University (Westerhof et al. 2014). 
Patient materials. Fibroblast cell lines from classical FD individuals 
were obtained from the Lysosomal Outpatient Clinic of the Academic 
Medical Center in Amsterdam (AMC). The cells were cultured in 
Dulbecco’s modified Eagle’s medium/Nutrient Mixture F-12 (DMEM/F-
12, Sigma) media, supplemented with 10% fetal calf serum and 1% 
penicillin/streptomycin, at 37 °C with 5% CO2 in a humidified incubator. 
Plasma specimens from FD individuals were obtained from the Lysosomal 
Outpatient Clinic of the Academic Medical Center in Amsterdam (see 
supplementary material). All patient materials were obtained after 
approval of the Academic Medical Center’s review board and abide by the 
Declaration of Helsinki principles. 
 
ABP ME741, synthesis. The α-galactopyranose-configured cyclophellitol 
aziridine grafted with Cy5 as fluorophore ABP (TB474) was synthesized as 
described previously (Kytidou et al. 2017).The biotinylated α-
galactopyranoside cyclophellitol aziridine (ME741) was synthesized by 
copper-catalyzed click chemistry of azido cyclophellitol aziridine 
intermediate with biotin alkyne (Scheme S1). The α-galactose- configured 
azido cyclophellitol aziridine (Willems et al. 2014a) (14.6 mg, 0.043 mmol) 
synthesized in 15 steps form D-xylose, and the desired biotin-alkynes (18.5 
mg, 0.047 mmol) were dissolved in N,N- dimethylformamide (2 ml). CuSO4 
(0.043 ml, 1 M in H2O) and sodium ascorbate (0.043 ml, 1 M in H2O) were 
added, and the reaction mixture was stirred at room temperature under 
argon atmosphere for 18 h. Then the solution was diluted with CH2Cl2, 
washed with H2O, dried over MgSO4, and concentrated under reduced 
pressure. The crude was purified by semi- preparative reversed-phase 
HPLC (linear gradient: 15–24% B in A, 12 min, solutions used A, 50 mM 
NH4HCO3 in H2O, and B, MeCN) and lyophilized to yield biotinylated ABP 
ME741 as a white powder (8.0 mg, 11 µ,mol, 26%). 1H NMR (600 MHz, 
CD3OD) contained the following: 3 7.85 (d, J = 3.7 Hz, 1H, CH); 4.90 (s, 1H, 
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NH); 4.49 (dd, J = 7.9, 4.9 Hz, 1H, CH); 4.42 (d, J = 2.3 Hz, 2H, CH2); 4.38 (td, J 
= 7.1, 2.5 Hz, 2H, CH2); 4.30 (dd, J = 7.9, 4.5 Hz, 1H, CH); 4.08 (dd, J = 8.6, 3.9 
Hz, 1H, CH); 3.85–3.87 (m, 1H, CH); 3.81–3.68 (m, 2H, CH2); 3.36 (dd, J = 8.6, 
1.7 Hz,  1H, CH); 3.24 –3.17 (m, 1H, CH); 3.16 (td, J = 7.0, 2.5 Hz, 2H, CH2); 
2.92 (dd, J = 12.7, 5.0 Hz, 1H, 1/2CH2); 2.70 (d, J = 12.7 Hz, 1H, 1/2CH2); 2.61 
(d, J = 6.1 Hz, 1H, CH); 1.91–1.86 (m, 4H, 2CH2); 1.75–1.56 (m, 4H, 2CH2); 
1.51 (p, J = 7.2 Hz, 2H, CH2); 1.43 (p, J = 8.8, 8.2 Hz, 2H, CH2); 1.39 –1.26 (m, 
4H, 2CH2). 13C NMR (151 MHz,  CD3OD)   contained   the  following:   3  188.7,   
176.0, 176.0, 166.1, 146.2, 146.2, 74.3, 74.2, 73.2, 73.1, 70.5, 69.5, 63.4, 62.8, 61.6, 
57.0, 51.4, 51.3, 44.8, 43.3, 41.1, 40.2, 39.4, 37.1, 36.8, 36.8, 35.6, 31.3, 31.2, 30.4, 
30.1, 30.0, 29.9, 29.8, 29.7, 29.5, 27.5, 27.4, 27.3, 27.2, 26.9, 26.5, 25.8 ppm; 
HRMS was calculated for C34H56N8O8S [M + H]+ 737.40201 and found was 
737.40146. 
N. benthamiana leaf extracts. Leaves of 5– 6-week-old N. benthamiana 
plants were col- lected, snap-frozen in liquid nitrogen, and homogenized by 
grinding with a mortar and a pestle. To 1 g of leaf, 4 ml of ice-cold extraction 
buffer (30 mM citrate/phosphate buffer, pH 6, containing 2% w/v 
polyvinylpolypyrrolidone, 0.1% v/v Tween 20, 0.15 M NaCl, and protease 
inhibitor by Roche Applied Science, EDTA- free) was added, and the material 
was again homogenized. The homogenates were centrifuged at 16,000 rcf, at 4 
°C, for 10 min, and the supernatant containing soluble proteins was collected. 
Isolation of apoplast proteins. For the isolation of apoplast proteins, N. 
benthamiana leaves were gently submerged in ice-cold extraction buffer (50 
mM PBS, pH 6, 0.1 M NaCl, and 0.1% v/v Tween 20) and exposed to vacuum 
for 10 min. Then the vacuum was released very slowly to ensure infiltration 
of the apoplast. The leaves were then col- lected and carefully placed in 10-
ml syringes plugged in 50-ml tubes. The samples were centrifuged for 10 
min at 2000 rcf, and apoplast fluid was collected (Wilbers et al. 2017). 
Small-scale ABP labeling of α-galactosidases in N. benthamiana plant leaf 
extracts and apoplast fluid. 10 µl of N. benthamiana plant leaf extracts (4.5 
mg of total soluble protein/ml) and 20 µl of apoplast sample (0.21 mg of total 
soluble protein/ml) were incubated with 0.25 µM fluorescent TB474 in 150 
mM citrate/phosphate buffer at different pH values, for 30 min at room 
temperature. Gel loading buffer (with additional β-mercaptoethanol) was 
added to samples, followed by incubation for 5 min at 95 °C. The proteins 
in the samples were separated by 10% polyacrylamide gels. Labeled 
proteins were visualized by fluorescence scanning as described earlier 
(Willems et al. 2014c). 
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Analysis of N-glycosylation by concanavalin A lectin binding. Concanavalin 
A-Sepharose 4B beads (ConA beads) were first washed three times in 0.1 M 
sodium acetate, 0.1 M NaCl, 1 mM MgCl2,1 mM CaCl2,1 mM MnCl2, pH 6.0, 
washing buffer using brief centrifugation at 2000 rcf for 2 min. Next, 150 µl 
of beads were mixed with 300 µl of plant leaf extracts or 150 µl of apoplast 
sample and incubated for2h at4 °C while rotating. After this incubation, 
the mixture was centrifuged at 16,000 rcf at 4 °C for 10 min. The 
supernatant was collected, and the beads were washed three times with 
washing buffer. The samples were stored for a short period at 4 °C until 
further use. 
Competitive ABPP using ME741 ABP. The ability of biotinylated ME741 to 
label α-galactosidases was first established by performing competition 
experiments. Homogenates were first labeled with Cy5 functionalized 
TB474 at 0.25 µM for 30 min at room temperature, followed by labeling the 
homogenate with biotinylated ME741 ABP at 0.25 µM and the other way 
around. Subsequently, SDS-PAGE and Western blot analysis with HRP-
streptavidin was performed as described previously (Jiang et al. 2016; Wu et 
al. 2017). 
In vitro biotin pulldown of bound targets, followed by on-bead tryptic 
digestion and LC-MS/MS identification. Plant leaf extracts (4.5 mg of total 
soluble protein/ml) and apoplast samples (0.21 mg of total soluble 
protein/ml (no. 1) and 0.6 mg of total soluble protein/ml (no. 2)) were pre-
incubated or not with 5 µ,M TB474 for 2 h at room temperature, following 
overnight incubation with 5 µ,M ME741, room temperature at a final 
volume of 500 µl. Then the reaction was stopped by the addition of 120 µ,l 
of 10% (w/v) SDS and subsequent incubation of the sample at 95 °C for 5 
min. Preparation of proteins for on-bead and tryptic digestion following 
LC- MS/MS identification was performed exactly as described previously 
(Jiang et al. 2016). Prior to LC-MS analysis, peptides were desalted by 
Stagetips as described by Rappsilber et al. (Rappsilber et al. 2007) 
EmporeTM C18 47-mm extraction discs were used to fabricate the 
StageTips. Typically, two discs were placed on top of each other to make 
StageTips with two layers of column material inserted in a yellow pipette 
tip. 
MS acquisition. The Synapt G2Si mass spectrometer (Waters) operating 
with Masslynx for acquisition and ProteinLynx Global Server (PLGS) for 
peptide identification was used for analysis. The following settings in 
positive resolution mode were used: source temperature of 80 °C; capillary 
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voltage 3.0 kV; nano flow gas of 0.25 bar; purge gas 250 liters/h; trap gas flow 
2.0 ml/min; cone gas 100 liters/h; sampling cone 25 V; source offset 25; lock 
mass acquisition was done with a mixture of Leu-enkephalin (556.2771) and 
Glu-fibrinogen (785.84265) and lockspray volt- age 3.5 kV; and Glu-
fibrinogen fragmentation was used as calibrant. An UDMSe data-
independent acquisition method was used for analysis. Briefly, the mass 
range is set from 50 to 2000 Da with a scan time of 0.6 s in positive 
resolution mode. The collision energy is set to4V in the trap cell for low-
energy MS mode. For the elevated energy scan, the transfer cell collision 
energy is ramped to higher collision energies, and data are recorded. The 
lock mass is sampled every 30 s and used for accurate determination of 
parent ions mass after peak picking. Peak lists containing parent and 
daughter ions were compiled in .mgf format and searched against the 
Swiss-Prot (version June 2017) database. The identified peptides were 
manually curated. 
Plant expression vector for overexpression of A1.1. The N. benthamiana α-
galactosidase A1.1 (gene accession ID: GJZM-1660), was amplified from an 
N. benthamiana cDNA library made by our laboratory using the 
InvitrogenTM CloneMinerTM II cDNA library construction kit (Thermo 
Fisher Scientific). The gene was amplified with its native signal peptide, 
using Phusion® High Fidelity PCR Master Mix (Bio- Labs), with the 
following primers: sense, 5'-CCCATGGGTTT- 
GCCACCAATTTTAAAGCTGCTACTAT-3', and antisense, 5'-
GGGTACCTTATTTTTTAGGAGTCAGAACATACATCCTGCA-3'. The gene 
was flanked between NcoI and Acc65I restriction sites, and it was cloned 
into a pGEM®-T Easy Vector System (Promega). Confirmation of sequences 
was done by sequencing (Macrogen, the Netherlands), and the complete 
ORF of the gene was inserted into the pHYG plant expression vector, as 
described previously (Westerhof et al. 2012). The construct was under the 
control of cauliflower mosaic virus 35S constitutive promoter, with 
duplicate enhancer and the nopaline synthase terminator (Kytidou et al. 
2017). The pHYG vectors harboring the genes were used for transformation 
of A. tumefaciens strain MOG101, following N. benthamiana plant leaf 
infiltrations. 
A. tumefaciens transient transformation assay and plant infiltrations. 
A. tumefaciens cultures were grown as described previously 
(Westerhof et al. 2012, 2014). The constructs were co-expressed with 
the tomato bushy stunt virus silencing inhibitor p19 to ensure 
optimum expression levels (Kytidou et al. 2017; Wilbers et al. 2017). 
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The inoculated bacterial cultures were used for infiltration of 5– 6-
week-old N. benthamiana plants, as described previously (Westerhof 
et al. 2014). 
Isolation of apoplast overexpressing A1.1. The isolation of apoplast fluid 
was performed as described previously (Wilbers et al. 2017), using as 
extraction buffer 30 mM citrate/phosphate, pH 6, 0.5 M NaCl, and 0.1% (v/v) 
Tween 20. The sample was passed through a G-25 Sephadex column for 
desalting and snap-frozen in liquid nitrogen. The sample was stored at-
80 °C until further use. 
Enzyme purification. Chromatography with 5 ml of concanavalin A-
Sepharose column (GE Healthcare) was used as a first step for purification. 
The column was equilibrated with 40 ml of washing buffer (0.1 M sodium 
acetate, 0.1 M NaCl, 1 mM MgCl2,1 mM CaCl2,1 mM MnCl2, pH 6.0). Then, 
40 ml of apoplast fluid overexpressing A1.1 was applied to the column, 1:1, 
diluted in washing buffer (1 ml/min loading conditions). The enzyme was 
present in the (unbound) flow-through fractions, ensuring separation from 
bound plant glycoproteins. About 40 ml of sample was collected and tested 
for enzymatic activity. Next, the sample was extensively dialyzed in 20 mM 
sodium acetate buffer, pH 5.5, 4 °C, for 2 days. Subsequently, the dialyzed 
fraction was subjected to chromatography on two HiTrap SP HP columns, 1 
ml each, plugged on top of each other (GE Healthcare), and equilibrated 
with 30 ml of binding buffer: 20 mM sodium acetate buffer, pH 5.0. The 
sample, 40 ml, was applied on the columns, which were extensively washed 
with 30 ml of binding buffer afterward. Then, protein was eluted using a 
15-ml gradient of 0 – 400 mM NaCl. Fractions containing the highest protein 
activity and purity were pooled. Next, the pooled sample (4.5 ml) was 
applied to a HiLoadTM 16/600 SuperdexTM 200 preparation grade column 
(GE Healthcare). The column was first equilibrated with 500 ml of 20 mM 
sodium acetate buffer with 150 mM NaCl, pH 5.5, and the sample was applied 
to the column at a flow rate of 1 ml/min. Four samples of 2 ml each, with the 
highest purity and activity, were collected and concentrated using Centricon 
Plus-20, 15 ml with 10-kDa molecular cutoff (Millipore, Bed- ford, MA) until 0.8 
ml. The final material was snap-frozen in liquid nitrogen and stored at -80 °C 
until further use. 
Protein determination. Total soluble protein content from cell lysates was 
measured using the Pierce BCA protein assay kit (Thermo Fisher 
Scientific), using BSA as a standard, according to the manufacturer’s 
protocol. Pure protein concentrations were measured in Nano- Drop 2000c 
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(Thermo Fisher Scientific). 
Enzymatic assays and determination of kinetic parameters. Different 4-MU 
substrates were used to test the specificity of A1.1. Tested substrates were 
the following glycosides linked to 4-MU: β-D-glucopyranoside, α-D-
galactopyranoside, β-D-galactopyranoside, α-D-mannopyranoside, α-L-
fucopyranoside, N-acetyl-α-D-galactosaminide, and N-acetyl-β-D-
glucosaminide at the following assay concentrations and pH conditions: 
1.36 mg/ml, pH 5.2, 5.8, and 7; 1.25 mg/ml, pH 4.6 and 6; 0.144 mg/ml, pH 
4.3; 2.7 mg/ml, pH 4; 0.26 mg/ml, pH 5.5; 0.4 mg/ml, pH 4.6; 1.52 mg/ml, pH 
4.4, respectively. All substrates were dissolved in 150 mM citrate/phosphate 
(McIlvaine) buffer, at the appropriate pH for each enzyme, supplemented 
with 0.1% (w/v) BSA. Released 4-MU was fluorometrically quantified as 
described earlier (Aerts et al. 1986; Blom et al. 2003). Km and kcat values 
were determined using 4-MU–α-GAL substrate. Reactions were performed 
for 25 min at 37 °C at 10 different 4-MU–α-GAL concentrations in 150 mM 
citrate/phosphate buffer, pH 6, for A1.1 or pH 4.6 for Fabrazyme 
supplemented with 0.1% (w/v) BSA. The 4-MU–α- GAL concentrations in 
the assays ranged from 0.074 to 4.72 mM. Protein concentrations in the 
assays were as follows: A1.1, 1.6 and 4 ng/ml; Fabrazyme, 2 and 5 ng/ml. 
GraphPad Prism7 was used for all calculations. 
Activity toward lipid substrates. For activity measurement, 50 ng of A1.1 
or Fabrazyme were incubated with 5 µM NBD-C12– globotriaosylceramide, 
(NBD- Gb3) for 1 h at 37 °C in 150 mM citrate/phosphate buffers at different 
pH values (4.5–7.5), containing 0.05% (v/v) Triton X-100 and 0.2% (w/v) sodium 
taurocholate. The lipids were next extracted by the Bligh and Dyer protocol 
and subjected to HPTLC as described earlier (Marques et al. 2016). The plate 
was scanned for fluorescent lipids with a Typhoon FLA 9500. Kinetics 
parameters Km and kcat were determined using NBD-Gb3 substrate, at pH 4.5. 
Alternatively, HPLC analysis and LC-MS/MS were used to study 
hydrolysis of C18-Gb3 (Matreya, State College, PA) and C18 –lyso-Gb3 
(Avanti, Alabaster, AL) by A1.1, respectively. For the degradation of C18-
Gb3, 5 µM natural lipid were incubated with 3 µg of pure A1.1 or Fabrazyme 
overnight at 37 °C. Following extraction (Bligh and Dyer protocol), neutral 
glycosphingolipids were analyzed by HPLC using C17-sphinganine as 
internal standard (Gold et al. 2013). For lyso-Gb3, eight different 
concentrations of the lipid, ranging from 2 to 200 µ,M, were incubated with 
2.5 µg/ml of A1.1 and Fabrazyme for 45 min at 37 °C. LC-MC/MS was used 
to measure glycosphingoid bases (lyso- glycosphingolipids), as described 
previously (Kytidou et al. 2017; Mirzaian et al. 2017). As internal standard 
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[13C]lyso-Gb3 was used (Mirzaian et al. 2017). Kinetics parameters Km and 
kcat were determined at pH 4.5, using GraphPad Prism7 for calculations. 
The mature form of A1.1, having a mass of 39 kDa, and the mature 
monomer human α-galactosidase (Fabrazyme), 51 kDa, adjusted to the 
carbohydrate mass, were used to calculate kcat values. 
Uptake of TB474-labeled A1.1 by FD fibroblasts and confocal microscopy. 
Fabry fibroblasts from two different patients were grown in 12-well plates. 
Different amounts of pre-labeled TB747 with A1.1 were added to 500 µl of 
the culture media. The amounts were 0, 2.5, 5, 35, 75, and 150 µg. After 
overnight incubation, the cells were extensively washed with PBS and lysed 
in 100 µl of ice-cold 50 mM phosphate buffer, pH 6.5, supplemented with 
0.1% Triton X-100. The total protein content of the cells was measured. 
Then 10 µg of total protein of the lysates, accounting to 15–20% of total cell 
lysate, were analyzed in SDS-PAGE. Quantification of the gels took place 
using ImageJ program. 
The pre-labeling of the enzyme was done for 4 h, at room temperature, in 
150 mM citrate/phosphate buffer, pH 5.5, at a final TB474 concentration of 
0.25 µ,M, 100-µ,l volume, followed by removal of unbound TB474 by passing 
the sample over a 0.7-ml PierceTM polyacrylamide spin desalting column 
7000 MWCO (Thermo Fisher Scientific), according to the manufacturer’s 
protocol. 
For the confocal microscopy experiments, the same Fabry fibroblasts were 
grown in 12-well plates containing coverslips, until they reached 70 – 80% 
confluency. On the day of the uptake, the culture medium was removed, and 
500 µl of fresh culture medium was placed in each well. 75 µg of A1.1 pre- 
labeled with TB474 was applied to the fibroblasts overnight. 
After the incubation, the fibroblasts were washed extensively with PBS 
and subsequently were fixed with 4% (w/v) formaldehyde/PBS for 25 min at 
room temperature. After the fixation, the cells were washed three times 
quickly with PBS and incubated for 10 min with 2% (w/v) BSA and 0.1% 
(w/v) saponin in PBS (“permeabilization buffer”). To stain for LAMP-1, the 
cells were incubated for 1 h at room temperature with rabbit anti- LAMP-1 
antibody (Abcam) at a dilution of 1:400 in permeabilization buffer. The cells 
were washed three times in permeabilization buffer and incubated for1h at 
room temperature with Alexa Fluor 488-coupled donkey anti-rabbit IgG 
(Invitrogen), 1:500 in permeabilization buffer. After the incubation, the cells 
were further washed in permeabilization buffer and quickly with distilled 
water. The coverslips were mounted on a micro- scope slide (VWR) with 
ProLong Diamond antifade reagent containing DAPI (Molecular Probes). 
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Imaging of the cells was performed with a Leica SP8 confocal microscope 
with a X63/1.40 NA HC Plan Apo CS2 oil immersion objective and equipped 
with a hybrid detector. TB474-labeled A1.1 was imaged with excitation at 
638 nm and emission at 650 –700 nm; LAMP-1 with excitation at 488 nm 
and emission at 500 –540 nm; and DAPI at 405 nm excitation and emission 
at 420 – 480 nm. 
A1.1 treatment of FD fibroblasts. FD fibroblasts were grown in 12-well 
plates in a humidified incubator at 37 °C with 5% CO2. To 500 µl of the culture 
medium, 150 µg of A1.1 were added, followed by overnight incubation. Next, 
cells were extensively washed in PBS, collected, and lysed in 100 µl of ice-
cold 50 mM phosphate buffer, pH 6.5, supplemented with 0.1% Triton X-
100. Protein determination of lysates took place, and the lysates were used 
for lipid extractions, following LC-MS/MS analysis and 4MU–α- GAL 
activity assays. 
Crystallization conditions and data collection. Purified A1.1 was 
concentrated to 5 mg/ml and incubated with 10 µM TB474 for 30 min at 
room temperature. After incubation, crystallization conditions were 
screened by sitting- drop vapor diffusion using the JCSG+ kit Premier 
(Molecular Dimensions). The screenings were performed by the NT8 robot 
(Formulatrix) at 20 °C, using 200 nl drops, with a well volume of 70 µl. After 
12 h the crystals were formed at the H9 condition of the JCSG+ screening. 
The condition consisted of 0.1 M BisTris buffer, pH 5.5, 0.2 M LiSO4, 25% w/v 
PEG 3350. The crystal had a rhombus shape with 30.7/37-µm size. The 
crystal was flash- frozen in liquid nitrogen using 20% glycerol as a cryo-
protectant. X-ray data collection was performed at the ESRF (Grenoble, France) 
on beamline ID30A-3, using a PIXEL, Eiger_4M (DECTRIS), X-ray 
detector. A total of 1900 images were col- lected, with an oscillation of 0.05° 
and exposure time of 0.01 s (total of 19 s). Then the data were processed by 
XDS and scaled by AIMLESS. The structure was solved using the molecular 
replacement method (MOLREP), having 1UAS as search model, through the 
CCP4 suite and further refined using REFMAC. Manual model building was 
done using Coot. Images of structures were obtained using CCP4mg, and amino 
acid alignments were per- formed using ClustalOmega and ESPript3.0. 
The superposition of A1.1 and human proteins was per- formed by 
secondary structure-matching (Krissinel and Henrick 2004), using the A 
monomer of human α-galactosidase (PDB 3HG2) and our structure. 
Secondary structure matching aligned 348 residues with a root-mean-
square deviation of 1.3358 Å of the C-α atoms of the aligned residues. 
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Scheme S1. Synthesis of ME741 (Biotinylated α-Galactosidase ABP) 
α-Galactose configured biotinylated cyclophellitol aziridine ME741 was synthesized by copper–




Scheme S1. Synthesis of biotinylated α-Galactosidase ABP ME741. Reagents and conditions: 




Figure S1. Analytical gel filtration chromatography analysis of A1.1. Left panel. Gel filtration 
chromatogram of the N. benthamiana produced A1.1, after its application in Superdex™ 200 Increase 
10/300 GL. Right panel. Gel filtration chromatography calibration curve of proteins with known molecular 
weight, fitting the results of the plant produced A1.1. In black circle, β-amylase, alcohol dehydrogenase, 
albumin, carbonic anhydrase, cytochrome c from horse heart and Dextran. In red box A1.1.  
 




Figure S2. Determination of A1.1 N-glycosylation profile. MALDI-TOF MS analysis of 2- 
aminobenzoic acid derivatised PNGase-A possibly released N-glycans of plant produced A1.1. No N- 
linked glycans were detected. 
 




Figure S3. Activity of A1.1 and Fabrazyme towards lipid substrates, as measured by HPLC 
analysis. (A) HPLC analysis of degradation of C18-Gb3 to LacCer by different µg amounts of A1.1 or 




Figure S4. Detection of remaining Cy5 signal after exposure of FD fibroblasts to prelabelled A1.1, 
from Figure 6. After incubation of the 2 different FD fibroblasts, with prelabelled A1.1, extensive 
washing steps (x5) of the cells performed. To ensure that all of the not internalized to the cells prelabelled 
protein is washed out prior to lysate making, samples from both wash 1 and wash 5 (W1 and W5) were 
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analysed in SDS-PAGE, following the fluorescent signal. 10 % of the total wash volume was loaded on 




Figure S5. 4MU-α-GAL activities found in washing steps of Figure 7. After treatment with 300 μg/ 
mL of A1.1, the FD cells were extensively washed with PBS (x5 times). Activities in washing steps 1 and 
5 were performed to ensure that no remaining activity is found to the cells prior to lysate making. P1= 




Figure S6. LC-MS/MS analysis of lysoGb3 found in FD fibroblasts after incubation with 
Fabrazyme. Fibroblasts from FD patients were grown in 12 well plates. Overnight incubation with 5 
µg/mL of Fabrazyme took place, followed by lipid extraction and LC-MS/MS analysis. 13ClysoGb3 was 
used as internal standard. (n=2, error bars indicate mean ± standard deviation). 
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Figure S7. 4MU-α-Gal activity of recombinant galactosidases after incubation in FD serum, 
before and after ERT. A1.1 and Fabrazyme were incubated in Fabry serum at a concentration of 1 
mg/mL each, before and after ERT (T=0, T=1, respectively). (n=2, error bars indicate mean ± standard 
deviation). 
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Table S2. Proteomics analysis using Swissprot (version June 2017, including N. 
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Deficiency in lysosomal α-D-galactosidase leads to an X-linked inherited 
lysosomal storage disorder (LSD) known as Fabry disease. Current treatment 
of the disease involves the enzyme replacement therapy (ERT) agalsidase beta 
(Fabrazyme®) and the recently approved pharmacological chaperone 1-
deoxygalactonojirimycin (Gal-DNJ, Migalastat®). Co-treatment of ERT with 
enzyme active-site stabilizers has shown to improve the outcome of the 
treatment of LSDs. Herein we describe the use of a newly synthesized α-D-gal-
cyclophellitol cyclosulfamidate as a new class of neutral, competitive 
glycosidase inhibitor, and the already available chaperone 1-
deoxygalactonojirimycin as potential stabilizers of both human agalsidase beta 
and plant derived Nicotiana benthamiana, A1.1, α-D-galactosidases. Our 
results suggest that both α-D-gal-cyclophellitol cyclosulfamidate and Gal-DNJ 
are able to stabilize both enzymes in vitro and in situ, sharing a potential use 





















Lysosomal α-galactosidase A (α-gal A, EC 3.2.1.22, GH27), is a retaining 
glycosidase which catalyses the hydrolysis of α-1,4-linked galactosyl moieties 
from glycoconjugates, such as globotriaosylceramide (Gb3) and its sphingoid 
base, globotriaosylsphingosine (Lyso-Gb3). A-gal A is encoded by the GLA (ID: 
2717) gene at locus Xq22 (Desnick et al. 2003). Any mutation in the GLA gene 
might lead to a deficiency or complete loss of enzymatic activity, resulting in a 
lysosomal storage disorder (LSD) called Fabry disease (FD, OMIM #301500). 
This X-linked inherited LSD is characterized by toxic accumulation of Gb3 in 
lysosomes and Lyso-Gb3 in plasma and tissues (Aerts et al. 2008; Gold et al. 
2013). The accumulation of glycosphingolipid metabolites is thought to cause 
progressive renal and cardiac insufficiency and CNS pathology in Fabry 
patients (Desnick et al. 2001). Due to the vast number of different mutations 
occurring in GLA gene, there is a broad range of FD phenotypes. In classic male 
FD patients, there is absence of α-gal A, thus complete lack of enzymatic 
activity, whereas usually female carriers develop atypical disease 
manifestations, caused by missense mutations, having residual enzyme activity 
levels.  
A well-established treatment of FD involves replacement of the defective 
enzyme via enzyme replacement therapy (ERT), through the intravenous 
treatment with recombinant human α-gal A (agalsidase beta, Fabrazyme® or 
agalsidase alpha, Replagal®). Even though this treatment is currently 
available, its clinical efficacy is limited (Alegra et al. 2012; Arends et al. 2017b, 
a). 
Recently, we have identified a novel plant α-D-galactosidase, A1.1, derived 
from Nicotiana benthamiana (N. benthamiana), which shows great structural 
and biological similarities to the lysosomal enzyme ((Kytidou et al. 2018) 
Chapter 4). Crystal structure of A1.1 revealed that both human and plant 
enzymes share a highly conserved active site (Kytidou et al. 2018). In addition, 
A1.1 presents comparable pharmacokinetic abilities to human enzyme. In 
particular, in situ experiments with cultured Fabry fibroblasts treated with 
A1.1 showed correction of abnormal lipid levels, suggesting that A1.1 could be 
considered as a promising candidate for treatment of Fabry disease.  
Another available treatment approach is the use of pharmacological 
chaperones (PC), to improve enzyme’s folding, thus its activity. 1-
Deoxygalactonojirimycin (Gal-DNJ 8, Migalastat®, Figure 1) has recently been 
approved as pharmacological chaperone (PC) for the treatment of Fabry disease 
in patients with amenable mutations (Markham 2016). Gal-DNJ, after biding 
to mutant α-gal A, it stabilizes its protein fold, allowing the mutant enzyme to 




be trafficked to lysosomes. This treatment only targets individuals with specific 
mutations and its efficacy is greatly debated (Fan and Ishii 2007; Hughes et al. 
2017; Sunder-Plassmann et al. 2018).   
An alternative therapeutic intervention strategy has recently been 
proposed, which comprises jointly-administering recombinant enzyme and a 
pharmacological chaperone or enzyme stabilizer (Porto et al. 2009; Benjamin et 
al. 2012). This strategy aims to stabilize the recombinant enzyme in circulation 
such that larger proportions may reach the disease affected tissues; permitting 
the use of extended intervals between injections and lower enzyme dosages 
which should diminish side effects, improve patient’s life-style and reduce 
treatment costs (Castelli et al. 2012; Warnock et al. 2015). The design and 
availability of inhibitors with good selectivity and 
pharmacokinetic/pharmacodynamic properties are highly required in order to 
drive this strategy into clinic (Castelli et al. 2012; Porto et al. 2012; Pisani et 
al. 2014).  
We here report the biological evaluation of a newly synthesized enzyme 
stabilizer, α-gal-cyclosulfamidate (4), as a new class of neutral, 
conformationally-constrained competitive α-galactosidase inhibitor that acts by 
mimicry of the Michaelis complex conformation (Figure 1) (Artola et al. 2019). 
Together with this new inhibitor, the already available pharmacological 
chaperone, Gal-DNJ (8) is also tested for their ability to stabilize human and 
plant derived N. benthamiana α-D-galactosidases. Our results reveal that both 
inhibitors are promising candidates in co-administration therapeutic strategy 









Figure 1. Reaction coordinates of α-galactosidases and inhibitors. A. Reaction itinerary of retaining 
α-galactosidase, showing conformations of the 4C1 Michaelis complex, 
4H3 transition state, and 
1S3 
covalent intermediate. B. Chemical structures of 1-deoxygalactonojirimycin 8 and cyclosulfamidate 4, 
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The rational design and synthesis of α-D-galactose configured cyclosulfamidate 
4 together with crystallographic studies in complex with human α-D-
galactosidase is described in Artola et al. 2019. 
Stabilization of human α-galactosidase by Gal-DNJ 8 and α-cyclosulfamidate 4 
in cell culture medium.  
The lysosomal α-gal A shows poor stability in plasma at pH of 7.3 - 7.4, with 
only ~25 % of the hydrolytic activity being retained after incubation of enzyme 
at 1 µg/mL in human plasma for 30 minutes (Kytidou et al. 2017; Kizhner et al. 
2017). At first, we investigated the ability of Gal-DNJ 8 and α-cyclosulfamidate 
4 to stabilize human α-gal A in cell culture medium, pH 7.2, mirroring plasma 
conditions. Incubation of α-gal A (25 µL of 2.5 µg/µL) in cell culture medium 
(Dulbecco's Modified Eagles Medium/Nutrient Mixture F-12 (DMEM/F12), 
supplemented with 10 % fetal calf serum and 1 % penicillin/streptomycin) led 
to 80 % loss of activity within 15 min, in line with the poor stability of this 
enzyme in blood plasma. To assess the stabilizing effects of Gal-DNJ 8 and α-
cyclosulfamidate 4 in cell culture media, α-gal A was incubated with increasing 
concentrations of these compounds, followed by capture of the enzyme on 
concanavalin A (ConA) sepharose beads, washing to remove unbound inhibitor. 
Then, residual α-galactosidase activity with fluorogenic 4-methylumbelliferyl 
(4MU)-α-D-galactopyranose substrate was quantified (Figure 2A). Gal-DNJ 8 
and α-cyclosulfamidate 4 both prevented inactivation of agalsidase beta in cell 
culture media (pH 7.2) - ~75 % residual α-gal-A activity was retained after 



















Figure 2. Human α-gal A stabilization by Gal-DNJ 8 and α-cyclosulfamidate 4 in culture medium. 
Upper part. Schematic representation of stabilization assay. Recombinant human α-gal A (Fabrazyme) 
was incubated with inhibitor for 15 min in DMEM/F-12 medium and subsequently incubated with ConA 
sepharose beads for 1 h at 4 °C and washed to remove unbound inhibitor. Residual α-Gal activity was 
quantified with 4-MU-α-gal substrate. Lower part. Percentage of α-gal A residual activity measured after 
15 min incubation in DMEM/F-12 medium in the presence of inhibitor α-gal-cyclosulfamidate 4 (at 0, 
100, 200, 500 µM) and Gal-DNJ 8 (0, 1, 10 and 50 µM), followed by post final ConA purification. 
Percentages are calculated considering the 100 % activity of α-gal A obtained at 0 min incubation time 
(n=2, error bars indicate mean ± standard deviation). 
 
Stabilization of plant alpha galactosidase A1.1 by Gal-DNJ 8 and α-
cyclosulfamidate 4 in human plasma.  
Similar to agalsidase beta, the plant alpha galactosidase A1.1 (chapter 4) 
presents poor stability in human plasma. A combination of α-galactosidase A1.1 
with an enzyme stabilizer could be a potential therapeutic alternative for Fabry 
disease. Therefore, the ability of Gal-DNJ 8 and α-cyclosulfamidate 4 to 
stabilize an enzyme other than the human origin was also tested. Thus, A1.1 
(400 ng) was first pre-incubated with and without 250 μM of 25 μM of Gal-DNJ 
8 or α-cyclosulfamidate 4 for 20 min at 37 oC in 20 μL of 150 mM Mcllvaine 
buffer pH 5.3. The enzyme-inhibitor mixture was then passed over a 0.7-ml 
PierceTM polyacrylamide spin desalting column (see materials and methods), 
in order to remove the excess of inhibitor. Afterwards, samples were incubated 
in 400 μL of human plasma (AB) for different time periods (0, 15, 30, 45 and 60 
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successfully stabilized by both Gal-DNJ 8 and α-cyclosulfamidate (Figure 3). 
Interestingly, A1.1 maintained over 90 % of its activity after 60 min incubation 
with Gal-DNJ 8 (25 μM) or α-cyclosulfamidate 4 (250 μM) in human plasma, 
whereas the absence of inhibitor resulted in loss of enzymatic activity with just 
~20 % remaining. These results suggest that competitive cyclosulfamidate 
inhibitors are also enzyme stabilizers of plant derived A1.1, an enzyme that 








Figure 3. Stabilization of A1.1 by Gal-DNJ 8 and α-cyclosulfamidate 4 in human plasma over time. 
A. Schematic representation of stabilization assay. A1.1 (400 ng) was incubated with and without 25 µM 
of Gal-DNJ 8 or 250 µM of 4 for 20 min at 37 oC in 20 µL of 150 mM Mcllvaine buffer pH 5.3. The enzyme 
plus inhibitor mixtures were passed through a desalting column to remove the excess of inhibitors follow 
by incubations in 400 µL of human plasma (AB) (protein concentration in plasma 1 µg/mL). B. Samples 
were taken at different time intervals (0, 15, 30, 45, 60 min) and α-galactosidase activity was measured 
using fluorogenic 4-methylumbelliferyl (4MU)-α-D-galactopyranose substrate. Only 20 % of A1.1 activity 
remained after 60 min incubation in human plasma, whereas higher than 90 % enzyme activity was 
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Competitive activity-based protein profile (ABPP) on recombinant α-
galactosidases. 
Next, we investigated the binding efficiency of both enzyme stabilizers  Gal-
DNJ 8 and α-cyclosulfamidate 4, towards human commercial agalsidase beta 
(Fabrazyme®) and agalsidase alpha (Replagal®), and the plant produced α-
galactosidase B (N-acetylgalactosaminidase, NAGA) (Chapter 3 (Kytidou et al. 
2017)) via competitive activity-based protein profiling (ABPP, Figure 4). NAGA 
enzyme is reported to have residual α-galactosidase activity (Kytidou et al. 
2017) and mutant form of NAGA, NAGAEL, with further improved α-gal 
activity, has been recently proposed as a promising alternative recombinant 
enzyme for the treatment of Fabry (Tajima et al. 2009; Kytidou et al. 2017). All 
enzymes were first incubated with increasing concentrations of Gal-DNJ 8 and 
α-cyclosulfamidate 4  for 30 min at 37 °C, followed by incubation with 0.2 µM of 
an α-galactosidase Cy5 activity-based probe (ABP 10) for 30 min at 37 °C. 
Afterwards, the samples were analysed by sodium dodecyl sulfate-
polyacrylamide gels (SDS- PAGE) and scanned as previously described 
(Willems et al. 2014; Kytidou et al. 2017). Competitive ABPP revealed that Gal-
DNJ 8 (1-10 µM) and α-cyclosulfamidate 4 (100-500 µM) inhibit both 
recombinant human agalsidase alpha and agalsidase beta, and plant produced 
N-acetylgalactosaminidase NAGA and its mutant form NAGAEL (data not 
shown). 
 






Figure 4. Competitive ABPP in α-galactosidases. Agalsidase alpha (Replagal, 200 ng), agalsidase 
beta (Fabrazyme, 200 ng),  α-N-acetylgalactosaminidase (NAGA, 200 ng) and its mutant form NAGAEL 
(200 ng) were pre-incubated with Gal-DNJ 8 (0-1000 µM) or α-cyclosulfamidate 4 (0-1000 µM) for 30 
min at 37 °C, followed by fluorescent labelling with Cy5 α-galactosidase ABP (TB474) for 30 min at 37 
°C. ABP: activity-based probe, CBB: coomassie brilliant blue staining. 
 
In situ treatment of cultured fibroblasts from patients with Fabry disease. 
To further prove the stabilizing effect of both competitive inhibitors, we 
investigated their abilities in situ. First, 5 different primary cell lines from 
adult male Fabry patients were treated with either 8 (20 µM) or 4 (200 µM) (in 
blue), or with a combination of both enzyme agalsidase beta (100 ng) and 
stabilizing agent (in green) (Figure 5A). Treatment with 0.5 % DMSO was also 
performed, as a control. The cell lines used in this study were: wild-type (WT, 
Control) representing normal α-gal A activity, 2 classic Fabry mutant 
fibroblasts (R301X and D136Y) with no α-gal A activity and 2 atypical variant 
Fabry mutants (A143T and R112H) with substantially lowered residual α-gal 
A activity. After 24h treatment, the cells were harvested and lysed in ice cold 
lysis buffer and the intracellular α-gal A activity of the corresponding cell 
lysates was measured. WT cell line presented normal α-gal A activity whereas 





samples (A143T and R112H) showed reduced enzymatic activity. None of the 
cell lines, not even classical Fabry fibroblasts R301X and D136Y, showed 
significant increase in α-gal A activity when incubated with 8 (20 µM) or 4 (200 
µM) alone for 24 h. Of note, Gal-DNJ 8 is known to enhance α-gal A activity in 
R301Q lymphoblasts after in situ 4-day treatment of a 100 µM daily dose 
(Asano et al. 2000). Treatment with Fabrazyme showed a considerable increase 
in α-gal A activity in all the studied cell lines.  
 
Figure 5. Effect on α-gal A activity in fibroblasts culture and medium following treatment with 
Gal-DNJ 8 and α-cyclosulfamidate 4. A. Fibroblasts of WT, classic Fabry (R301X and D136Y) and 
variant Fabry (A143T and R112H) were treated with 0.5% DMSO or incubated with Gal-DNJ 8 (20 µM), 
α-cyclosulfamidate 4 (200 µM), agalsidase beta (200 ng/mL) or a combination of enzyme and stabilizing 
agent for 24 h. Then, the medium was collected, cells were harvested, and α-gal A activity was 
measured in the cell homogenates by 4-MU-α-gal assay. In all cell lines co-administration of Gal-DNJ 8 
or α-cyclosulfamidate 4 with agalsidase beta increased intracellular α-gal A activity when compared to 
cells treated with only agalsidase beta. B. α-Gal A activity in cell culture medium samples was measured 
after ConA purification. α-Gal A activity is at least two times higher in all the cell lines treated with Gal-
DNJ 8 (20 µM) or α-cyclosulfamidate 4 (200 µM). Reported activities are mean ± standard deviation 
from two biological replicates, each with two technical replicates, * p < 0.5; **, p < 0.01; ***, p < 0.001. 
This effect was improved in most cases with the combinatorial treatment of 
Fabrazyme and 8 or 4 after 24 h incubation. In addition, we also measured α-
gal A activity in media in order to confirm that the increase in α-gal A activity 
in cell lysates is due to stabilization of the enzyme (Figure 5B). Thus, culture 
media were collected before harvesting the cells and α-gal A activity was 
measured after ConA purification. α-Gal A activity in media was at least double 
in all the cell lines treated with 8 (20 µM) or 4 (200 µM), in accordance with 
these compounds preventing α-gal A degradation during cell culture. 




Correction of Gb3 and LysoGb3 by Gal-DNJ 8 and α-cyclosulfamidate 4 in 
Fabry fibroblasts. 
Elevated Gb3 metabolite is present in Fabry patients, which is further 
metabolized by acid ceramidase into LysoGb3 in lysosomes (Ferraz et al. 2016). 
LysoGb3 is a well-established hallmark of Fabry disease which allows 
diagnostic monitoring of disease progression (Aerts et al. 2008; Gold et al. 2013; 
Mirzaian et al. 2017; Maruyama et al. 2019), and has been linked to 
neuronopathic pain and renal failure through its effect on nociceptive neurons 
and podocytes (Choi et al. 2015; Sanchez-Niño et al. 2015; Colpart and Félix 
2017). We here studied the co-administration of Fabrazyme together with Gal-
DNJ 8 and α-cyclosulfamidate 4, and its efficiency in correcting these toxic 
metabolites. Lipids (Gb3 and LysoGb3) were measured by LC-MS/MS, after in 
situ treatment of cells (Figures 6A, B). Levels of Gb3 and LysoGb3 in wild type 
fibroblasts ranged around 2000 pmol/ml and 2 pmol/ml, respectively. Cultured 
fibroblasts from classic Fabry patients (R301X and D136Y) treated with 
Fabrazyme, resulted in a reduction of Gb3 and lysoGb3, to levels close to the 
ones observed in wild type cells. This reduction was similar when fibroblasts 
were treated with the combination of Gal-DNJ 8 (20 µM) or α-cyclosulfamidate 
4 (200 µM) and Fabrazyme. Variant Fabry A143T cell line presents normal Gb3 
and lysoGb3 basal levels, whereas in R112H fibroblasts, these metabolites are 
increased and not corrected by Fabrazyme itself or inhibitor-Fabrazyme 







Figure 6. Gb3 and Lyso-Gb3 quantification in cultured fibroblasts treated with Fabrazyme co-
administrated with Gal-DNJ 8 and α-cyclosulfamidate 4. Gb3 (A) and lysoGb3 (B) levels (pmol/mL 
of sample) measured by LC-MS/MS in Fabry fibroblasts from WT and classic Fabry patients (R301X 
and D136Y) treated with Fabrazyme (200 ng/mL) with or without Gal-DNJ 8 (20 µM) and α-
cyclosulfamidate 4 (200 µM) for 24 h. Reported activities are mean ± standard deviation from two 
biological replicates, each with two technical replicates, * p < 0.5; **, p < 0.01. 
4-Day treatment of cultured fibroblasts with co-administration treatment 
increased α-gal A activity and Gb3 metabolites correction by α-cyclosulfamidate 
4 and Gal-DNJ 8. 
The potential beneficial effect of co-administration treatment in situ was 
further studied via extended incubation-time treatments. WT and classic Fabry 
(R301X) fibroblasts were treated with Fabrazyme (200 ng/mL) or with a 
combination of enzyme (200 ng/mL) and Gal-DNJ 8 (20 µM) or α-
cyclosulfamidate 4 (200 µM) for 4 days. Fibroblasts were treated every 24 h 
with new medium supplemented with enzyme with or without inhibitor, and 
medium samples were collected for α-gal A activity measurements. α-Gal A 
activity was 3-4 times higher in fibroblasts treated with the combination of 
recombinant α-gal A and Gal-DNJ 8 (20 µM) or α-cyclosulfamidate 4 (200 µM) 
than those treated with Fabrazyme alone (Figure 7A). This increase in α-gal A 
activity correlates with the reduction of Lyso-Gb3 from ~14 pmol/mL to ~4 
pmol/mL in the cell lysates of Fabry (classic R301X) fibroblasts (Figure 7B). We 
finally studied whether the amount of required ERT could be decreased when 
stabilized with 8 or 4 and still produce a similar effect. WT and Fabry (classic 




R301X) fibroblasts were treated with Fabrazyme at 200 ng/mL and 100 ng/mL. 
This reduction in toxic metabolites can be achieved in 4 days with half the 
concentration of enzyme (100 ng/mL) when either Gal-DNJ 8 (20 µM) or α-
cyclosulfamidate 4 (200 µM) is added (Figure 7C, D), with a similar reduction 
of toxic LysoGb3 from ~10 pmol/mL to ~5-6 pmol/mL in the cell lysates of Fabry 




Figure 7. Effect on α-gal A activity and Lyso-Gb3 correction in cultured fibroblasts treated with 
Gal-DNJ 8 and α-cyclosulfamidate 4. Fibroblasts of WT and classic Fabry (R301X) were incubated 
with agalsidase beta (200 ng/mL) or the combination of enzyme (200 ng/mL or 100 ng/mL) and 
stabilizing agent (8 at 20 µM or 4 at 200 µM) for 4 days. Then, the medium was collected, cells were 
harvested, and α-gal A activity was measured in the cell homogenates by 4-MU-α-gal assay. A. 
Intracellular α-gal A activity in fibroblasts treated with agalsidase beta (200 ng/mL) or the combination 
of Gal-DNJ 8 (20 µM) or α-cyclosulfamidate 4 (200 µM) with agalsidase beta (200 ng/mL) for 4 days. B. 
LysoGb3 levels measured by LC-MS/MS in Fabry fibroblasts from panel A. C. Intracellular α-gal A 
activity is comparable in cell lines treated with the combination of Gal-DNJ 8 (20 µM) or α-
cyclosulfamidate 4 (200 µM) but this requires only half the concentration of agalsidase beta (100 ng/mL). 
D. Intracellular α-gal A activity per ng of agalsidase beta in fibroblasts treated with agalsidase beta (100 
ng/mL) or the combination of Gal-DNJ 8 (20 µM) or α-cyclosulfamidate 4 (200 µM) with half 
concentration of agalsidase beta (100 ng/mL). E. LysoGb3 levels measured by LC-MS/MS in Fabry 
fibroblasts from panel C or D. Reported lipid levels are mean ± standard deviation from two biological 










Current ERT treatment for Fabry disease employs intravenous administration 
of recombinant human α-galactosidase (agalsidase beta, Fabrazyme® or 
agalsidase alpha, Replagal®) and reduces the levels of Gb3 and lyso-Gb3 in 
some tissues of Fabry patients, but its clinical efficacy is still limited (Alegra et 
al. 2012; van Dussen et al. 2014; Arends et al. 2017b, a). One approach to 
overcome such limitations is to apply an alternative recombinant enzyme. 
Tajima and colleagues, first suggested the use of modified NAGA enzyme 
(NAGAEL), which has improved α-gal activity and can eliminate possible 
immunoreactions raised by current ERT treatments (Tajima et al. 2009).  Their 
findings were recapitulated in chapter 3 of this thesis (Kytidou et al. 2017). 
Another promising ERT candidate, is the Ν. benthamiana α-galactosidase, 
A1.1, recently identified and biochemically characterized (chapter 4, (Kytidou 
et al. 2018)). This enzyme holds great promise as an improved ERT for Fabry 
due to its high α-gal activity, great similarity with human enzyme and its easy 
production. In addition, a chemically cross-linked recombinant α-galactosidase, 
with improved stability in human plasma has also been recently reported and 
studied (Ruderfer et al. 2018). This enzyme, Pegunigalsidase Alfa, is currently 
under clinical trials (Holida et al. 2019). 
 Since the limited enzyme stability in plasma is a major drawback, another 
therapeutic approach employs the use of enzyme active site binders that 
stabilize recombinant enzyme in circulation. Gal-DNJ 8 (Migalastat®) is 
currently in use in the clinic as the first pharmacological chaperone for Fabry 
disease. However it lacks selectivity versus the lysosomal -glucosidase (GBA) 
(Artola et al. 2019). Here, we investigate the use of a new, first-in-class 
conformational α-galactosidase inhibitor, α-cyclosulfamidate 4, as a potential 
stabilizer of both human (Fabrazyme) and plant (A1.1) α-galactosidases. -
Cyclosulfamidate 4 reversibly and selectively inhibits Fabrazyme with an IC50 
value of  67 µM and a Ki of 110 µM (Artola et al. 2019). We demonstrate that α-
cyclosulfamidate 4 stabilizes recombinant human α-D-galactosidase 
(agalsidase beta, Fabrazyme®) in cell culture medium. Interestingly, the same 
stabilization effect is observed with plant α-galactosidase A1.1 in human 
plasma when incubated with 25 μM of Gal-DNJ 8 or 250 μM of α-gal-
cyclosulfamidate 4 . 
To further study this stabilizing effect, we investigated whether Gal-DNJ 8 
and α-gal-cyclosulfamidate 4 would stabilize α-gal A activity in situ conditions. 
Treatment of fibroblasts (WT, classic and variant Fabry cell lines) with only 
Gal-DNJ 8 (at 20 µM) and α-gal-cyclosulfamidate 4 (at 200 µM) for 24 h showed 
no effect on α-D-galactosidase activity. However, we observe an increased α-D-




galactosidase activity in all cells treated with the combination of Fabrazyme 
and stabilizing agents (8 at 20 µM and 4 at 200 µM) when compared to the cells 
treated only with Fabrazyme. This result also correlates with an increased α-
D-galactosidase activity in the cell medium of the cells treated with enzyme and 
8 or 4. The stabilizing effect is more pronounced when cells are treated for 
longer time (4 days), suggesting that the Fabrazyme complexed with Gal-DNJ 
8 or α-gal-cyclosulfamidate 4 is stabilized in the cell medium, internalized and 
dissociated from the reversible inhibitor in the lysosomes. Finally, co-
administration of Gal-DNJ 8 or α-gal-cyclosulfamidate 4 with Fabrazyme 
highlights a similar correction of toxic Gb3 and lyso-Gb3 metabolite levels as 
with the ERT alone. Importantly, similar α-gal A activity and correction of toxic 
metabolites is achieved with half the concentration of Fabrazyme when this is 
stabilized by Gal-DNJ 8 or α-gal-cyclosulfamidate 4. The synergy between Gal-
DNJ 8 and the human recombinant α-gal A in cultured fibroblasts from Fabry 
patients has recently been demonstrated both in Fabrazyme and Replagal 
(Porto et al. 2012; Pisani et al. 2014). This synergism, together with our 
Fabrazyme stabilization results, supports the idea that the efficacy of a 
combination treatment may be superior to ERT or PC alone for several reasons. 
Co-administration of ERT and active site inhibitor may be effective in all Fabry 
patients, independent of mutations in their endogenous α-gal A. Furthermore, 
stabilization of the recombinant human α-gal A by a stabilizing agent may 
reduce the required enzyme dosages or extend IV injections intervals, and 
therefore improve patient’s life-style and reduce side effects and treatment 
costs. 
 In conclusion, the combination treatment of recombinant enzyme together 
with chaperones or enzyme stabilizers prompts great expectations for Fabry 
treatment. The newly developed inhibitor cyclosulfamidate 4 although it is a 
1000-fold weaker inhibitor of recombinant α-gal A compared to Gal-DNJ 8 in 
vitro, it stabilizes α-gal A in situ at only 10 fold higher concentration and proves 
that competitive glycosidase inhibitors are attractive starting points for clinical 
development as stabilizers of (recombinant) glycosidases in the context of 
lysosomal storage disorders. The improvement of recombinant enzyme stability 











Material and Methods.  
 
Tissue and cell samples. Patients with Fabry disease were diagnosed on the 
basis of reduced α-gal A activity and/or demonstration of an abnormal genotype. 
Wild-type male human fibroblasts (c104) were obtained from Cambrex-Lonza 
(CC-2511, lot nr 104564, East Rutherford, NJ, USA). Fibroblast cell lines from 
classical FD (R301X and D136Y) and variant FD (A143T and R112H) 
individuals were obtained from the Lysosomal Outpatient Clinic of the 
Academic Medical Center in Amsterdam (AMC). Informed consent was 
obtained from all patients for investigations in accordance with the Declaration 
of Helsinki. For lysis, cells were washed three times with PBS, subsequently 
lysed by scraping in potassium phosphate buffer (K2HPO4– KH2PO4, 25 mM, 
pH 6.5, supplemented with 0.1 % (v/v) Triton X-100 and protease inhibitor 
cocktail (Roche, Basel, Switzerland), aliquoted and stored at -20 °C until use. 
Lysate protein concentrations were determined with a Bradford assay using 
BSA as a standard. Naga enzyme was produced in Nicotiana benthamiana 
plants and purified in house as described in chapter 3, (Kytidou et al. 2017). 
 
In vitro stabilization of Fabrazyme in cell culture medium. Inhibitors’ 
stabilization effect was studied in Dulbecco's Modified Eagles Medium/Nutrient 
Mixture F-12 (DMEM/F12, Sigma-Aldrich) medium, supplemented with 10 % 
fetal calf serum and 1 % penicillin/streptomycin at pH 7.2, mimicking 
fibroblasts cell culture conditions. Agalsidase beta (25 μL, 2.5 mg/mL) was 
incubated at 37 °C in cell culture medium at pH 7.2 for 5, 10, 15, 20, 30 and 60 
min. After 15 min, 80 % degradation was observed, and this time point was 
used for further analysis. Thus, inhibitors (12.5 μL) at increasing 
concentrations (starting around the IC50 value of the corresponding inhibitor) 
were incubated with agalsidase beta (12.5 μL, 5 mg/mL) in cell medium 
conditions at pH 7.2 for 15 min and 0 min (for 100 % hydrolytic activity 
reference). Then, in duplicates 25 μL of sample (12.5 μL enzyme plus 12.5 μL 
inhibitor in cell culture medium and 1 % DMSO) were incubated in a shaker at 
4 °C for 1 hour with 25 μL of ConA beads. The samples were next centrifuged 
at 16000 rcf for 10 minutes at 4 °C and the supernatant was discarded. The 
ConA beads were likewise washed 3x with 500 μL of washing buffer (sodium 
acetate buffer pH 6 supplemented with 0.1 M NaCl, 1 mM CaCl2 and 1 mM 
MnCl2). Afterwards, 100 μL of 4-MU-α-D-galactopyranoside substrate (4.2 mM) 
in 150 mM McIlvaine buffer pH 4.6 supplemented with 0.1 % BSA (w/v) was 
added to the ConA beads and the mixture was incubated for 30 min at 37 oC. 
Finally, all enzyme reactions were quenched with 200 μL 1 M NaOH-Glycine 
(pH 10.3), and liberated 4MU fluorescence was measured with a LS55 




fluorescence spectrophotometer (Perkin Elmer; λEX 366 nm, λEM 445 nm). 
Values plotted for [I] are those in the final reaction mixture, containing E + I + 
S and the percentage of α-galactosidase activity was calculated considering 
incubation time 0 min as 100 % activity. 
 
In vitro stabilization of A1.1 in human plasma. The N. benthamiana α-
galactosidase A1.1 (400 ng), was first incubated with 25 μM of Gal-DNJ or 250 
μM of α-gal-cyclosulfamidate 2 or 0.5 % DMSO (assay total volume 20 μL) for 
20 min, at 37 oC (water bath) in 150 mM citric/phosphate (Mcllvaine) buffer, pH 
5.3. Then the samples were passed through 0.7-ml PierceTM polyacrylamide 
spin desalting columns, pre-equilibrated with 150 mM citric/phosphate 
(Mcllvaine) buffer, pH 5.3. Then, samples were incubated in 400 μL human 
plasma (AB) (protein concentration, 1 μg per mL of plasma) and samples were 
taken at different time points (0, 15, 30, 45, 60 min). Measurement of 4-MU-α-
galactosidase activities of the different samples followed, exactly as described 
earlier (Blom et al. 2003; Kytidou et al. 2017).  
 
Competitive activity-based protein profile (ABPP) in recombinant α-
galactosidases. Agalsidase beta or alpha (200 ng), or N-acetylgalactosaminidase 
(NAGA, 200 ng) were incubated with different concentrations of both inhibitor 
2 and GalDNJ 1, ranging from 1 to 1000 μM, for 15 min. Then, enzymes were 
also incubated with 0.2 μM of Cy5 α-Gal ABP TB474, for 30 min in a water bath 
at 37 °C. After ABP incubation, proteins were denatured by boiling the samples 
with Laemmli buffer (50 % (v/v) 1 M Tris-HCl, pH 6.8, 50 % (v/v) 100 % glycerol, 
10 % (w/v) DTT, 10 % (w/v) SDS, 0.01 % (w/v) bromophenol blue) for 5 min at 
98 °C, and separated by electrophoresis on sodium dodecyl sulphate-
polyacrylamide gels, 10 % (SDS-PAGE), following fluorescent scanning of the 
gels as previously described (Willems et al. 2014; Kytidou et al. 2017). 
Coomassie brilliant blue staining of the gels was performed in order to show 
equal protein loading. 
 
In situ treatment of cultured fibroblasts from patients with Fabry disease.24 h 
Treatment. Fibroblasts (5 cell lines (males): WT, Fabry variants R112H and 
A143T, and Fabry classic D136Y and R301X) were grown in 12 well plates (0.5 
mL of medium) in a humidified incubator at 37 °C with 5 % CO2. Experiments 
were performed in triplicates. Fibroblasts were untreated as control (1 μL 
DMSO), or treated with 1 μL of 100 μg/mL of agalsidase beta, with inhibitor 4 
(1 μL of 100 mM stock solution, final concentration 200 μM) or Gal-DNJ 8 (1 
μL of 10 mM stock solution, final concentration 20 μM), or with the combination 





20 μM, respectively, followed by 24 h incubation. Next, the medium was 
collected for α-galactosidase activity assays and cells were washed, collected 
(combine the triplicates) and lysed in ice-cold 25 mM phosphate buffer, pH 6.5, 
supplemented with 0.1 % Triton X-100 and protease inhibitor cocktail table 
(Roche). The lysates were stored at -20 oC until further use. 
 
4-day Treatment. Fibroblasts WT and classic Fabry (R301X) cell lines were 
grown in 12 well plates (0.5 mL of medium) in a humidified incubator at 37 °C 
with 5 % CO2. Experiments were performed in triplicates. Fibroblasts were 
untreated as control (1 μL DMSO), or treated with 1 μL of 100 ng/μL of 
agalsidase beta, or with the combination of 1 μL of·100 ng/μL agalsidase beta 
and inhibitor 4 (1 μL of 100 mM stock solution, final concentration 200 μM) or 
Gal-DNJ 8 (1 μL of 10 mM stock solution, final concentration 20 μM), followed 
by a 4-day incubation. The medium was collected for α-galactosidase activity 
assays every 24 h and new medium supplemented with DMSO, agalsidase beta 
or the combination of enzyme and inhibitor was added. On the fifth day, cells 
were washed, collected (combine the triplicates) and lysed in ice-cold 25 mM 
phosphate buffer, pH 6.5, supplemented with 0.1 % Triton X-100 and protease 
inhibitor cocktail table (Roche). The lysates were stored at -20 oC until further 
use. A second experiment was performed in treated fibroblast WT and classic 
Fabry (R301X) with 1 μL of DMSO as control, or treated with 1 μL of·100 ng/μL 
of agalsidase beta, or with the combination of half amount of enzyme (1 μL of·50 
ng/μL agalsidase beta) and inhibitor 4 (1 μL of 100 mM stock solution, final 
concentration 200 μM) or Gal-DNJ 8 (1 μL of 10 mM stock solution, final 
concentration 20 μM), followed by 4-day incubation. Released 4-MU was 
fluorometrically quantified in fibroblast lysates as described above (Blom et al. 
2003). Reactions were performed in duplicates for 30 min at 37 oC at 4.2 mM of 
4-methylumbeliferone(4-MU)-α-D-galactopyranoside in 150 mM citrate-
phosphate buffer pH 4.6 supplemented with 0.1 % (w/v) BSA. Reaction were as 
follow: 15 μL of Buffer with α-GAL B inhibitor NAGA (100 μM) was incubated 
for 30 minutes at 37 oC with 10 μL of fibroblast lysate, then 100 μL of 4MU 
substrate (4.2 mM) was added and the mixture was incubated for 30 min. 
Finally, stop buffer was added (200 μL) and fluorescence was measured. α-
Galactosidase activity in the cell medium samples was measured with a ConA 
purification pre-step to wash away the competitive inhibitors. Thus, in 
duplicate 25 μL of sample medium was incubated in a shaker at 4 °C for 1 hour 
with 25 μL of ConA beads. Then, the samples were centrifuged at 16000 rcf for 
5 minutes at 4 °C and the supernatant was discarded. The conA beads were 
likewise washed 3x with 200 μL of washing buffer (sodium acetate buffer pH 6 
supplemented with 0.1 M NaCl, 1 mM CaCl2 and 1 mM MnCl2). Afterwards, 




100 μL of 4-MU substrate (4.2 mM) was added to the ConA beads and the 
mixture was incubated for 30 min at 37 oC. Finally, stop buffer was added (200 
μL) and fluorescence was measured. 
 
Gb3 and LysoGb3 determination. Gb3 and LysoGb3 were extracted as 
previously described by a modification of the Bligh and Dyer method using 
acidic buffer (100 mM ammonium formate buffer pH 3.1) (Mirzaian et al. 2017). 
Prior to extraction, 20 μL of the internal standard C17-dh-Ceramide (20 μM) 
and 20 μL of 13C5-LysoGb3 (0.1 μM) were added to 50 μL of cell homogenate.10 
Briefly, lipids were extracted by adding methanol, chloroform, and ammonium 
formate buffer (1:1:0.9; v/v/v) which resulted in 2 phases. The upper phase was 
dried under N2 stream and further extracted with water/butanol (1:1; v/v) 
before being applied to the UPLC-MS. The lower phase was transferred to a 
Pyrex tube and de-acylated in a microwave for 1 h with 500 μL of methanolic 
NaOH (0.1 M). De-acylated lipids were additionally extracted with 
water/butanol (1:1; v/v) before being applied to the UPLC-MS. Lipids were 
analysed by reverse-phase liquid Chromatography using a Waters UPLC-Xevo-
TQS micro and a BEH C18 column, 2.1 × 50 mm with 1.7 μm particle size 
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The potential use of ABPs cross species was investigated. Studied were lysates 
derived from Bright Yellow tobacco cell lines (BY2) and the food supplement 
Beano containing a fungal (A. niger) α-galactosidase.  
        The investigations with BY2 cell lysates led to the discovery of a plant β-
glucosidase that is potently labeled by the β-glucose configured epoxide 
cyclophellitol ABP and its identity was next established by proteomics. The 
enzyme, here named B56, is active towards NBD-GlcCer lipid, revealing its 
potential use in therapy of Gaucher disease.  
ABPs could be also successfully applied to label the α-galactosidase from A. 
niger present in the food supplement Beano. The enzyme was found to be active 
towards artificial 4-methulumbelliferyl-α-galactoside but not towards NBD-
Gb3.  
        As Fabry patients suffer from intestinal complications, possibly induced 
by accumulating lysoGb3 in the intestine, future application of other αGAL 








Retaining glycosidases are remarkably conserved among species in their 
catalytic mechanism based on double displacement. This reaction is essentially 
governed by appropriately placed nucleophile and acid/base residues in the 
catalytic pocket (Davies and Henrissat 1995). Due to the conserved structural 
prerequisites for catalytic activity, glycosidases across species are found to be 
targeted by activity-based probes (ABPs) consisting of a correctly configured 
cyclophellitol with a reporter group linked to it (Witte et al. 2010).   
        Retaining glycosidases fulfil important functions in human physiology. For 
example, in the lysosomes of cells specialized glycosidases are essential in 
turnover of glycoconjugates. Examples are the acid β-glucosidase 
(glucocerebrosidase, GBA) hydrolyzing glucosylceramide (GlcCer) and α-
galactosidase A (GLA) hydrolyzing globotriaosylceramide (Gb3) (Ferraz et al. 
2014). Inherited deficiencies in these enzymes of glycosphingolipid metabolism 
cause the lysosomal storage disorders Gaucher disease and Fabry disease, 
respectively (Beutler and Grabowski 2001; Desnick et al. 2003). 
        Cyclophellitol and cyclophellitol-aziridine are known suicide inhibitors of 
β-glucosidases (Kallemeijn et al. 2014b; Li et al. 2014; Kuo et al. 2018). Different 
sets of ABPs have been designed to label the retaining β-glucosidases present 
in human cells and tissues. One set consists of cyclophellitol (-epoxide) with 
linked to C6 (C8 cyclophellitol numbering) a spacer with attached reporter 
(fluorophore or biotin) (Witte et al. 2011). The other set consists of 
cyclophellitol-aziridine with linked to the nitrogen a spacer with attached 
reporter. The first set of ABPs specifically labels GBA, whilst the second set 
labels all human β-glucosidases (GBA, GBA2, GBA3 and LPH) (Kallemeijn et 
al. 2012, 2014a). 
        Differently configured cyclophellitol-aziridines have been subsequently 
designed to label various classes of retaining glycosidase (Witte et al. 2011; 
Kallemeijn et al. 2012; Willems et al. 2014a; Kallemeijn et al. 2014a; Jiang et 
al. 2015, 2016; Marques et al. 2017; Wu et al. 2017; Artola et al. 2018). For 
example, galactose-configured cyclophellitol-aziridine ABP labels the highly 
homologous α-galactosidase enzymes GLA and α-N-acetylgalactosaminidase 
(NAGA) (Kytidou et al. 2017). Earlier we labeled with the same ABP an 
ubiquitous retaining α-galactosidase in Nicotiana benthamiana (N. 
benthamiana) (Kytidou et al. 2018). The protein, named A1.1, was identified, 
cloned and characterized. Crystallography revealed a high similarity in 3D-
structure with the human counterparts GLA and NAGA (Kytidou et al. 2018). 
The A1.1 enzyme shows activity towards Gb3, albeit this lipid does not occur in 




plants. The A1.1. α-galactosidase differs from GLA and NAGA in complete lack 
of N-glycans and a broader pH optimum (Kytidou et al. 2018). Its potential 
value to treat patients suffering from Fabry disease with recombinant A1.1 is 
being investigated.  
        The metabolism of the glycosphingolipid GlcCer is of great interest in 
relation to various diseases. Impaired lysosomal degradation due to deficient 
GBA activity causes formation of lipid-laden macrophages (Gaucher cells) that 
are thought to contribute to the hepatomegaly, splenomegaly, and cytopenia in 
Gaucher patients (Ferraz et al. 2014). Accumulation of GlcCer is partly 
prevented by its conversion to glucosylsphingosine (GlcSph) by the lysosomal 
enzyme acid ceramidase (Dekker et al. 2011; Ferraz et al. 2016).  Recent studies 
suggest that GlcSph is a toxic agent that promotes gammopathy in Gaucher 
patients and multiple myeloma as well as increases the risk for Parkinson 
disease in carriers of a mutant GBA allele (Siebert et al. 2014; Nair et al. 2016). 
GlcCer is also degraded by the cytosol-face GBA2, a membrane-bound β-
glucosidase (Ferraz et al. 2014). GBA2 not only acts as hydrolase but also as 
transglucosidase transferring glucose from GlcCer to cholesterol to yield 
glucosylcholesterol (GlcChol) (Marques et al. 2016). For a number of decades 
type Gaucher patients are treated by enzyme replacement therapy (ERT) 
involving chronic intravenous infusion with recombinant GBA (Barton et al. 
1991; Brady 2003). ERT allows correction of Gaucher cells, but does not prevent 
all complications in Gaucher patients, for example skeletal disease and 
neurological impairment (Ferraz et al. 2014).  
        Plants contain also the glycosphingolipid GlcCer and therefore very likely 
also possess a glucosyl-ceramidase fragmenting the lipid to ceramide and 
glucose, similar in function to GBA1 (chapter 2). Plants might also contain a 
transglucosylating β-glucosidase, similar in function to GBA2. Glucosylated 
sterols are also abundant plants and yet unidentified enzymes involved in their 
synthesis and degradation have to exist (Grille et al. 2010). In this 
investigation, cyclophellitol and cyclophellitol-aziridine ABPs (Figure 1) were 
used in Nicotiana tabacum Bright yellow-2 cells (BY-2) to study the retaining 
β-glucosidases in plants.  
        Another example of cross species use of glycosidase ABPs is provided by 
experiments performed with Beano®, a dietary supplement used to reduce 
flatulence after consumption of beans and cabbage. The supplement degrades 
complex carbohydrates present in such foods and thus prevents intestinal 
bacteria producing excessively intestinal gas (Prestige Brands Holdings, Inc., 
2016a). A key component of Beano is an α-galactosidase from the fungus 
Aspergillus niger (A. niger) according to the producer (Prestige Brands 
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Targeting Nicotiana tabacum BY-2 cells β-glucosidases 
An investigation regarding β-glucosidases involved in glycolipid metabolism in 
N. tabacum BY-2 cells was conducted.  In this study use was made of the 
cyclophellitol ABP and cyclophellitol-aziridine ABP and lysates of cultured BY-
2 cells as source of enzymes (Figure 2). Cells were cultured in Linsmaier and 
Skoog medium (Linsmaier and Skoog 1965) supplemented with 0,09 M sucrose 
and 0.2 mg/lt 2,4-dichlorophenoxyacetic acid and were harvested at day 7 of 
sub-culturing. Cell lysates were prepared in ice cold lysis buffer (10 mM 
Na2HPO4/NaH2PO4 buffer, pH 6, with 0,15 M NaCl and 0,1 % Triton X-100), 
using the FastPrep-24 machine (MP Biomedicals). Then, lysates were used 
directly for experiments or were further fractionated into soluble or insoluble 
fractions after centrifugation for 10 min at 16,000 rpm, 4 oC.  B-glucosidase 
activity present in all fractions was first measured using 1.25 mg/mL of the 4-
methylumbelliferyl (4MU) -β-D-glucopyranoside substrate, at pH5 (Figure 2A). 
Activity present in soluble fraction was around 10 times lower than the one 
measured in full lysate. Insoluble fraction contained the highest activity, 
possibly due to high protein content of the preparation.  Then, the fractions 
were incubated with 0.5 μM ME569, JJB367 or TB474 at pH5 conditions, for 
30min, 37 oC. Figure 2B shows that a single protein with apparent MW at 57 
kDa was labeled by the epoxide ABP, ME569. The protein was more prominent 
in the soluble fraction. Multiple proteins were labelled using the epoxide ABP, 
JJB367 at apparent MWs of 79, 73, 70, 65 kDa. Some of them were present in 
the soluble and others in the insoluble fraction. Use was made of the α-
galactosidase configure ABP, TB474 to visualize α-galactosidases in the various 
fractions. Proteins with  MWs of 45 and 39 kDa were labeled, as earlier 















Figure 2. Targeting retaining glycosidases in BY2 cells. A. 4MU activities of BY2 lysates, as 
measured using the 4MU-β-D-glucopyranoside substrate. error bars indicate standard deviations, n=4 
biological replicates. B. Full and fractionated BY2 cell lysates were incubated for 30min, 37oC, pH5 with 
0.5μM JJB367, ME569 or TB474 ABPs. The samples were then applied to 10 % SDS-PAGE gels and 
fluorescent scanning of the gels followed. Interestingly, a specific protein was labeled using the epoxide 
ME569, at 57 kDa. Multiple proteins were identified using JJB367 and the already characterized α-
galactosidases using TB474.  
 
N-glycosylation profile of the labeled BY2 β-glucosidases as revealed by 
Concanavalin A binding.  
Lysates were incubated with Concanavalin A (Con A) beads to separate 
proteins into a lectin binding fraction and non-binding fraction. Enzymatic 
activity was first measured, using 4-MU-β-glucoside, in all fractions (Figure 
3A). Results revealed that most enzymatic activity was present in the 
supernatant (non-binding fraction) fractions. Then, samples were incubated 
with 0.5 μM MDW941 at a pH of 5 or 0.5 µM JJB367 at a pH of 5 (conditions 
determined to be optimal for labeling). According to figure 3B the ME569-ABP-
identified protein (MW 57 kDa) was present in the non-binding fraction upon 
Con A separation, suggesting that the protein might not contain N-linked 
glycans. Some of the proteins labeled with JJB367 were in the Con A binding 





















































Figure 3. Studying the N-glycosylation profile of BY2 β -glucosidases. Concanavalin A (Con A) 
treatment of BY2 cell lysates following 4MU activity measurements (A) and ABP labeling (B). BY2 cell 
lysates were first incubated for 1hr, 4oC while rolling with ConA beads. After incubation, centrifuge of 
the samples took place and the different fractions were obtained (beads (B), supernatant/ unbound (S), 
wash 1,2,3 (W1, W2, W3)). Then, the fractions were incubated for 30 min, 37 oC, with 0.5 μM JJB367 
or MDW941.  
        Next, biotinylated versions of the ABPs (JJB111 and ME869) (Figure 1) 
were used to target proteins followed by a pulldown with streptavidin-beads, as 
earlier described (Jiang et al. 2015, 2016). The nature of the enriched proteins 
was determined using LC-MS/MS based proteomics exactly as earlier described 
(Jiang et al. 2015, 2016). Measurement of the biotinylated targets was 
performed via on bead and in gel trypsin digestions, using the aziridine 
biotinylated ABP, JJB11 and also the newly synthesized cyclophellitol-epoxide-






























































using JJB111 in soluble fraction. The ME869, was found to label the protein 
A0A1S4CL56, named as B56, with predicted MW of 57 kDa, consistent with 
that observed for the labeled protein (Table 1). In the CAZy database, B56 is 
based on its amino acid composition classified as member of GH family 5. The 
GH5 family consists of glycoside hydrolases with various functions, including  
endo-β-1,4-glucanase / cellulase, endo-β-1,4-xylanase, β-glucosidase, β-
mannosidase, glucan β-1,3-glucosidase, exo-β-1,4-glucanase / cellodextrinase, 
glucan endo-1,6-β-glucosidase, mannan endo-β-1,4-mannosidase, cellulose β-
1,4-cellobiosidase, chitosanase, β-primeverosidase, xyloglucan-specific endo-β-
1,4-glucanase, endo-β-1,6-galactanase, β-1,3-mannanase, arabinoxylan-specific 
endo-β-1,4-xylanase, mannan transglycosylase, lichenase / endo-β-1,3-1,4-
glucanase, β-glycosidase,  endo-β-1,3-glucanase / laminarinase, β-N-acetyl-
hexosaminidase, chitosanase, β-D-galactofuranosidase, β-
galactosylceramidase,  endoglycoceramidase, β-glucosylceramidase and steryl 
β-glucosidase (www.cazy.org).  More recently human GBA1 has been classified 
from GH5 to GH30 (Ben Bdira et al. 2018). 
 
















A0A1S4CR57 beta-glucosidase BoGH3B-like 68860 685 30 3
A0A1S3ZME1 probable beta-D-xylosidase 6 88005 418 23 3
A0A1S4CL56 probable glucan 1,3-beta-glucosidase A isoform X2 57212 269 44 5
A0A1S4C677 beta-galactosidase 98264 163 24 35
A0A1S3XJ27 beta-glucosidase BoGH3B-like isoform X1 69022 136 17 3
A0A1S4AT57 glucan endo-1,3-beta-glucosidase, basic vacuolar 40474 100 25 17
A0A1S3ZFV9 lysosomal beta glucosidase-like 70183 81 6 3
A0A1S3ZJI2 beta-galactosidase 17-like 36223 72 24 35
A0A1S4C5S1 probable beta-D-xylosidase 5 89322 67 1 3
A0A1S3YQ73 beta-glucosidase 18-like 61221 44 7 1
A0A1S3XGA2 beta-xylosidase/alpha-L-arabinofuranosidase 2-like 86389 40 5 3




Activity of BY2 glycosidases towards NBD-GlcCer substrate.  
It will be of great interest to study more closely A56 regarding various 
enzymatic and structural features.  It has been observed that part of the 
enzymatic activity towards the fluorogenic substrate 4MU-β-glucoside in the 
soluble fraction of BY2 lysate is inhibited by MDW941. Its pH optimum is about 
5.0 and the activity seems not to be bound by Concanavalin A (Figure 3). 
Lysates of BY2 cell were found to degrade NBD-glucosylceramide to NBD-
ceramide and this activity was inhibitable with ABP1 and ABP2 (Figure 4). 
 
Figure 4. NBD-GlcCer lipid hydrolysis via BY2 cell lysates. Full and fractionated BY2 cell lysates 
were pre-incubated with or without 10uM ME569 or JJB367, for 2h, 37oC. Then, the samples were 
incubated with 2uM of C6: NBD-GlcCer, for 2h 37oC, pH5. Cerezyme was used as a positive control of 
the lipid hydrolysis reaction. BY2 cell lysates contain enzymes able to hydrolyse the human NBD-lipid, 
and they are inhibited by both epoxide and aziridine ABPs (ME569 and JJB367, respectively).  
        A straight-forward approach to characterize better B56 would be to 
overexpress the enzyme and purify it, along the same line as earlier performed 
for the A1.1. α-galactosidase (Kytidou et al. 2018). It should be in particular 
established whether the B56 protein shows activity towards natural GlcCer and 
GlcChol (chapter 2). In addition, its ability to act as transglucosidase should be 
tested (Marques et al. 2016). Moreover, its subcellular localization will be 
interest. Information on stability of the protein and resistance towards 
proteases is required to get an impression of its value to modulate glycolipid 
metabolism in humans. Presently available data suggest, but do not proof, that 
A56 lacks N-glycans given its poor binding to Concanavalin A.  
        Cyclophellitol-aziridine ABPs were found to label proteins A0A1S4CR57, 
A0A1S3ZME1 and A0A1S3ZFV9 with MWs of 69, 88 and 70 kDa, respectively. 
All three proteins are predicted to belong to GH3, a family of various β-
glucosidases including cell wall degrading enzymes [β-glucosidase, xylan 1,4-β-
xylosidase, β-glucosylceramidase, β-N-acetylhexosaminidase, α-L-
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arabinofuranosidase, glucan 1,3-β-glucosidase, glucan 1,4-β-glucosidase, 
isoprimeverose-producing oligoxyloglucan hydrolase, coniferin β-glucosidase, 
exo-1,3-1,4-glucanase, β-N-acetylglucosaminide phosphorylases, β-1,2-
glucosidase, β-1,3-glucosidase, xyloglucan-specific exo-β-1,4-glucanase / exo-
xyloglucanase (http://www.cazy.org/GH3.html) .  
        Indeed, fluorescence microscopy revealed labeling of the cell wall by 
fluorescent cyclophellitol-aziridine ABP (Figure 5). The labeling was inhibited 
after overnight incubation with an ABP without the fluorophore (KY358), 
revealing that it was specific targeting enzyme molecules. Both JJB367 and 
JJB75 fluorescent ABPs were used for the same microscopy experiment, here 
presented only results using JJB75 (Figure 5). Since the BY2 cultures used 
during these experiments were harvested at day 3 of post culturing, the ABP-
labelled proteins seem to be mainly the ones at MW of ~69 (Figure S1). Possibly 
targeting, the enzyme β-glucosidase BoGH3B (A0A1S4CR57) of GH3 family, as 
also measured during in-gel proteomics analysis. In addition, to further support 
the previous, in situ ABP labeling presented at figure S2, reveals that using 0.5 
μM concentration of JJB75 probe (concentration used during microscopy 
experiments) mainly targets enzyme(s) present at MW of 69 kDa. One can 
further exploit the localization of targeted proteins after ABP labeling also via 
fractionating the samples and isolating the vacuoles or extracellular area of 
BY2 cells.  
 




Figure 5. Live confocal microscopy of BY2 cells using ABPs. 3 days old BY2 cells (500 μL) were 
incubated in a 12-well plate with 0.5 uM of JJB75 for 2-3 h.  To ensure that the labeling was specific, 
samples were also pre-incubated overnight with the non-fluorescent ABP, KY358 and then JJB75 
labeling followed as before. The signal was lost after pre-incubation with the non-fluorescent ABP 
suggesting that the labeling was specific. 
 
In silico model of B56 and its active site similarities with human GBA1 enzyme   
There are no striking amino acid sequence similarities of B56 with the human 
GBA1 enzyme, and its homologues in mice (Mus musculus) and zebrafish 
(Danio rerio). The protein shows amino acid sequence similarities with 
bacterial and yeast enzymes. A hypothetical structural model of the β-
glucosidase B56 was made, in Swiss-model program, using as a structural 
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The proteins have 36 % sequence similarity and both belong to GH family 5. 
The modeled 3D-structure was superimposed on the established 3D-structure 
of human GBA1 (PBD code: 2NT0). Overall the proteins were very different but 
their active site shared conserved moieties. Most importantly, two glutamic 
acid residues serving as the nucleophile and acid/base moieties of the retaining 
mechanism, were conserved among the two enzymes. In human GBA1 the 
catalytic residues are E235 and E340 and in B56 putatively E346 and E450. 
B56 is a predicted monomer, without N-linked glycans in contrast to the human 
enzyme which is a natural dimer, having 5 predicted N-linked glycosylation 












Figure 6. In silico structural models of B56 and the human GBA1 (PBD code: 2NT0). Superimposed 
active sites of human GBA1 (light blue) and B56 (light orange). The two catalytic residues (E235/E340 
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Screening for different retaining glycosidases in BY-2 cells using different 
configured ABPs   
In a pilot investigation lysate of BY-2 cells were labeled with ABPs directed 
against different classes of retaining glycosidases (see figure 1; α-glucosidase, 
α-galactosidase, β-mannosidase, α-fucosidase, β-galactosidases, β-
glucuronidase, α-mannosidase). Discrete proteins were visualized with most 
probes (Figure 7), except for α-fucosidase. Thus, the same approach could be 
used to identify retaining glycosidases for other research questions of interest. 
Figure 7. Screening for different retaining glycosidases in BY2 cell lysates, using different ABPs.  
20ug of total protein were incubated with 0.5uM of different Cy5-labeled ABPs (ME569, JJB383, TB474, 
TB492,JJB381,TB652,ME-JJB392,TB480). Most of the ABP labeling revealed possible candidate 
enzymes, yet to be characterized and identified.  
 
Fungal α-galactosidase: investigations with ABP (ABP labeling Beano® α-
galactosidase) 
Alpha-galactose configured TB474 was used to study the content on α-
galactosidases of Beano® (Figure 1). For this purpose, Beano tablets were 
dissolved in water. The obtained solution was analyzed on protein content and 
incubated with TB474. A-galactosidases belong to family GH27 and GH36. 
They hydrolyze on galactose oligosaccharides, galactomannans and 
galactolipids, whose terminal 1,6-α-D-galactosyl moieties are release 



























known to express 4 α-galactosidases (α-Gal I-IV) (Ademark et al. 2001a). The 
enzymes α-Gal II, III and IV are isoforms of AglB (GH27), whilst α-Gal I (GH36) 
is entirely distinct (Ademark et al. 2001b).   
        Using TB474 directed against α-galactosidases in the Beano solution, 
discrete proteins were labeled. Proteins with apparent MW of 60-65 kDa were 
labelled. Ademark and colleagues found that a protein closely related to A. niger 
α-galactosidase B consisted of two subunits with a molecular weight of 64 kDa 
(Ademark et al. 2001a, b). Beano contains also an invertase with sucrose 
activity (Prestige Brands Holdings, Inc., 2016b). This protein of approximately 
135 kDa is unlikely to be the labelled protein with apparent MW of about 100 
kDa reflects. 
Figure 8. ABP labeling of alpha galactosidases present in Beano® supplement. The ABP labeling 
performed using 0.5uM of TB474 and the incubations performed in different pH buffer conditions (pH 
range 2.2- 6.5). The proteins are optimum labeled at pH 4.5-5. Coomassie staining of the gel followed 
to ensure equal loading and detect the general protein content of the supplement.  
It was next examined whether incubation of Beano solution with TB474 led to 
inactivation of α-galactosidase activity. Most activity was lost following 
incubation with ABP and enzyme assay for 1 hour.  
        Next, apparent IC50 values of the potential natural substrate raffinose 
and D-galactose against human, fungal and plant α-galactosidases were 
determined (table 2).  Competition of ABP labeling by the same substrates and 
with the additional tetrasaccharide stachyose was also tested (Figure 8). In this 
experiment Beano α-galactosidase, human α-galactosidase GLA, and 
recombinant plant α-galactosidase A1.1 were compared. It was noted that 
raffinose and stachyose strongly competed labeling of A. niger enzyme, 
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indicating that these are likely substrates. This was also the case for plant A 
1.1., but not so for human GLA.  
 
Table 2. Apparent IC50 values for in vitro inhibition of fungal, human and plant α-galactosidases 









Figure 9. ABP signal competition with raffinose, D-galactose and stachyose. All enzymes, were 
pre-incubated for 1h, 37oC, with and without 500mM of the trisaccharide raffinose, monosaccharide D-
galactose or the tetrasaccharide stachyose. Then ABP labeling followed using 0.5 μM of TB474, for 
30min, 37 oC. The samples were then run on 10% SDS-PAGE gels and competition of the ABP signal 
revealed that Beano and A1.1 enzymes were highly inhibited by all saccharides, whereas human 
enzyme (Fabrazyme) was inhibited by D-galactose.  
 
        Finally, it was tested whether Beano solution was able to degrade 
NBD-GB3 (Figure 9). The enzyme despite its high activity towards the 
artificial fluorogenic 4MU-α-galactoside, which was comparable to that 
of Fabrazyme (recombinant human α-galactosidase A), it was not found 
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Figure 10. Beano and Fabrazyme activity towards NBD-Gb3. NBD-Gb3 lipid (2μM) was incubated 
with the same 4MU-aGAL activity input of Beano and Fabrazyme enzymes in different time points 
(30min and 4h). Beano enzyme cannot degrade the lipid substrate in contrast to Fabrazyme.  
 
Investigations on intestinal α-galactosidases may be of great interest in relation 
to Fabry disease (Ferraz et al. 2014). As the result of deficiency of the lysosomal 
enzyme α-galactosidase A, Fabry disease patients accumulate Gb3 and the de-
acylated form of the lipid called globotriaosylsphingosine or lysoGb3 (Aerts et 
al. 2008).  LysoGb3 is formed from Gb3 by lysosomal acid ceramidase and part 
of the water-soluble lipid may leave the body via urine and bile (Ferraz et al. 
2016). It has recently been reported that lysoGb3 impacts on microbiota and 
decreases production of the beneficial short-chain fatty acid butyrate (Aguilera-
Correa et al. 2019). The investigation indicates that intestinal lysoGb3 has 
harmful effects and may contribute to the commonly reported intestinal 
complaints of Fabry patients (Hoffmann et al. 2007). Our investigations suggest 
that the Beano α-galactosidase may have no therapeutic potential regarding 


















The studies described in this chapter further illustrate how ABPs can 
conveniently be used in fundamental research. Firstly, ABPs can be used to 
identify likely substrates by testing competition of ABP labeling by compounds 
(Figure 7). The same principle is applied in ABPP (activity-based profiling) 
screening of drug laboratories as was demonstrate by Lahav et al. in their 
search for potent inhibitors of the retaining human β-glucosidase GBA2 (Lahav 
et al. 2017). Secondly, ABPs can be used to identify the various classes of 
retaining glycosidase in different species. Examples for this are provided by the 
work of the van der Hoorn laboratory regarding plant glycosidase 
(Chandrasekar et al. 2014; Husaini et al. 2018). Along the same line, the panel 
of available ABPs labeling distinct glycosidases was used by Kuo et al. to 
determine target and off-target interactions of inhibitors such as conduritol B-
epoxide and cyclophellitol, aiming to covalently inhibit the lysosomal β-
glucosidase GBA1 (Kuo et al. 2019). The outcome of this investigation allowed 
design of a very specific GBA1 suicide inhibitor allowing generation of genuine 


















Materials and methods  
 
BY2 cell culturing and lysis. BY-2 cells were cultured in Linsmaier and Skoog 
medium (Linsmaier and Skoog 1965) supplemented with 0,09 M sucrose and 
2,4-dichlorophenoxyacetic acid (0.2 mg/l). The medium was autoclaved and kept 
at 4 °C until further use. Cells were sub-cultured every seven days (1-5 mL cells 
into 100 mL medium). BY2 cultures were kept in dark on a rotary shaker , 130 
rpm at 27 °C (Nagata et al. 1992). Cell lysates were made using ice cold lysis 
buffer (10 mM Na2HPO4/NaH2PO4, pH 6, 0,15 M NaCl, 0,1 % Triton X-100 with 
additional protease inhibitor), using 500 μL of buffer per gram of cells. Then 
the cells were further lysed using the FastPrep-24 (MP Biomedicals). After 
lysis, part of the samples was collected (Full lysate) and the rest was 
fractionated, after centrifuge at 16,000rpm for 10 min, 4 oC. The obtained 
supernatant was collected (soluble fraction) and also the pellet (insoluble 
fraction). Protein concentration of the samples was measured using the Micro 
BCA Protein Assay Reagent Kit (PIERCE), according to manufacturer protocol. 
The samples were stored at -20 oC until further use.   
Beano® lysates. 1 tablet of Beano® (Prestige Brands Holdings, Inc), was 
dissolved in 1 mL MQ. Protein content of the sample followed, using the Micro 
BCA Protein Assay Reagent Kit (PIERCE). The sample was aliquoted and 
stored at -20 oC until further use.  
Fluorescent ABP labeling and SDS-PAGE analysis. In vitro ABP labeling assay 
was performed at 37 oC, for 30 min to 1h, using different ABPs (Figure 1) at 
final concentration 0.5 μM, volume 20 μL. The incubation was done in 150 mM 
Mcllvaine buffer, pH5, using 20 μg of total protein concentration. SDS-PAGE 
loading buffer was then added to the samples, following boiling at 95 oC, for 
5min. Then samples were applied on 10 % SDS-PAGE gels and fluorescent 
scanning of the gels tool place as previously described (Willems et al. 2014b).  
Concanavalin A beads. Cell lysates were incubated for 1h, 4oC while rolling 
with Concanavalin-A (ConA) Sepharose beads (GE healthcare Bio-Sciences) 
and the protocol was followed exactly as previously described (Kytidou et al. 
2018).  
Proteomics analysis. On bead proteomics analysis: 450 μL of BY2 cell lysates 
(Full lysate, soluble, insoluble fraction), having a protein content between 2-5 
mg/mL, were incubated with 5 μM of the biotinylated aziridine ABP, JJB111 or 
with DMSO (control) overnight at room temperature. After incubations, 




proteins were linearized with 2 % SDS, precipitated using chloroform/ methanol 
precipitation, cystine bridges were reduced and alkylated following the exact 
protocol described at Jiang et al. 2016 (Jiang et al. 2016). Pull downs with 
avidin agarose beads (Pierce) 50 μL per sample were followed. The beads were 
washed with PBS and added to each sample in 1 mL PBS with beads per 
sample. The samples were incubated with the beads overnight at 4 °C while 
rolling. The beads were isolated through centrifugation (2500 g, 2 min) and a 
sample was taken of the supernatant: post-pulldown sample. This sample, 
together with the pre-pulldown sample, was used for SDS-PAGE analysis of the 
pulldown efficiency. The beads were washed with 0,5 % (w/v) SDS in PBS (1x) 
and PBS (3x). Then samples were prepared for proteomics analysis exactly as 
described at (Jiang et al. 2016; Kytidou et al. 2018).  
In gel proteomics analysis :50 mL BY2 lysates were first incubated with 50 mL 
of diluted (x10) ConA beads overnight, 4 oC while rotating. Then, the sample 
was centrifuged max. speed, for 15min, 4 oC and supernatant was collected. The 
supernatant sample was then concentrated using the Amicon ultra-centrifugal 
tubes, according to the manufacture’s protocol, up to 2 mL. Then, 200 μL of the 
sample were incubated with or without 2 μM of ME869 or JJB111 probes, 
overnight at room temperature. After ABP incubations the samples were 
treated exactly as described for the on-bead proteomics analysis, until the 
streptavidin bead incubations. In these experiments, the Dynabeads™ 
MyOne™ Streptavidin beads were used and the protocol was exactly as 
previously described (Kytidou et al. 2018). After binding to streptavidin beads, 
samples were applied on 10 % pre-cast SDS-PAGE gels (Bio rad). Excise of the 
bands followed, and the samples were further treated for proteomics analysis 
as previously described (Jiang et al. 2016; Wu et al. 2017). The Synapt G2Si 
mass spectrometer (Waters) operating with Masslynx for acquisition and 
ProteinLynx Global Server (PLGS) for peptide identification was used for 
analysis. Peak lists containing parent and daughter ions were compiled in .mgf 
format and searched against the Swiss-Prot (version 2017).  
Enzyme activity assays. 4MU activity assays were performed exactly as 
previously described (Kallemeijn et al. 2012; Kytidou et al. 2017).  
Microscopy. BY2 cultures at day 3 of sub-culturing were transferred in 12-well 
plates (500 μL). 0.5 μM of JJB75 (red bodipy) or JJB367 (Cy5) ABPs were 
applied directly to the cells and they were incubated for 2-3 h, at 130 rpm, 27 
oC in the dark. Cells were also pre-incubated overnight with 60 μM of KY358, 
non-fluorescent ABP and then fluorescent ABP labeling followed. Then, the 





left and placed in champers for fluorescent detection at EVOS microscope 
(Thermo Fisher Scientific). For Cy5, λex= 638 nm, λem= 650–700 nm. For red 
bodipy, λex 594 nm, λem = 605-645 nm. 
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β-Glucosidase profile in BY2 cell cultures over time.  
Activity based probe profiling was performed for BY2 cells cultured for different 
days. The results reveal that β-glucosidases are differently expressed over time. 
In parallel, 4MU activities of the lysates were measured, reflecting changed β-









Figure S1. Βeta-glucosidases of BY-2 cells with increasing of duration of cell culture. A: Detection by 
labeling with 0,5 μM β-glucosidase ABPs containing aziridine (JJB 367) and epoxide (MDW 941) 
warheads (0,5 % DMSO, 2 h, pH 5.0). B: Detection by measurement of activity towards 4-MU β-D-
glucopyranoside at pH 5.  
In situ Labelling of Cells with Activity Based Probes 
The cell permeability of ABPs was examined by incubation of BY-2 cells. ABPs 
were added in the medium and cells were harvested after 120 minutes and 
lysed. Then, ABP labeling was analysed through SDS-PAGE and enzyme 
activity assays. ABP1 was used during in situ incubation; ABP2 is the one 
added in excess at lysis to ensure that the observed labelling with ABP1 did not 
happen during the preparation of lysates. As is clear from the gels in figure S2, 
 






































JJB75 (aziridine-Bodipy Red) labels enzymes at a lower concentration than 
JJB367 (aziridine-Cy5), suggesting that either the cell permeability of the more 
hydrophobic JJB75 is better or that JJB75 has a higher affinity for its 
counterpart enzymes. Interestingly, JJB367 labels a protein around 70 kDa 
that is not labelled by JJB75 at the same concentration. Therefore, this protein 
seems to have a higher affinity for JJB367. When incubating with high 
concentrations, JJB75 shows binding to a wider range of proteins than JJB 367. 
This is also reflected in the activity assay, where the in situ addition of JJB 75 













Figure S2. Incubation of BY-2 cells with the β-glucosidase aziridine ABPs JJB 367 (Cy5) and JJB 75 
(Bodipy Red) in varying concentrations for 2 h. A: Lysis buffer supplemented with 5 μM of the contrasting 
colour to label residual protein. B: Activity in 4-MU β-D-glucopyranoside, without probe in the lysis buffer. 
M: Marker, band size shown in kDa. 
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inherited glycosidase deficiencies 




Kassiani Kytidou, Ivanna Denysiuk, Chi-Lin Kuo, Marta Artola, Herman S. 
Overkleeft, Johannes M.F.G Aerts  
 












Diagnosis of diseases caused by deficiencies in retaining glycosidases activities 
receives considerable interest because of new developments in their treatment. 
We here report the use of activity-based probes (ABPs) targeting retaining 
glycosidase to visualize active enzyme in biological materials such as cell 
lysates and urine samples. Proof-of-concept for diagnostic application of ABPs 
























Retaining glycosidases hydrolyze glycosidic bonds in glycoconjugates via a 
double displacement mechanism involving a nucleophile and acid/base catalytic 
residue in their catalytic pocket (Wu et al. 2019). Appropriate cyclophellitol 
analogues bind covalently to the catalytic nucleophile of these enzymes, as was 
first demonstrated for the human acid β-glucosidase (Atsumi et al. 1990). Using 
cyclophellitol as scaffold, selective activity-based probes (ABPs) toward GBA 
were designed. A reporter group (biotin or BODIPY) was attached to the C8 of 
cyclophellitol via a pentyl linker rendering ABPs allowing ultrasensitive and 
specific visualization of GBA in vitro and in vivo (Witte et al. 2010). 
Subsequently, cyclophellitol aziridine ABPs with attached reporter groups via 
alkyl or acyl linkers were designed reacting with multiple retaining 
glycosidases in the same class (Kallemeijn et al. 2012; Jiang et al. 2015a). 
Cyclophellitol aziridine ABPs labeling α-galactosidases, α-glucosidases, α-
fucosidase, α-iduronidase, β-galactosidases, and β-glucuronidase as well as 
cyclophellitol ABPs labelling galactocerebrosidase have next been developed 
(Willems et al. 2014; Jiang et al. 2015b, 2016; Marques et al. 2016; Wu et al. 
2017; Artola et al. 2018). Applications of ABPs are the quantitative detection of 
glycosidases in cells and tissues, as well as identification and characterization 
of glycosidase inhibitors by competitive ABP profiling (Lahav et al. 2017; Kuo 
et al. 2018; Van Meel et al. 2019).  
        Inherited deficiencies in retaining glycosidases with an acid pH optimum 
occur relatively common and form the molecular basis of several lysosomal 
storage disorders (LSDs)(Platt et al. 2018). Examples of such LSDs are Gaucher 
disease – deficiency of acid β-glucosidase (GBA, glucocerebrosidase, EC 
3.2.1.45), Fabry disease – deficiency of α-galactosidase A (αGAL, EC 3.2.1.22) 
and Pompe disease – deficiency of acid α-glucosidase (GAA, EC 3.2.1.20). 
Historically, diagnosis of lysosomal enzyme defects implied demonstration of 
reduced enzyme activities as conveniently measured with fluorogenic 4-
methylumbelliferyl (MU)-glycoside substrates (Neufeld 1991). Presently, gene 
sequencing is used to confirm diagnosis of an inherited lysosomal glycosidase 
deficiency, however increasingly mutations with unknown significance are 
identified for several disorders (Schiffmann et al. 2016). The analysis by LC-
MS.MS of accumulating metabolites during an enzyme deficiency becomes 
increasingly popular (Nowak et al. 2018). Our present study aims to look more 
closely into the value of ABPs for diagnostic purposes. Important advantages of 
ABPs are the selective labeling of active enzyme molecules in a complex 
biological sample and the additional information provided regarding the degree 
of proteolytic processing of lysosomal enzymes associated with their post-Golgi 




maturation. In our study we analyzed lysates of cultured fibroblasts, a 
commonly used cell type in diagnosis, as well as urine samples. Urine is an 
attractive material for diagnosis because of the convenience of collection and its 
high content on lysosomal enzymes that constitute a major part of the total 
glycoprotein content allowing their enrichment with immobilized lectin 
Concanavalin A (Aerts et al. 1986). Already 40 years ago measurement of 
urinary GAA activity was employed for diagnosis of Pompe disease and later 
that of GBA for the diagnosis of Gaucher disease (Kokichi et al. 1977; Aerts et 

























Results and Discussion 
 
Method development.  
To develop a suitable procedure, first lysates of cultured human fibroblast 
known to contain lysosomal enzymes were examined by means of measurement 
of enzymatic activity with corresponding 4MU-glycoside substrate (Figure 1A) 
and ABP labeling followed by SDS-PAGE and fluorescence scanning (Witte et 
al. 2010; Kuo et al. 2018) (Figure 1B). Seven distinct fluorophore Cy5-equipped 
ABPs were used for detection of the corresponding enzymes: GBA, GAA, αGAL, 
αFUC, βGAL, βGLUR and αMAN. All enzymes except αFUC, present in low 
quantity, were successfully detected by ABP labeling (Figure 1B). The loss of 
the enzymatic activities after ABP labeling was checked and found to be nearly 
complete (Figure 1C). For most enzymes the inactivation by ABP was more than 
70 % indicating after significant labelling. Only in the case of αMAN, little 
inactivation was observed, suggesting that the enzyme activity is not due to the 
lysosomal α-mannosidase but another of the five cellular α-mannosidases (C.L. 
Kuo, unpublished observations). To enrich the signal of ABP-labeled lysosomal 
enzymes, enrichment with Concanavalin A (ConA) beads was performed 
(Figure 1B). The efficiency of binding to ConA beads was checked by enzyme 
activity measurements (Figure 1D). More than 80 % of each enzyme activity 



























4MU activity  
(nmol/h/mg)  
β-glucosidase (GBA) 373.4 ± 24.5  
α-glucosidase (GAA) 130.3 ± 18  
α-galactosidase (αGAL)  59.2 ± 13.6
 
 
α-fucosidase (αFUC) 198.5 ± 14.5  
β-galactosidase (βGAL) 833.3 ± 143.6 
β-glucuronidase (βGLUR)  56.2 ± 5.6 















Figure 1. Lysosomal enzymes in human fibroblasts. A. Enzymatic activities of 7 different lysosomal 
glycosidases. B. ABP labeling of 7 glycosidases, prior and after ConA enrichment. C. Inactivation of 
enzymes by ABP incubation. D. Enriched glycosidase activity by ConA bead binding.  
 
 
ABP labeling of lysosomal enzymes in urine samples.   
In freshly collected urine, the activities of various lysosomal enzymes were first 
determined activity measurements. The highest to lowest levels were observed 
for GAA, βGAL, βGLUR, αGAL, αFUC, αMAN and GBA, respectively (Figure 
2A). ABP labeling of urinary lysosomal enzymes was performed using the U-
ABP method described in Scheme 1. Lysosomal enzymes in urine samples were 
enriched by binding to ConA beads, labeled with ABP and subjected to SDS-
PAGE followed by visualization with fluorescence scanning (Figure 2B). The 
molecular weights of the various visualized lysosomal enzymes correspond with 








































































the expected ones. Labeling of lysosomal enzymes in urine samples is efficient 
as indicated by the high degree of inactivation (Figure 2D). Enrichment of 
lysosomal enzymes from urine samples by ConA bead precipitation is efficient 
(Figure 2D). To check the need for ConA enrichment, urine samples were also 
analyzed without such enrichment. We noted a prominent non-specific band 
with the fucosidase ABP that was not seen in the ConA enriched fractions 
(Figure 4B). In addition, as seen in Coomassie brilliant blue staining of the gel, 
(Figure 4B lower panel), urine samples after ConA enrichment contain much 
less total protein.  
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Urine sample  
or Fibroblast lysate: 
Preparation of Urine sample: 
Diagnosis: 









4MU activity  
(nmol/h/mg of creatinine)  
β-glucosidase (GBA) 5.8±1.2 
α-glucosidase (GAA) 142.1±39.8 
α-galactosidase (αGAL)  26.0±0.7 
α-fucosidase (αFUC) 25.3±9.8 
β-galactosidase (βGAL) 94.6±7.7 
β-glucuronidase (βGLUR)  30.9±1.4 












Figure 2. Lysosomal enzymes in human urine. A. Enzymatic activities of 7 different lysosomal 
glycosidases. B. ABP labeling of 7 glycosidases, prior and after ConA enrichment (U-ABP method). C. 
Inactivation of enzymes by ABP incubation. D. Enriched glycosidase activity by ConA bead binding. 
 
 
Diagnostic tests with ABPs.   
In lysates of control and Pompe fibroblasts, GAA was labeled with JJB38Cy5 
and GBA with MDW944-Bodipy. Pompe fibroblasts did not show any JJB383 
labelled protein, and normal levels of MDW944 labeled GBA.  
        Using the U-ABP method, 3 different glycosidases in urine samples of 
normal individuals and type 1 Gaucher patients were labeled with corresponding 
fluorescent Cy5-ABPs ABPs (ME569, TB474 and JJB383, respectively). The 
Gaucher patients could be clearly identified based on low level of labeled GBA 
and concomitant prominent labeling of αGAL and GAA.  














































































Figure 3. Diagnostic tests with ABPs. A. Visualization with ABP of GAA and GBA in lysates of control 
and Pompe disease fibroblasts. Incubation of lysate with both JJB383 (GAA) and MDW944 (GBA). B. 
Visualization of glycosidase in control and Gaucher urine samples using the U-ABP method. Three 
lysosomal glycosidases, GBA, αGAL and GAA were screened using ME569, TB474 and JJB383 
respectively.  
 
Overall, the use of ABP labeling of glycosidases in lysates of cells and urine 
samples for diagnostic purposes holds great promise. The method is sensitive, 
allowing detecting of low amounts of active enzyme molecules. Western blotting 
is in general far less sensitive and does not provide information of active 
enzyme molecules but rather total enzyme protein. Activity measurements with 
fluorogenic substrates do not provide information on the molecular weight of 
the enzyme which in the case of lysosomal enzymes may give insight in 
endolysosomal maturation of the protein (Oude Elferink, R P et al. 1986). 
Extension of ABP analyses of samples of patients suffering from various 
glycosidase deficiencies is warranted. Moreover, with the assays in place it 
might be interest to also test other disease conditions on abnormalities in 
lysosomal glycosidases. Secondary deficiencies in lysosomal enzymes in disease 
conditions may have so far been overlooked as illustrated by the only recent 
recognition that impairment of GBA is a major risk factor for Parkinson’s 































Materials and methods 
 
Fibroblast lysates. Normal and Pompe human fibroblasts were grown in T-25 
flasks and cultured in Dulbecco’s modified Eagle’s medium/Nutrient Mixture 
F-12 (DMEM/F-12, Sigma) media, supplemented with 10 % fetal calf serum and 
1 % penicillin/streptomycin, at 37 °C with 5 % CO2 in a humidified incubator. 
The cells were harvested when reached 80 % of confluency and lysed in ice cold 
lysis buffer (50 mM phosphate buffer pH 6.5, 0.1 % Triton X-100, with 
additional protease inhibitor) following sonication. The lysates were stored at -
20 oC until further use.  
 
Urine samples. Normal and Gaucher human urine was collected.  Samples were 
concentrated 50-100 times using the Amicon® Ultra-15 Centrifugal Filter Units 
according to manufacturer’s protocol. Next, the samples were passed through a 
0.7-ml PierceTM polyacrylamide spin desalting column 7000 MWCO (Thermo 
Fisher Scientific), according to the manufacturer’s protocol and buffer 
exchanged to 150 mM Citric/Phosphate buffer (McIlvaine), pH 5.3. Samples 
were stored at -20 oC until further use.  
 
Concanavalin A enrichment. Fibroblast lysates and urine samples were 
incubated for 1 or 2 h at 4 oC, while rotating with Concanavalin A-Sepharose 
4B beads (ConA beads), and the protocol followed exactly as previously 
described (Kytidou et al. 2018). The obtained samples were immediately used 
for measurements of enzyme activities and ABP labeling. 
 
Creatinine levels and total protein measurement. Creatinine levels of 
unconcentrated urine samples were determined using creatinine (3mg/dl) as 
standard (19). Total protein content of both fibroblast and urine samples was 
determined using the Micro BCA Protein Assay Reagent Kit by PIERCE with 
bovine serum albumin as a standard, according to the supplier’s protocol. 
 
4MU enzymatic activities.  Activities of GBA, GAA, αGAL, αFUC, βGAL, 
βGLUR and αMAN were measured with the corresponding 4MU-glycoside 
substrate. The respective assay mixtures contained 4MU-β-D-glucopyranoside 
(1.25 mg/mL) at pH 5.2; 4MU-α-D-galactopyranoside (1 mg/mL) at pH 4.0; 
4MU-α-D-galactopyranoside (1.5 mg/mL) at pH 4.6; 4MU-α-D-
mannopyranoside at (3.4 mg/mL) pH 4.0; 4MU-β-D-glucuropyranoside (0.69 
mg/mL) at pH 4.8 , 4MU-α-L-fucopyranoside (0.33 mg/mL) at pH 5.5; 4MU-β-





mM citrate-phosphate buffer at the appropriate pH supplemented with 0.1% 
(w/v) BSA. In the case of the GBA assay, the mixture contained also 0.1% Triton 
x-100 and 0.2 % taurocholic acid. Assays were performed by incubation of 25 μL 
sample with 100 μL of assay mix for 30 min to 1 h at 37 oC. The assays were 
stopped and released 4MU was quantified as earlier described (19). 
 
ABP labelling.  The following ABPs (all Cy5 labelled if not indicated differently) 
were used for detection of corresponding enzyme:  ME569 and MDW944 
(Bodipy red) labelling GBA; TB474 labelling αGAL; JJB383 labelling GAA; 
JJB392 labelling βGLUR; JJB381 labelling αFUC; TB652 labelling βGAL and 
TB482 labelling αMAN. Fibroblast lysates and urine samples were incubated 
with ABPs, dissolved in 150mM Mcllvaine buffer, at optimal conditions for each 
enzyme (20 μL total assay volume): GBA: 250 nM ME569 at pH 5.3;  αGAL: 
250nM TB474 at pH 4.8; GAA: 250nM JJB383 at pH 4.8; βGLUR: JJB392 at 
pH 5.3 (in the same mixture 500 nM of MDW944 for GBA1 was added to avoid 
cross labeling of GBA); αFUC: 1 μM JJB381 at pH4.8; βGAL: 1 μM TB652 at 
pH 4.8 (and in the same mixture 500 nM of MDW944 for GBA1 was added to 
avoid cross labeling of GBA), and αMAN: 1 μM of TB482 pH 5.3. All ABP 
incubations were performed for 1h at 37 oC. Next, the samples were either used 
for activity measurements or applied tp 10 % SDS-PAGE, where after the gels 
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General discussion and perspectives 
















The studies described in this thesis deal with glycosidases, in particular alpha-
galactosidases. Activity-based probes are a versatile research tool in many of 
the investigations on glycosidases and are examined regarding diagnostic 
application. A specific element of the thesis investigations is the focus on plants, 
either as source of endogenous glycosidases as well as production platform for 
therapeutic human enzymes. The introductory chapter 2 discusses also the 
abundant glycosylated metabolites of plants, such as flavonoids, cardiac 
glycosidases and phytosterols, with attention to their metabolism and the 
health effects of their consumption (chapter 2).  
        In this concluding chapter, the outcome of the thesis investigations is 
discussed and future developments are considered.  Special attention is paid to 
enzyme replacement therapy (ERT) for Fabry disease and Gaucher disease. In 
addition, the use of ABPs as a future diagnostic tool for various diseases is 
underlined.   
 
Plants as an appealing production platform.  
The use of plants as a production platform of pharmaceutical proteins has 
become feasible and popular. Important advantages of plant platforms are the 
lack of contaminations of products with animal viruses and prions (Desai et al. 
2010). Furthermore, the present ease to genetically manipulate plants, the low 
costs of their maintenance, and high yield of recombinant protein production 
puts plants in a highly competitive place among other production platforms 
such as yeast, bacterial or mammalian cell systems. For example, grams of 
monoclonal antibodies (mAbs) can be rapidly produced in Nicotiana tabacum, 
illustrating how plants are particularly attractive platforms when high 
production of recombinant protein has to be obtained in short notice (Schähs et 
al. 2007; Castilho and Steinkellner 2012; Arntzen 2015). Fortuitously, plants 
are easily manipulated in their N-glycosylation machinery, making them very 
appropriate for production of therapeutic recombinant glycoproteins (Schähs et 
al. 2007; Castilho and Steinkellner 2012; Bosch et al. 2013). This aspect is 
highly relevant for the production of lysosomal enzymes that are glycoproteins 
with essential  N-linked glycans (Storch and Braulke 2005). 
 
Recombinant glycosidases for ERT of LSDs.  
Over the years, mammalian cells have mainly been used to produce 
recombinant lysosomal enzymes for ERT of different lysosomal storage 
disorders, (chapter 2). As envisioned by Roscoe O. Brady, targeted 
supplementation of macrophages with recombinant GBA1 successfully 
prevents, and even corrects, visceral symptoms of Gaucher patients deficient in 





enzyme for ERT of Gaucher disease was isolated from human placenta and 
engineered to have terminal N-linked glycans with terminal mannose residues 
to favour uptake by mannose-receptor expressing macrophages (Brady 2003b). 
The approach was  commercialized by Genzyme Corp. and led to the 
registration in 1991 of Alglucerase (Ceredase®) (Ferraz et al. 2014). 
Subsequently, human GBA1 was recombinantly produced in Chinese hamster 
ovary cells (CHO), resulting in the registration of Imiglucerase (Cerezyme®; 
Genzyme) in 1994. Later, gene activation in cultured fibroblasts was used to 
recombinantly produce a competitive GBA1 enzyme, resulting in registration 
in 2010 of Velaglucerase (VRIV®; Shire/TKT) (Aerts et al. 2010). A few years 
later, Protalix managed to produce GBA1 in carrot cells and the product was 
named Taliglucerase (Elelyso®), registered in 2012 for treating Gaucher type 1 
patients. The recombinant GBA1 enzyme is targeted into carrot plant cell 
vacuoles via the insertion of a specific target signal peptide at its amino acid 
sequence, and it contains plant specific N-linked glycosylated residues; α-1,3 
fucose and β-1,4 xylose (Shaaltiel et al. 2007). These modifications seem not to 
induce immune responses or interfere with GBA1 enzymatic activity and 
effectiveness as was shown by extensive clinical trials (Rup et al. 2017).  
        Following the success of ERT for type 1 Gaucher disease, the same 
approach was soon pursued for other lysosomal storage diseases. Among the 
frontrunners was Pompe disease, a disorder characterized by lysosomal 
glycogen storage due to deficiency of acid α-glucosidase (GAA). In parallel, GAA 
was recombinantly produced in CHO cells and milk of transgenic animals (Geel 
et al. 2007). In the latter case, the GAA gene was linked to the promoter region 
of the casein gene that promotes high level expression in epithelial cells of the 
mammary gland. Despite promising data with recombinant GAA produced in 
rabbit milk, only recombinant human GAA was ultimately developed by 
Genzyme into a registered drug, Aglucosidase alfa or Myozyme/Lumizyme®) 
(Reuser et al. 2002). Importantly, targeting of therapeutic GAA is governed by 
the presence of mannose-6-phosphate moieties in its glycans and uptake and 
subsequent delivery to lysosomes by mannose-6-phosphate receptor (Reuser et 
al. 2002). More recently, cultured rice cells are explored as production platform 
of recombinant GAA with optimal N-glycan composition (Su et al. 2015; Choi et 
al. 2018).  
        Meanwhile, ERT products have been or are developed for several other 
lysosomal storage disorders: mucopolysaccharidosis type I (Hurler/Scheie 
disease), mucopolysaccharidosis type II (Hunter disease), 
Mucopolysaccharidosis type IIIA (Sanfilippo A syndrome),  
Mucopolysaccharidosis type IIIB (Sanfilippo B syndrome), 
Mucopolysaccharidosis type IVA (Morquio A syndrome),  




Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome),    
Mucopolysaccharidosis type VII (Sly syndrome),  Niemann-Pick disease type C, 
Alpha-Mannosidosis,  Lysosomal acid lipase deficiency (Wolmann disease), 
Neuronal ceroid lipofuscinosis type 2, Globotroaosylceramidosis (Fabry 
disease), Globoid cell leukodystrophy (Krabbe disease) and Ceramidosis 
(Farber disease). Of note, at present gene therapy and RNA therapy approaches 
are actively studied for several of lysosomal storage disorders. Enzyme 
supplementation (either direct by infusion of recombinant enzyme or indirect 
by gene or RNA therapy) may induce in some patient’s immune responses to 
the ‘foreign’ protein.  
 
ERT of Fabry disease. 
In the case of X-linked Fabry disease (lysosomal globoside Gb3 storage due to 
deficiency of acid α-galactosidase (GLA)), ERT is in use since 2001, when two 
therapeutic enzymes were approved at the same time by the EMEA, agalsidase 
beta (Fabrazyme® produced in CHO cells by Genzyme) and agalsidase alpha 
(Replagal®, produced in a human fibrosarcoma cell line by Shire).  Both GLA 
enzymes were found to be identical in catalytic properties, nevertheless they 
are administrated in different doses; 0.2 mg per kg for Fabrazyme vs 1 mg per 
kg for Replagal (Blom et al. 2003). 
        ERT of Fabry disease is not as successful as for Gaucher disease (Brady 
2003a). The poor clinical response is accompanied by poor correction of the lipid 
storage biomarker plasma lysoGb3 (Aerts et al. 2008). A major complication is 
the formation of neutralizing antibodies towards therapeutic enzyme in male 
Fabry patients impairing clinical and biomarker response (Linthorst et al. 
2004). In addition to poor efficacy, the high costs of current ERT treatments of 
Fabry disease prompted alternative products. Protalix Biotherapeutics has 
managed to produce GLA in BY2 Nicotiana tabacum cell cultures (ProCellEx 
system). The enzyme (Pegunigalsidase alfa) is chemically modified with 
polyethylene glycol (PEG).  It is currently examined in clinical trials 
(Schiffmann et al. 2019). Pegunigalsidase alfa shows a much higher half-life as 
active enzyme in blood than Replagal and Fabrazyme and its repeated infusion 
in Fabry patients has been found to lead to promising reductions in plasma 
lysoGb3 (Holida et al. 2019).  
        Another human GLA is currently produced in a moss cell line engineered 
to yield glycoproteins with high mannose N-linked glycans (Lenders and Brand 
2018). This thesis reports also the production of human GLA in Nicotiana 
benthamiana plants, via agrobacteria transformations, (Kytidou et al. 2017)( 
chapter 3). In conclusion, more and more recombinant lysosomal enzymes are 





Alternative enzymes for Fabry ERT. 
In 2009, Sakuraba and colleagues firstly suggested the use in ERT of Fabry 
disease of a modified NAGA enzyme (Tajima et al. 2009). NAGA is a closely 
related protein to GLA that is active towards α-N-acetyl-galactosiminides 
(Tajima et al. 2009; Tomasic et al. 2010). The proposed modification of NAGA 
involves substitution of alanine at position 191 into a leucine (L) and that of 
serine at position 188 into a glutamic acid (E). The modified NAGAEL is 
improved in degradation of alpha-galactosides such as the artificial 4MU-αGAL 
and natural lid substrate Gb3 (Tajima et al. 2009). In parallel, NAGA’s natural 
activity towards N-acetylgalactosaminides is lost. Independently, Garman and 
colleagues proposed the same substitutions in the active site of NAGA enzyme 
to improve  α-galactosidase activity (Tomasic et al. 2010). We have produced 
modified NAGAEL, as well as GLA and NAGA, in N. benthamiana leaves 
((Kytidou et al. 2017) chapter 3). Our findings with the enzymes confirm that 
NAGAEL is improved in activity towards 4MU-αGAL substrate over 5 times 
and shows no longer activity towards the 4MU-NAGA substrate. Interestingly, 
the wild type enzyme is also active towards Gb3, around 10 times less than 
NAGAEL. NAGA and NAGAEL were found to be more stable in human plasma 
than GLA. NAGAEL did not cross react with antibodies in serum of male Fabry 
patients receiving ERT.  
        During expression studies in N. benthamiana, we noticed a prominent 
endogenous α-galactosidase that is inactivated (and labelled) by an α-galactosyl 
configured cyclophellitol aziridine (Willems et al. 2014). We overexpressed and 
purified the enzyme, named A1.1 ((Kytidou et al. 2018) chapter 4). The enzyme 
A1.1 was found to be also active towards the lipid Gb3. Incubating fibroblasts 
from a male Fabry patient with recombinant A1.1. led to marked reductions of 
Gb3 and lysoGb3. Of note, the A1.1 protein does not contain any N-linked 
glycans. We were able to produce crystals and elucidate the 3D structure of the 
enzyme (Kytidou et al. 2018). A1.1 is lacking N-linked glycans. Interestingly, 
the enzyme is very similar to its human homologue in overall structure, sharing 
42 % amino acid sequence identity. Most importantly the active site of both 
enzymes is highly conserved.  
        A1.1 can be recombinantly produced in N. benthamiana at very high 
yields, accumulates in the apoplast, is stable and because of its homogeneity 
easy to purify.  Considering therapeutic application of A1.1 in Fabry patients, 
the lack of glycans is prohibits lectin-mediated endocytosis and delivery to 
lysosomes. It will be rather complicated to mutagenize the enzyme in such way 
that synthesized N-glycans can attached to newly generated asparagine 
residues (Priyanka et al. 2016).  The A1.1 is not neutralized by anti-human 
GLA antibodies of Fabry patients.  Given the broad pH optimum of A1.1, it 




might be considered to examine whether circulating A1.1 in the plasma is able 
to degrade lysoGb3 there. It is presently thought that lysoGb3 is a highly toxic 
agent in Fabry patients that has a negative effect on the vasculature, 
nociceptive neurons and podocytes (Choi et al. 2015; Sanchez-Niño et al. 2015; 
Aerts et al. 2017). The therapeutic potential A1.1 could be judged by AAV-9 
mediated overexpression of the enzyme in liver of Fabry mice. Similarly, it 
might be considered to administer A1.1 (or another plant-derived α-
galactosidase) orally in order to lower lysoGb3 in the lumen of the intestine of 
Fabry patients.  Fabry patients develop gastrointestinal symptoms that 
recently have been ascribed to a changed  the gut microbiome because of the 
presence of lysoGb3 (Aguilera-Correa et al. 2019).  
        An intestinal application of a recombinant α-galactosidase has earlier been 
conceived. The dietary supplement Beano, a fungal (Asperigilus niger) α-
galactosidase, offers relief of gastrointestinal problems after consumption of 
food rich in α-galactosides like beans (Ganiats et al. 1994; Lettieri and Dain 
1998; Levine and Weisman 2004). The enzyme also degrades 4MU-αGAL and 
is targeted by an α-galactose configured ABP, (chapter 6). Unfortunately, the 
enzyme is not able to degrade Gb3.  
 
Chaperone strategy for treatment of Fabry disease. 
Treatment of Fabry disease with orally administered small compound 
chaperones is presently investigated (Sunder-Plassmann et al. 2018; Müntze et 
al. 2019). Pharmacological chaperones are supposed to bind and stabilize newly 
formed mutant GLA. At present, PCT treatment is performed with Fabry 
patients with some residual endogenous αGAL activity, and not for classic 
Fabry patients lacking the enzyme. Deoxygalactonojirimycin, (Gal-DNJ or 
Migalastat®, Amicus), is now approved in Europe as pharmacological 
chaperone (PC) for the treatment of Fabry disease (Markham 2016; Müntze et 
al. 2019). Migalastat binds to mutant GLAs, that are otherwise targeted for 
degradation, and stabilizes them, allowing delivery to lysosomes. In principle, 
the same chaperone approach could be considered for stabilizing recombinant 
GLA during ERT given the instability of the enzyme (Artola et al. 2019).  For 
such purpose, therapeutic recombinant GLA and chaperones could be jointly 
infused. The synthesis and evaluation of an entire new class of inhibitors for 
GLA is described in chapter 5 (Artola et al. 2019). The novel inhibitor, α-
cyclosulfamidate 4, ME763, shows chaperone properties like Gal-DNJ, however 
it is much less effective at the same dose. Interestingly, ME763 and Gal-DNJ 
also stabilize human GLA and NAGA as well as plant A1.1. Incubation of A1.1 
with Gal-DNJ and ME763 at concentrations, 200 and 20 μM respectively, 
enhances its stability during incubation in human plasma.  
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        In conclusion, there is still an unmet need for Fabry disease. New 
therapeutic approaches besides existing ERTs warrant further attention, 
among these PCT as well as gene and RNA therapies (Liefhebber et al. 2019; 
Tuttolomondo and Pinto 2019; Zhu et al. 2019). 
Human GBA and plant homologs. 
The lysosomal acid β-glucosidase GBA1 ( EC 3.2.1.45; GH30) degrades 
glucosylceramide (GlcCer) to ceramide and glucose. Mutations in the GBA gene 
cause Gaucher disease (MIM#230800) (Ferraz et al. 2014). More recently it has 
been recognized that individuals with a mutant GBA allele are also at 
considerably increased risk for Parkinson disease (PD) (Riboldi and Di Fonzo 
2019). PD is caused by progressive loss of dopaminergic neurons in the 
substantia nigra and its symptoms mainly include motor difficulties such as 
bradykinesia, resting tremor and postural instability. Non-motor symptoms in 
PD are depression and anxiety.  
        GBA1 is a 497 amino acid protein with 4 N-linked glycans that are 
essential for its folding, intracellular trafficking and delivery to lysosomes (Ben 
Bdira et al. 2018). The protein, in contrast to other lysosomal enzymes, does not 
acquire mannose-6-phosphate residues at its N-linked glycans for lysosomal 
sorting (Aerts et al. 1988). GBA1 is transported to lysosomes bound to lysosomal 
integral membrane protein type 2 (LIMP2) (Reczek et al. 2007; Gaspar et al. 
2014). GBA1 was initially classified in the GH 5 family, a glycoside hydrolase 
family containing enzymes from various organisms able to metabolize GlcCer. 
GH5 and GH30 glycosidases are very closely related enzymes. They share an 
(α/β)8 TIM-barrel domain with two, highly conserved, catalytic residues, placed 
between 2 β-strands and serving as the nucleophile and acid/base. Proteins of 
the GH 5 and 30 families have some differences in overall structure. GH30 
enzymes besides the catalytic domain a β-structure consisting of an 
immunoglobulin -like fold which is absent in GH5 enzymes. 
        Earlier ABPs with a cyclophellitol epoxide scaffold have been designed 
that specifically label GBA1, but not other human β-glucosidases (GBA2, GH 
116 and GBA3, GH1) (Kallemeijn et al. 2012). Using such ABP, a specific 
protein was labelled in extracts of cultured tobacco cells. (chapter 6). Analysis 
by proteomics revealed its identity as an GH 5 glycosidase (‘glucan 1,3-β-
glucosidase A, isoform X2’). The enzyme, named B56, is a soluble protein that 
seems to lack N-glycans based on its inability to bind to Concanavalin A beads. 
It shows optimal activity between pH 4.5 to 5.5 and is able to degrade the lipid 
substrate GlcCer with a NB-fluorophore in the acyl moiety. Modelling reveals 
that the catalytic residues are similarly positioned as in GBA1. Further 
characterization of B56 is warranted. For this purpose, the enzyme should be 




overexpressed and purified. In particular, the ability of B56 to degrade natural 
GlcCer and its toxic metabolite glucosylsphingosine (GlcSph) should be further 
studied. For this purpose, B56 can be expressed in cells lacking endogenous 
GBA1 that accumulate GlcCer as well as GlcSph and the response in lipid 
abnormalities can be monitored with LC-MS/MS methods in place. The 
envisioned studies should reveal whether B56 has any therapeutic potential 
regarding Gaucher disease and other conditions with disturbed GlcCer 
metabolism.   
 
Activity-based probes and diagnosis.  
Activity-based probes (ABPs) for various glycosidases have meanwhile been 
designed and characterized. Examples are ABPs labelling β-glucosidases α-
galactosidases, α-glucosidases, α-fucosidase, α-iduronidase, β-galactosidases, 
and β-glucuronidase (Witte et al. 2010; Kallemeijn et al. 2012; Willems et al. 
2014; Jiang et al. 2015b, a, 2016; Marques et al. 2016; Wu et al. 2017; Artola et 
al. 2018).  
        So far, ABPs have been limited used for diagnosis of LSDs (Aerts et al. 
2011). A published application is the detection of active glycosidase in lysates 
of cells, for example the use of MDW944 to demonstrate GBA deficiency in 
fibroblasts of Gaucher patients (Aerts et al. 2011; Jiang et al. 2016).  
        In chapter 7 the feasibility of diagnosing LSDs with fluorescent ABPs is 
demonstrated for cultured cells as well as urine samples. Urine is long known 
to be a great source of lysosomal enzymes. For example, the presence of various 
lysosomal enzymes in urine has been studied with activity assays and Western 
blot analysis already in the 90’s (Aerts et al. 1991).  A novel protocol for the 
screening of lysosomal glycosidases by ABP detection was developed for urine 
samples (chapter 7). The method is very sensitive and can be used to screen for 
deficiencies in β-glucosidase (GBA1), α-galactosidase (αGAL), α-glucosidase 
(GAA), α-fucosidase (αFUC), α-mannosidase (αMAN), β-galactosidase (βGAL) 
and β-glucuronidase (βGLUR).  
The ABP screening of urine samples from individuals not suffering from an 
inherited LSD may also be of potential interest. A pilot investigation was 
performed with urine samples of individuals with diabetes type II. It was 
observed that 3 out of 4 tested diabetic urines were deficient in GBA1 enzyme, 
based on 4MU activities and also ABP labelling. These preliminary 
observations should be substantiated by further studies. The preliminary 
observation is surprising since no link between GBA deficiency and diabetic 
nephropathy is reported in literature. Insulin insensitivity occurs in some 
Gaucher patients, but this not associated with any hyperglycemia or kidney 
failure as reflected by albumineria (Langeveld et al. 2008). In view of the 
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findings with urine samples described above, it might be also of interest to 
study urine samples of individuals with Parkinson disease and Lewy Bodies 
regarding GBA1 enzyme deficiencies. Use of ABP urinary screenings for other 
disease conditions might provide clues to a not yet appreciated connection with 
lysosomal enzymes and impaired endolysosomal apparatus.  
        Another enzyme of interest to study in urine samples is heparanase 
(HPSE). The enzyme HPSE is responsible for the degradation of the polymer 
heparan sulfate (HS) into smaller oligosaccharides, present in both cell surface 
and the intracellular matrix.  HPSE is an endo- retaining glycosidase cleaving 
HS moieties at internal sites of the polymeric chain. The increased activity of 
HPSE in blood tumour metastasis and also during tumour angiogenesis 
prompts the development of potent HPSE inhibitors to use as anti-cancer drugs 
(Shu and Santulli 2019). The enzyme is encoded by the HPSE1 gene, and it is 
first synthesized as an inactive form of 65 kDa at the Golgi apparatus. From 
there it is destined into late endosomes, following its transport to lysosomes 
where it is proteolytic cleaved and activated into a heterodimer consisting of an 
8 and 50 kDa molecules (Wu et al. 2015). The crystal structure of HPSE has 
been solved in 2015 (Wu et al. 2015). Recently, ABPs were developed to target 
the exo-glycosidase β-glucuronidase (βGLUR) (Wu et al. 2017). The developed 
ABP (JJB392) was able to label both HPSE and βGLUR enzymes found in 
human platelets and spleen. It is presently being studied with the methods 
developed along chapter 7 whether HSPE levels can be studied in urine samples 
from diabetic and cancer patients. 
        A pilot investigation with JJB392 and different blood cell type lysates was 
performed. The same ABP was used to screen control urine samples. Both the 
precursor and mature HSPE could be visualized. The importance of monitoring 
HPSE in human urine is of great interest. Shafat et al. used a relatively 
insensitive  ELISA type of assay to detect nanograms of active HPSE in urine 
of diabetic type II individuals (Shafat et al. 2011). This assay is no longer 
commercially available. Thus, there is a clear need for a reliable and sensitive 
method to measure HPSE levels in urine. We envision the use of urinary ABP 
screenings for monitoring HPSE levels of urines from diabetic and cancer 
patients. The assay might be optimized for screening large numbers of samples. 
Concluding remarks 
This thesis deals with glycosidases used to treat lysosomal disorders caused by 
a deficiency in such enzymes. ABPs have proven to be valuable tools to identify 
glycosidases of interest cross species. Moreover, they assist detection of 
glycosidases and abnormalities in their levels in relation to disease. Newly 
identified plant glycosidases warrant further research regarding possible 
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Lysosomal storage disorders (LSDs) are a group of over 50 discrete genetic 
metabolic diseases, each one caused by a deficiency in a lysosomal process. A 
large proportion of LSDs stems from defects in lysosomal hydrolases. One of the 
most common LSD is Gaucher disease, with incidence over 1 in 57000 births. It 
is caused by mutations in the GBA gene, resulting in deficient activity of 
glucocerebrosidase, the acid β-glucosidase responsible for the hydrolysis of the 
glycosphingolipid glucosylceramide (GlcCer) into ceramide and glucose. Fabry 
disease, an X-linked disorder also manifesting in female heterozygotes, is the 
most common LSD with an incidence of up to 1 in 3000 individuals. It is caused 
by deficiency of the lysosomal hydrolase α-galactosidase A, which primarily 
cleaves terminal galactoses from globotriaosylceramide (Gb3), 
globotriaosylsphingosine (lysoGb3), galabiosylceramide, and blood group B, B1, 
and P1 antigens. Gaucher disease and Fabry disease are both multisystemic 
with symptoms manifesting in several organs. In Gaucher disease the 
enlargement of spleen and liver and hematological abnormalities are prominent 
whereas in Fabry disease kidney and heart are primarily affected. Both 
disorders show remarkable heterogeneity in nature and severity of symptoms 
among individual patients.  
        Enzyme replacement therapy (ERT) has been conceived and developed by 
Roscoe O. Brady as treatment for Gaucher disease and Fabry disease. ERT 
implies chronic, intravenous infusions of recombinant enzymes aiming to 
correct the deficiency in the patients. ERT is successful for treating visceral 
symptoms in Gaucher patients, but there are major limitations in clinical 
efficacy in the treatment of Fabry disease. Antibodies against the recombinant 
enzyme commonly develop in male Fabry patients completely lacking α-
galactosidase A protein. Furthermore, the presently used recombinant enzymes 
are intrinsically very unstable in human plasma. In this thesis, alternative 
recombinant enzymes for treatment of Fabry disease are discussed and special 
attention is paid to the potential use of plants as production platform and even 
as source of enzyme for treating lysosomal storage disorders. 
        Chapter 1 provides a general introduction and the scope of the 
investigations that were undertaken. 
        Chapter 2 describes the value of plant-derived glycoconjugates to 
beneficially modulate metabolism in man as well as the potential therapeutic 
value of plant glycosidases and the present production of therapeutic human 
glycosidases in plant platforms. Plants provide a convenient and highly 
profitable production platform of therapeutic lysosomal hydrolases. Successful 
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examples of this are Elelyso, produced in carrot cells for treatment of Gaucher 
disease, and Pegunigalsidase, produced in a tobacco cell line for treatment of 
Fabry disease. The recent use of smartly designed suicide inhibitors, so-called 
the activity-based probes (ABPs), as new tools to explore the plethora of 
retaining plant glucosidases is also discussed in chapter 2. Many applications 
of ABPs in plant science are underlined such as their use to follow metabolic 
processes in plants, the discovery of novel enzymes, and the identification of 
potential therapeutic inhibitors and chaperones.  
        In chapter 3, the transient production of human α-galactosidases in N. 
benthamiana leaves is described. An alternative recombinant enzyme that 
might not suffer from antigenicity in Fabry patients is suggested. The enzyme 
is a modified version of the lysosomal α-N-acetyl-galactosaminidase (NAGAL) 
with increased α-galactosidase activity (NAGALEL). To study feasibility, in N. 
benthamiana leaves three functional lysosomal enzymes, αGAL (human α-
galactosidase A), NAGAL and NAGALEL were transiently produced. All 
enzymes were produced efficiently in plant leaves, and were visualized with 
ABPs. In vitro studies revealed that the NAGALEL enzyme showed the desired 
increased activity towards 4MU-α-galactopyranoside substrate. Both NAGAEL 
and NAGAL enzymes were not neutralized by antibody-positive Fabry patient’s 
serum, and they were significantly more stable in human plasma than αGAL. 
Further, their ability to hydrolyse lipid substrates was tested using LS-MS/MS 
analysis. All enzymes were found able to degrade the lipid substrates Gb3 and 
lyso-Gb3 accumulating in Fabry patients. The activity towards the lipids was 
highest for αGAL, followed by NAGALEL and finally NAGAL. It was observed 
that NAGAEL and to lesser extent NAGAL is able to reduce the toxic lyso-Gb3 
in Fabry serum. Based on these findings, the use of NAGALEL, aiming at 
reduction of circulating lysoGb3, might be considered for treatment of Fabry.  
        In chapter 4, the identification of a novel α-galactosidase from N. 
benthamiana is reported. Use of α-galactose configured ABPs in N. 
benthamiana proteome resulted in the identification of a novel enzyme, named 
A1.1. The enzyme was found to be able to hydrolyse 4MU-α-galactopyranoside 
substrate with a comparable activity to human recombinant α-galactosidase 
(Fabrazyme). The 3D structure of A1.1 was solved using X-ray crystallography, 
revealing remarkable similarities with human α-galactosidases. This similarity 
likely explains A1.1’s ability to hydrolyse Gb3 and lyso-Gb3, which are not 
endogenous lipids in plants. Interestingly, uptake of A1.1 by Fabry fibroblasts 
reduced the accumulated lipids Gb3 and lysoGb3 to normal levels. The delivery 
of the enzyme into cells was also studied via confocal microscopy. The easy 
production of A1.1 in plants, its stability over a broad pH range combined with 
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its capacity to degrade glycosphingolipids provides important advantages for 
use in ERT of Fabry disease.  
        In chapter 5, the challenging topic of stabilization of recombinant α-
galactosidases for ERT of Fabry disease is addressed. Due to the lability of 
recombinant enzyme preparations, a combined use of recombinant enzyme with 
active-site stabilizers is thought to improve the outcome of the treatment of 
LSDs. An already established pharmacological chaperone for α-galactosidase A 
is 1-deoxygalactonojirimycin (Gal-DNJ, Migalastat®). Chapter 5, reports the 
use of newly synthesized α-D-gal-cyclophellitol cyclosulfamidate 4 as a 
stabilizer of both human and plant derived α-galactosidases. The results reveal 
that such stabilizers improve the stability of enzyme in human plasma and in 
Fabry fibroblasts. Therefore, such agents prompt great expectations for therapy 
of Fabry disease.  
        Chapter 6 reports investigations on the potential use of ABPs cross species. 
Studied were lysates from Bright Yellow tobacco cells (BY2) and the food 
supplement Beano containing a fungal (A. niger) α-galactosidase.  
The investigations with BY2 cell lysates led to the discovery of a plant β-
glucosidase that is potently labeled by the β-glucose configured epoxide 
cyclophellitol ABP and its identity was next established by proteomics. The 
enzyme, here named B56, is active towards NBD-GlcCer lipid, revealing its 
potential use in therapy of Gaucher disease.  
ABPs could be also successfully applied to label the α-galactosidase from A. 
niger present in the food supplement Beano. The enzyme was found to be active 
towards artificial 4-methulumbelliferyl-α-galactoside but not towards NBD-
Gb3. As Fabry patients suffer from intestinal complications, possibly induced 
by accumulating lysoGb3 in the intestine, future application of other αGAL 
enzymes might be considered for diminishing such toxic agents.   
        In chapter 7, the potential use of ABPs for the diagnosis of LSDs is 
addressed. Described is a sensitive diagnostic method using cell lysates and 
urine samples. Seven different lysosomal hydrolases could be detected using 
the corresponding ABPs:  β-glucosidase (GBA), α-glucosidase (GAA), α-
galactosidase (αGAL), α-fucosidase (αFUC), β-galactosidase (βGAL), β-
glucuronidase(βGLUR) and α-mannosidase (αMAN). As urine is a convenient 
source of lysosomal enzymes, its use in diagnosis of the diseases is proposed. A 
proof-of-concept for diagnostic application of ABPs is presented.   
        In chapter 8 the studies described in the thesis are discussed and 






Lysosomale stapelingsziekten (LSDs) vormen een groep van 50 discrete 
erfelijke stofwisselingsziekten die elk veroorzaakt worden door een specifiek 
defect in een lysosomaal proces. Een belangrijk deel van de LSDs betreft 
defecten in lysosomale hydrolasen.   Een van de meest voorkomend LSDs is de 
ziekte van Gaucher, met een incidentie van 1 op 57.000 geboortes. Deze ziekte 
wordt veroorzaakt door mutaties in het GBA gen, resulterend in een deficiënte 
activiteit van glucocerebrosidase, het zure acid β-glucosidase dat zorg draagt 
voor de hydrolyse van het glycosfingolipide glucosylceramide (GlcCer) tot 
ceramide en glucose. De ziekte van Fabry, een X-gebonden afwijking die zich 
ook manifesteert in vrouwelijke heterozygoten, is de meest frequente LSD met 
een incidentie oplopend tot 1 in 3000 individuen. Deze aandoening wordt 
veroorzaakt door deficiëntie van het lysosomale α-galactosidase A, een enzym 
dat terminale galactoses afsplitst van globotriaosylceramide (Gb3), 
globotriaosylsphingosine (lysoGb3), galabiosylceramide, en bloed groep B, B1, 
en P1 antigenen. De ziekte van Gaucher en de ziekte van Fabry zijn multi-
systemisch met symptomen in verschillende organen. Bij de ziekte van Gaucher 
zijn vergroting van milt en lever en hematologisch afwijkingen prominent, 
terwijl bij de ziekte van Fabry de nier en het hart ernstig worden aangetast. 
Beide ziektebeelden vertonen opmerkelijke heterogeniteit in aard en ernst van 
symptomen bij individuele patiënten.  
        Enzyme replacement therapy (enzym vervangingstherapie; ERT) is 
bedacht en ontwikkeld door Roscoe O. Brady ter behandeling van de ziekte van 
Gaucher en de ziekte van Fabry. ERT impliceert herhaalde, intraveneuze 
infusies van recombinante enzymen met als doel het tekort hierin bij patiënten 
te corrigeren.  ERT is zeer effectief bij de behandeling van viscerale symptomen 
van Gaucher patiënten, maar in veel mindere mate als behandeling voor de 
ziekte van Fabry. Antilichamen tegen het toegediende recombinante 
therapeutische enzym ontwikkelen zich doorgaans bij mannelijke Fabry 
patiënten zonder eigen α-galactosidase A eiwit. Bovendien zijn de huidige 
therapeutische enzymen relatief instabiel in menselijk plasma. In dit 
proefschrift worden alternatieve recombinant enzymen voor de behandeling 
van de ziekte van Fabry beschreven. In het bijzonder wordt aandacht besteed 
aan het gebruik van planten als productieplatform als ook het gebruik van 
plant eigen enzymen voor de behandeling van lysosomale stapelingsziekten.  
        Hoofdstuk 1 behelst een algemene introductie en beschrijft de scope van 
het uitgevoerde onderzoek.   
255 
 
        Hoofdstuk 2 beschrijft de waarde van plantaardige glycoconjugaten om het 
metabolisme bij te sturen.  Hiernaast wordt aandacht gevestigd op de potentiële 
therapeutische betekenis van plantaardige glucosidasen als ook de productie 
van therapeutische recombinante enzymen in plant platformen. Succesvolle 
voorbeelden hiervan zijn Elelyso, geproduceerd in wortel cellen voor de 
behandeling van de ziekte van Gaucher en Pegunigalsidase, geproduceerd in 
een tabak cellijn voor de behandeling van de ziekte van Fabry. In het hoofdstuk 
worden ook beschreven activity-based probes (ABPs) waarmee retaining plant 
glucosidasen van planten bestudeerd kunnen worden. Diverse toepassingen 
voor ABPs in plant science worden bediscussieerd zoals het gebruik bij 
fundamenteel onderzoek aan plant metabolisme, de ontdekking van nieuwe 
enzymen en de identificatie van potentiele therapeutische remmers en 
chaperones.  
        In hoofdstuk 3 wordt de productie van menselijke α-galactosidasen in N. 
benthamiana bladeren beschreven. Een alternatief recombinant enzym dat 
wellicht niet antigeen is wordt overwogen voor behandeling van de ziekte van 
Fabry. Het betreft een gemodificeerd lysosomaal α-N-acetyl-galactosaminidase 
(NAGAL) met een verhoogde α-galactosidase activiteit (NAGALEL). Om de 
haalbaarheid hiervan te bestuderen werden in N. benthamiana bladeren drie 
lysosomale enzymen, αGAL (human α-galactosidase A), NAGAL en NAGALEL 
geproduceerd. Alle enzymen, elk reagerend met ABP, konden met hoge 
opbrengst verkregen worden. In vitro studies toonden aan dat het recombinante 
NAGALEL enzym actief was ten opzichte van 4MU-α-galactopyranoside 
substraat. Zowel het NAGAEL als NAGAL enzym reageerde niet met 
neutraliserend Fabry patiënt serum. De verkregen enzymen waren significant 
stabieler in menselijk plasma dan αGAL. Zoals gemeten met LS-MS/MS 
analysis, alle enzymen waren staat tot afbraak van de lipide substraten Gb3 en 
lyso-Gb3 die ophopen bij de ziekte van Fabry. De activiteit was het hoogst bij 
αGAL, gevolgd door NAGALEL en tot slot NAGAL. NAGAEL en in mindere 
mate NAGAL bleken ook in staat het toxische lyso-Gb3 in Fabry serum af te 
breken. Op basis van deze bevindingen zou een gebruik van NAGALEL, met 
als doel circulerend lysoGb3 te verlagen, overwogen kunnen worden voor een 
behandeling van Fabry patiënten.  
        Hoofdstuk 4 beschrijft de ontdekking van een nieuw α-galactosidase uit N. 
benthamiana. Met een α-galactose geconfigureerd ABP werd in het proteoom 
van N. benthamiana bladeren dit enzym, genaamd A1.1, geïdentificeerd. A1.1 
kan 4MU-α-galactopyranoside hydrolyseren met vergelijkbare activiteit aan 
recombinant menselijk α-galactosidase (Fabrazyme). De 3D structuur van A1.1, 
zoals vastgesteld met X-ray kristallografie, wijst op grote overeenkomsten met 
menselijke α-galactosidasen. Dit verklaart wellicht waarom A1.1 uitstekend in 
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staat is Gb3 en lyso-Gb3 te splitsen, terwijl dit geen endogene lipiden van 
planten zijn. De opname van A1.1 door Fabry fibroblasten leidt tot een afname 
van het opgehoopte Gb3 en lysoGb3. Opname van enzym door cellen kon 
worden bevestigd met behulp van confocal microscopy. Het gemak van de 
productie van A1.1 in planten, de stabiliteit van het enzym bij verschillende 
pH’s, en het vermogen om relevante glycosfingolipiden af te breken maakt dit 
enzym een interessante kandidaat voor een therapie van de ziekte van Fabry.  
        In hoofdstuk 5 staat stabilisering van recombinant α-galactosidasen 
centraal. Vanwege de labiliteit van recombinante enzymen wordt het 
gecombineerde gebruik van enzym met een active-site stabilizer overwogen. 
Een reeds geregistreerd ‘pharmacological chaperone’ voor α-galactosidase A is 
1-deoxygalactonojirimycin (Gal-DNJ, Migalastat®). Hoofstuk 5 beschrijft een
α-D-gal-cyclophellitol cyclosulfamidate als stabilizer van menselijk en
plantaardige α-galactosidasen. Deze verbinding vergroot inderdaad de enzym
stabiliteit in plasma en Fabry fibroblasten.
        Hoofdstuk 6 beschrijft onderzoek aan het gebruik van ABPs cross species. 
Bestudeerd werden hiermee enzymen in lysaten van Bright Yellow tobacco 
cellen (BY2) en het voedingssupplement Beano welk een fungaal (A. niger) α-
galactosidase bevat.  
Het onderzoek met BY2 cel-lysaten heeft geleid tot de ontdekking van een plant 
β-glucosidase dat gelabeld kan worden met een β-glucose geconfigureerd 
epoxide cyclophellitol ABP en waarvan de identiteit vervolgens met behulp van 
proteomics werd vastgesteld. Het enzym, vernoemd B56, splitst met hoge 
affiniteit NBD-GlcCer lipide, waardoor een mogelijk therapeutische toepassing 
voor de ziekte van Gaucher niet valt uit te sluiten.  
Beschikbare ABPs kunnen ook het α-galactosidase van A. niger in het 
voedingssupplement Beano labelen. Het enzym bleek actief ten opzichte van 
het artificiële substraat 4-methulumbelliferyl-α-galactoside maar niet NBD-
Gb3. Fabry patiënten kunnen darmklachten ontwikkelen die wellicht 
veroorzaakt worden door lokaal excessief lysoGb3. Een behandeling hiervan 
met een geschikt αGAL enzym zou overwogen kunnen worden.  
        In hoofdstuk7 wordt de potentiele toepassing van ABPs in de diagnostiek 
van LSDs behandeld. Beschreven wordt een sensitieve diagnostische methode 
die gebruik maakt van cel-lysaten en urinemonsters. Zeven verschillende 
lysosomale hydrolasen konden gedetecteerd worden met corresponderende 
ABPs: β-glucosidase (GBA), α-glucosidase (GAA), α-galactosidase (αGAL), α-
fucosidase (αFUC), β-galactosidase (βGAL), β-glucuronidase (βGLUR) en α-
mannosidase (αMAN). Aangezien urine een gemakkelijk verkrijgbare bron aan 
lysosomale enzymen is, wordt mogelijke diagnostiek hiermee beschreven. Een 
proof-of-concept voor de diagnostische toepassing van ABPs wordt 
gepresenteerd.   
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        In hoofdstuk 8 worden de in dit proefschrift beschreven studies 
bediscussieerd en wordt toekomstig onderzoek voorgesteld. 
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As you set out for Ithaka 
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Arriving there is what you’re destined for. 
But don’t hurry the journey at all. 
Better if it lasts for years, 
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